The Role of T-helper 17 and T-helper 22 Lymphocytes in Beta-Lactam Hypersensitivity by Sullivan, AD
The Role of T-helper 17 and T-
helper 22 Lymphocytes in Beta-
Lactam Hypersensitivity 
 
 
 
 
 
 
 
 
 
This thesis is submitted in accordance with the requirements of the University 
of Liverpool for the degree of Doctor of Philosophy by 
 
Andrew Sullivan 
June 2016 
  
DECLARATION 
 
 
 
 
 
 
I declare that the work presented in this thesis is all my own work and has not 
been submitted for any other degree 
 
 
 
 
________________________________________ 
 
 
Andrew Sullivan (B.Sc, M.Res) 
  
ACKNOWLEDGEMENTS 
 
I would first like to thank my supervisors Professor Kevin Park and Dr Dean 
Naisbitt.  Having started in the department as a researcher who knew nothing 
about Immunology, I have been lucky enough to develop my knowledge over 
these past years under their supervision and progress to being a researcher 
who knows a little bit about Immunology.  Special thanks to Dean, who has put 
up with my unorthodox attitude towards work hours.  I wouldn’t have come 
close to finishing my Ph.D without you. 
On a day to day basis, I owe a debt of gratitude to both Dr Lee Faulkner and 
John Farrell.  Lee for explaining the lab, cell culture and fixing expensive 
machines when I didn’t know what was wrong and John for general enjoyment 
and distracting conversations when I just didn’t want to be doing work.  
Additional thanks go to Dr. Monday Ogese, by far the friendliest person I have, 
or will ever meet. 
Many thanks to all the members of the Department, both past and present.  All 
of you have made my studies here enjoyable, even allowing for the multiple 
stupid conversations that have happened.  I’ll never forget Agnes and her 
inability to speak English, Rich and his blossoming beer empire, 2 hour lunches 
outside when we got some rare sunshine, or going straight from work to a 
night out finishing at 4am, via the AJ with the old guard of Ryan, Jack, Jamie, Liz 
and the rest dancing around laptop bags.  Gibson deserves a special mention, 
becoming a close friend over my studies despite his cheery outlook on life. 
Conferences, nights out, catch the dart, random grinding, holidays and Indian 
Delights.  Ah, the memories. 
Final thanks go to my mother, who has put up with my insistence to not get a 
real job for multiple years now.  Even after thinking I had finally left home, I 
have been welcomed back whenever needed, such as not having / being able to 
afford a place to live.  She has worked hard to make sure I had everything that I 
needed in life, for which I am eternally grateful.  Still working on sorting that 
beachside apartment in Spain for you though.   
 
Finally finished this goddamn thesis, knew I would get round to it eventually!  
CONTENTS 
 
 
ABBREVIATIONS ............................................................................................................................... I 
PUBLICATIONS ................................................................................................................................ VI 
ABSTRACT ...................................................................................................................................... VIII 
CHAPTER 1 – GENERAL INTRODUCTION ................................................................................. 1 
1.1 The Immune System ....................................................................................................... 1 
1.2 Drug Metabolism ........................................................................................................... 36 
1.3 Mechanisms of Lymphocyte Activation ................................................................. 42 
1.4 Adverse Drug Reactions .............................................................................................. 61 
1.5 Cystic Fibrosis ................................................................................................................. 82 
1.6 Beta Lactam Antibiotics .............................................................................................. 90 
1.7 Thesis Outline ................................................................................................................. 94 
CHAPTER 2 – MATERIALS AND METHODS ............................................................................ 95 
2.1       Reagents and Materials .............................................................................................. 96 
2.2 Cell Culture Medium ..................................................................................................... 98 
2.3 Instrumentation ............................................................................................................ 99 
2.4       Sample Recruitment ................................................................................................. 100 
2.5 Methods ......................................................................................................................... 101 
CHAPTER 3 – DETERMINATION OF THE NAÏVE T-CELL RESPONSE TO 
PIPERACILLIN USING A DENDRITIC CELL CO-CULTURE T-CELL ASSAY ................... 115 
3.1        Introduction ............................................................................................................... 116 
3.2 Aims and Hypothesis ................................................................................................. 120 
3.3 Methods ......................................................................................................................... 121 
3.4 Results ............................................................................................................................ 122 
3.5 Discussion ..................................................................................................................... 143 
CHAPTER 4 - CHARACTERISATION OF THE PHENOTYPE AND FUNCTION 
OF PIPERACILLIN-SPECIFIC T-LYMPHOCYTES ISOLATED FROM THE 
BLOOD OF HYPERSENSITIVE PATIENTS ............................................................................. 151 
4.1 Introduction ................................................................................................................. 152 
4.2 Aims and Hypothesis ................................................................................................. 157 
4.3 Methods ......................................................................................................................... 158 
4.4 Results ............................................................................................................................ 159 
4.5 Discussion ..................................................................................................................... 183 
CHAPTER 5 – CHARACTERISATION OF THE DRUG-SPECIFIC LYMPHOCYTIC 
RESPONSE THAT IS OBSERVED IN INFLAMED SKIN OF HYPERSENSITIVE 
PATIENTS WITH CYSTIC FIBROSIS ....................................................................................... 192 
5.1       Introduction ................................................................................................................ 193 
5.2 Aims and Hypothesis ................................................................................................. 196 
5.3 Methods ......................................................................................................................... 197 
5.4 Results ............................................................................................................................ 198 
5.5 Discussion ..................................................................................................................... 227 
CHAPTER 6 – INVESTIGATION INTO THE IMMUNOGENICITY OF THE COX-2 
SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY LUMIRACOXIB ...................... 239 
6.1       Introduction ................................................................................................................ 240 
6.2 Aims and Hypothesis ................................................................................................. 244 
6.3 Methods ......................................................................................................................... 245 
6.4 Results ............................................................................................................................ 246 
6.5 Discussion ..................................................................................................................... 263 
CHAPTER 7 – FINAL DISCUSSION .......................................................................................... 268 
REFERENCES ................................................................................................................................. 279 
 
 
  
I 
 
ABBREVIATIONS 
 
aa – amino acids 
ABC – abacavir 
ACD – allergic contact dermatitis 
ACN - acetonitrile 
ADR – adverse drug reaction 
AGEP – acute generalised exanthematous pustulosis 
AhR – aryl hydrocarbon receptor 
AHS – abacavir hypersensitivity syndrome 
ALP – alkaline phosphatase 
ALT – alanine aminotransferase 
ANOVA – analysis of variance 
APC – antigen presenting cell 
APC2 – allophycocyanin 
Bak – Bcl-2 homologous antagonist killer 
Bax – Bcl-2 associated x protein 
Bcl-6 – B-cell lymphoma 6 
Bcl-10 – B-cell lymphoma 10 
BLIMP – PR domain zinc finger protein 1 
BSA – bovine serum albumin 
CBZ – carbamazepine 
CCL – chemokine ligand 
CCR – chemokine receptor 
CD – cluster of differentiation 
CFSE – carboxyfluorescein diacetate succinimidyl ester 
CLA – cutaneous leukocyte antigen 
COX – cyclooxygenase 
II 
 
CPM – counts per minute 
CRM – chemically reactive metabolite 
CSA – cyclosporin A 
CTL – cytotoxic T-lymphocyte 
CTLA4 – cytotoxic T-lymphocyte associated protein-4 
CXCL – CXC chemokine ligand 
CXCR – CXC chemokine receptor 
CYP – cytochrome enzyme 
DAMP – damage associated molecular pattern 
DC – dendritic cell 
DHS – drug hypersensitivity syndrome 
DIHS – drug induced hypersensitivity syndrome 
DILI – drug induced liver injury 
DMSO – dimethyl sulfoxide 
DNA – deoxyribose nucleic acid 
DNCB – dinitrochlorobenzene 
DRESS – drug reaction with eosinophilia and systemic symptoms 
EBV – Epstein-Barr virus 
EDTA – ethylenediaminetetraacetic acid 
ELISA – enzyme linked immunosorbent assay 
ELISpot – enzyme linked immunosorbent spot assay 
ER – endoplasmic reticulum 
Erk – extracellular signal regulated kinase 
FACS – fluorescence activated cell sorter 
FasL – fas ligand 
FBS – foetal bovine serum 
FITC – fluorescein isothiocyanate 
FoxP3 – forkhead box P3 
FSC – forward scatter 
III 
 
GABA – gamma-aminobutyric acid 
GATA – anti-GABA transporter 
GM-CSF – granulocyte macrophage colony stimulating factor 
HBSS – Hanks’ balanced salt solution 
HEPES – hydroxyethyl piperazineethanesufonic acid 
HIV – human immunodeficiency virus 
HLA – human leukocyte antigen 
HRP – horseradish peroxidise 
h – hours 
HSA – human serum albumin 
ICAM – intracellular adhesion molecule 
ICOS – inducible co-stimulator 
ICOSL – inducible co-stimulator ligand 
IFN – interferon 
Ig – immunoglobulin 
IL – interleukin 
IP3 – inositol triphosphate 
ITAM – immunoreceptor tyrosine based activation motif 
IV – intravenous 
Jak – janus kinase 
LAT – linker for activation of T-cells protein 
LC – langerhans cell 
Lck – lymphocyte specific protein tyrosine kinase 
LPS – lipopolysaccharide 
LTT – lymphocyte transformation test 
MAPK – mitogen activated protein kinase 
MFI – mean fluorescence intensity 
MHC – major histocompatability complex 
mins – minutes 
IV 
 
MPE – maculopapular exanthema 
NADH – nicotinamide adenine dinucleotide 
NADPH – nicotinamide adenine dinucleotide phosphate 
NAT – n-acetyl transferase 
NF-κβ – nuclear factor kappa beta 
NK – natural killer 
NKT – natural killer T-cell 
PAMP – pathogen associated molecular pattern 
PAX – paired box transcription factor 
PBMC – peripheral blood mononuclear cell 
PBS – phosphate buffered saline 
PD – programmed death 
PE – phycoerythrin 
PHA – phytohemaglutinin 
PI – pharmacological interaction 
Pip - piperacillin 
PKC – protein kinase C 
PLC – peptide loading complex 
RANTES – regulated upon activation, normal T-cell expressed and secreted 
RORγt – retinoic acid receptor related orphan nuclear receptor gamma 
ROS – reactive oxygen species 
RPMI – Roswell Park Memorial Institute 
SD – standard deviation 
SEM – standard error of mean 
SFU – spot forming units 
SI – stimulation index 
SJS – Stevens Johnson syndrome 
SMX – sulfamethoxazole 
SMX-NO – sulfamethoxazole nitroso 
V 
 
SSC – side scatter 
STAT – signal transducer and activator of transcription 
TAP – transporter associated with antigen processing 
T-bet – T-box transcription factor 
TCR – T-cell receptor 
TGFβ – transforming growth factor beta 
Th – T-helper lymphocyte 
TEN – toxic epidermal necrolysis 
TIM – T-cell immunoglobulin and mucin domain protein 
TLR – toll like receptor 
TNF – tumour necrosis factor 
Treg – T-regulatory cell 
TT – tetanus toxoid 
v/v – volume / volume 
WHO – world health organisation 
w/v – weight / volume 
zap-70 – zeta chain associated protein kinase 70 
β2m – beta 2 microglobulin 
  
VI 
 
PUBLICATIONS 
 
Papers  
 
Farrell, J., Lichtenfels, M., Sullivan, A., Elliott, E.C., Alfirevic, A., Stachulski, A.V., 
Pirmohamed, M., Naisbitt, D.J., Park, B.K. 
Activation of carbamazepine-responsive T-cell clones with metabolically inert 
halogenated derivatives 
(2013) Journal of Allergy and Clinical Immunology, 132 (2), pp. 493-495.  
 
Gibson, A., Ogese, M., Sullivan, A., Wang, E., Saide, K., Whitaker, P., Peckham, D., 
Faulkner, L., Park, B.K., Naisbitt, D.J. 
Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T 
cells and the influence of PD-1 on effector T cell function 
(2014) Journal of Immunology, 192 (6), pp. 2611-2621. 
 
Sullivan, A., Gibson, A., Park, B.K., Naisbitt, D.J. 
Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions? 
(2015) Expert Opinion on Drug Metabolism and Toxicology, 11 (3), pp. 357-
368. 
 
Faulkner, L., Gibson, A., Sullivan, A., Tailor, A., Usui, T., Alfirevic, A., 
Pirmohamed, M., Naisbitt, D.J., Park, B.K. 
Detection of primary T-cell responses to drugs and chemicals in HLA-typed 
volunteers 
(2016) Toxicological Sciences, 153 (2). 
 
Amali, M., Sullivan, A., Jenkins, R., Meng, X., Faulkner, L., Whitaker, P., Peckham, 
D., Park, B.K., Naisbitt, D.J. 
Detection of drug-responsive B-lymphocytes and anti-drug IgG in patients with 
piperacillin hypersensitivity 
(2016) Allergy, In press. 
 
Sullivan, A., Wang, E., Farrell, J., Whitaker, P., Peckham, D., Park, B.K., Naisbitt, 
D.J. 
Beta-lactam hypersensitivity involves expansion of circulating and skin-resident 
Th22  cells 
(2016) Journal of Allergy and Clinical Immunology, In press. 
 
 
 
VII 
 
Abstracts 
 
Poster - Investigating the role of B-cells in the progression of delayed type drug 
hypersensitivity in patients with cystic fibrosis.  EAACI DHM5, Munich 2012. 
Poster – Detection of interleukin-22 secreting T-cells in piperacillin 
hypersensitive patients with cystic fibrosis.  EAACI DHM6, Bern 2014 
Talk – Drug-specific CD4+ and CD8+ T-cells isolated from skin and blood of 
hypersensitive patients secrete interleukin-22, but not interleukin-17.  EAACI 
Winter Conference, Les Arcs 2015 – Awarded travel scholarship. 
Talk – CD4+ and CD8+ T-cells isolated from blood and skin of patients with beta-
lactam hypersensitivity secrete interleukin-22, but not interleukin-17.  EAACI 
World Congress, Barcelona 2015 – Awarded travel scholarship. 
Poster – Interleukin-22 and its role in piperacillin hypersensitivity reactions.  
British Toxicological Society Meeting, Edinburgh 2015. 
Poster – The role of interleukin-22 in beta-lactam hypersensitivity reactions.  
EAACI DHM7, Barcelona 2016 – Awarded travel scholarship. 
 
  
VIII 
 
ABSTRACT 
 
Beta-lactam antibiotics are used to treat recurrent opportunistic infections that occur in 
patients with cystic fibrosis.  However, the incidence of reported hypersensitivity in these 
patients is greatly higher than the healthy population.  Due to the delayed nature of beta-
lactam hypersensitivity, a T-cell mediated immune response is implicated.  Type IV drug 
hypersensitivity is a major clinical concern, with a cutaneous aetiology driven through antigen 
specific T cells.  Pro- and anti-inflammatory cytokines can be detected in reactions to β-lactam 
drugs in responsive T cells from hypersensitive patients.  Classical Th1/Th2 phenotypes are 
currently used to classify the reactions, though these do not accurately characterise the 
function of the immune cells.  In addition, this classification does not reference the newer Th 
subsets such as Th9, Th17 and Th22.   
To characterise the nature of the T-cell response observed in piperacillin hypersensitive 
patients with cystic fibrosis, T-cell clones from both blood and inflamed skin of hypersensitive 
patients were generated, then characterised in terms of phenotype and function.  Additional 
investigations into PBMC responses were conducted.  Naïve T cells from healthy donors were 
also primed to piperacillin, as well as attempted regulation of the cytokine response through 
modulation of a selected nuclear receptor involved in the progression of a Th22 mediated 
response. 
Drug-specific clones were generated from both blood (n=570, 84% CD4) and skin (n=96, 83% 
CD4) samples obtained from patients hypersensitive to piperacillin.  All clones secreted high 
levels of IFN-γ and IL-13.  Interleukin-22, perforin and granzyme B were secreted in over 50% 
of clones, with none from either blood or skin showing any detectable level of IL-17A.  Naïve T 
cells primed to piperacillin via autologous dendritic cells showed proliferative responses 
(p=0.001, SI>2).  Clones generated from primed T-cells showed similar patterns of cytokine 
secretion when compared alongside clones generated from hypersensitive patients.  
Significant differences in chemokine receptor expressions were observed between blood-
derived piperacillin-specific clones, skin-derived piperacillin-specific clones and skin-derived 
non piperacillin-specific clones.  CLA, CXCR6 and CCR1 expression was higher on piperacillin-
specific skin derived clones when compared to non-piperacillin specific skin derived clones 
(p=0.01).  CCR2, CCR4, CXCR1 and E-cadherin were higher on skin specific clones when 
compared to blood specific clones (p=0.01).  Piperacillin specific clones isolated from blood and 
skin of hypersensitive patients, as well as healthy donor PBMC migrated in the presence of 
chemokines specific to their respective cell surface receptors, with migration to CCR4 and 
CCR10 most prevalent.  In addition, modulation of the aryl hydrocarbon receptor showed that 
an abrogation of the cytokine response was observed in cells treated with an AhR inhibitor.  
This abrogation was only observed in the secretion of interleukin-22, a key cytokine in a Th22 
response. 
Currently, T-cell mediated hypersensitivity involving drug binding to the HLA molecule has 
only been shown for HLA class I molecules; no data has provided evidence for HLA class II 
interactions with drugs being able to activate CD4+ T-cells.  To investigate whether HLA class II 
molecules binding to drugs could activate T-cells, an investigation into the COX-2 specific 
NSAID lumiracoxib was performed.  Lumiracoxib was withdrawn from use after incidences of 
liver toxicity were reported in 2008. 
Utilising a naïve T-cell dendritic cell co-culture assay, attempts were made to generate drug-
specific responses from lymphocytes to either lumiracoxib or its major / minor metabolites.  
No positive responses were generated, with all assays performed showing no activation of 
drug-specific T-cells following re-challenge with the drugs. 
In conclusion, the data generated over the course of this thesis has shown that there is a subset 
of piperacillin-specific T-cells in hypersensitive patients with cystic fibrosis that secrete IL-22, 
IFN-γ, perforin and granzyme B in response to antigen challenge.  No cells secreted IL17, 
suggesting a strong Th22 phenotype rather than Th17.  In addition, The AhR signalling pathway 
is also heavily implicated in the development of hypersensitivity, giving further evidence for 
the role of both IL-22 and Th22 lymphocytes in beta-lactam hypersensitivity.  
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1.1 THE IMMUNE SYSTEM 
 
The primary role of the immune system is to recognise, protect and mount a 
response to antigens that are present throughout the body (Akira, Uematsu et 
al. 2006).  The response that is generated can vary greatly, due to the 
numerous components involved in the immune response.  Antigens can be 
both micro and macro in size, with different cells and molecules responsible 
for the immune response in each instance.   
Physiologically, the immune system functions to protect the body from harmful 
foreign molecules, including bacteria and viruses.  Early stage responses are 
mediated through the innate immune system, with the adaptive immune 
system complementing and eventually being the primary driving force behind 
the response (Medzhitov and Janeway Jr 1997). 
In order to be able to mount a response to a wide array of antigens, both T- and 
B-lymphocytes undergo genetic recombination, developing a diverse range of 
receptors able to recognise many different molecules.  All cells involved in the 
immune response in blood, as well as tissues, are generated in either the bone 
marrow or the thymus, with cells maturing and later having the ability to 
migrate to their site of residency or action (Cooper 2015). 
The innate immune response is mediated through physiological barriers such 
as the skin, alongside inflammatory cells such as mast cells and phagocytes, but 
does not confer long term immunity.  The adaptive immune system is triggered 
after the innate immune system, conferring immunity to specific pathogens.  It 
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is mediated through the T- and B-lymphocytic responses that are long lasting, 
conferring a memory immunity for multiple years after initial exposure. 
Due to the nature of the response times, the innate immune system responds 
to a broad array of different antigens, with little specificity for individual 
molecules.  In contrast, the delayed adaptive immune response is highly 
specific and able to recognise individual antigens.  The physiological role of 
both the innate and adaptive immune systems are described in greater detail 
in the following sections. 
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1.1.1 INNATE IMMUNE SYSTEM 
 
Innate immunity involves both physiochemical (skin) and inflammatory 
mediators such as defensin, as well as cellular components of the innate 
immune system that can work independently (i.e. cells such as phagocytes and 
natural killer cells).  Working in concert with each other, components of the 
innate immune system provides a highly effective defence to most micro-
organisms and pathogens.  The complex interplay of cytokine secretion, as well 
as interactions with the complement system comprises the humoral barrier, 
providing an additional layer of immediate immune defence to multiple 
pathogens (Fearon and Locksley 1996; Abbas 2010). 
The innate immune response is triggered through receptor recognition of 
pathogen-associated molecular patterns (PAMPs).  These pathogen recognition 
receptors (PRRs) can be soluble or associated with cell surfaces, with 
expression highest on innate immune cells such as macrophages and dendritic 
cells (Medzhitov and Janeway Jr 1997).  Soluble PRR activation by PAMPs leads 
to multiple effects, including up-regulated phagocytosis, lysosome interactions 
triggering microsomal lysis and direct action of the soluble PRR molecules on 
the microorganisms themselves (Medzhitov and Janeway 2002).  Cell-
associated PRR activation bring about cytokine secretion cascades, resulting in 
the release of inflammatory mediators, as well as increased phagocytosis 
similar to the soluble PRR response.  Also involved in the innate immune 
system, are the danger associated molecular patterns (DAMPs) (Kumar, Kawai 
et al. 2011).  These molecules are released during non-senescent necrotic 
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death as well as traumatic tissue damage, are also able to trigger an innate 
immune response (Pétrilli, Dostert et al. 2007). 
 
1.1.1.1 CELLULAR COMPONENTS – MONOCYTES 
 
Monocytes are a type of white blood cell comprising up to 10% of the 
peripheral leukocytes found in human blood.  Furthermore, a large reservoir, 
approximately half of the total monocyte population are found in the spleen 
(Swirski, Nahrendorf et al. 2009).  They are progenitor cells able to 
differentiate into three distinct cell types; macrophages, dendritic cells and 
foam cells (Huh, Pearce et al. 1996).  They have a diverse array of functions 
throughout the body, including differentiation to the aforementioned cells, 
phagocytosis and cytokine production (Turrini, Ginsburg et al. 1992; Friebe, 
Siegling et al. 2004).  Phagocytosis occurs primarily through the opsonisation 
of pathogens via proteins such as antibodies, in addition to the activation of 
specific complement receptors (Newman and Tucci 1990).   
Monocyte’s ability to differentiate in vivo has been reported for many decades, 
with initial work by Ebert and Florey showing terminal differentiation into 
macrophages as far back as 1939 (Ebert and Florey 1939).  Migration into 
peripheral tissues occurs through the action of chemokines such as CCL2 and 
CCL7 – allowing for differentiation into the previously mentioned cell types 
(Shi and Pamer 2011). 
It has been reported that there are two distinct subsets of monocytes, based on 
their expression of CD14 and CD16; a CD14+CD16- and a CD14+CD16+ variant.  
 5 
 
Specific phenotypic differences can be noted between these two monocytes, 
with the CD14+CD16- expressing higher levels of CCR2 compared to the 
CD14+CD16+ subtype.  However, The CD16+ cells have been shown to express 
higher amounts of the MHC class II molecule, suggesting that these are more 
likely to be involved in antigen presentation.  Both classes of monocyte are able 
to differentiate into macrophages in the presence of cytokines such as GM-CSF 
and IL-4 (Ziegler-Heitbrock, Fingerle et al. 1993; Sallusto and Lanzavecchia 
1994; Weber, Belge et al. 2000).    
More recently, a third subtype of monocytes has been reported, a 
CD14+CD16+CD64+ phenotype.  This type of monocyte secretes large amounts 
of TNFα and IL-6 following phagocytosis.  The authors suggest that these cells 
have the propensity to differentiate into either macrophages or DCs, depending 
on local environmental stimuli (Grage-Griebenow, Flad et al. 2001; Grage-
Griebenow, Zawatzky et al. 2001). 
 
1.1.1.2 CELLULAR COMPONENTS – MACROPHAGES 
 
Derived from monocytes present in the blood, macrophages are CD14+ 
expressing cells (Khazen, M’Bika et al. 2005).  When fully mature, they express 
additional markers specific to macrophages including CD11b, CD40, CD64 and 
CD68 (Joshi, Fong et al. 2009).    They are involved in both the innate and 
adaptive immune response, with their primary roles throughout the body to 
act as antigen presenting cells for the immune system, as well as having a 
functional role in the phagocytosis of cell fragments.  Phagocytosis of 
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microorganisms triggered by IFN-γ proceeds through the actions of endosomal 
enzymes.    Activation of macrophages leads to the presentation of antigens in 
the context of MHC class I and II molecules to specific helper T-lymphocytes 
(Mosser 2003; Mantovani, Sica et al. 2004).   
 
1.1.1.3 CELLULAR COMPONENTS – DENDRITIC CELLS 
 
Dendritic cells are the primary antigen presenting cells of the immune system.  
They develop from monocytes in the bone marrow, and are able to migrate and 
reside in different tissues monitoring damage and infection (Banchereau and 
Steinman 1998).  They are present in most tissues, and usually have specific 
names depending on their location; for example, in skin, they are called 
Langerhans cells, while microglia are in the brain and spinal cord (Ginhoux, 
Tacke et al. 2006).   
Presentation through dendritic cells occurs via the following process:  first, the 
engulfment of extracellular protein antigens which are then processed into 
smaller peptide fragments.  Secondly, these fragments are presented by MHC 
on the surface of the dendritic cells to allow for recognition by T-lymphocytes 
(Ingulli, Mondino et al. 1997).  Antigen presentation occurs typically on fully 
matured dendritic cells.  The immature cells express lower levels of the co-
stimulatory molecules CD80 and CD86.  These cells are implicated in 
phagocytosis rather than antigen presentation (Zheng, Manzotti et al. 2004; 
Spaggiari, Abdelrazik et al. 2009).  Maturation from immature dendritic cells is 
triggered by PAMP / DAMP signals from bacterial components such as LPS.  
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High levels of immature dendritic cells are found in the extremities of the body, 
such as the epidermis, due to the higher rate of contact with antigens.  
Encountering an antigen drives immature dendritic cells to phagocytose 
pathogens and migrate to lymph nodes, where they prime naïve T-lymphocytes 
(Kapsenberg 2003).  This process leads to the formation of a pool of residual 
memory T-lymphocytes specific to the presented antigen.  Presentation via 
immature dendritic cells often leads to immune tolerance through regulatory 
T-cell (Treg) expansion, as opposed to the immune response triggered through 
mature dendritic cell presentation.  T-lymphocyte activation mediated through 
dendritic cells occur through two distinct pathways; co-stimulatory receptor 
ligand interactions (non-specific to the antigen), and direct antigenic 
stimulation  (Steinman 1991).  Dendritic cell function is up-regulated via IL-4 
and GM-CSF, and in certain in vitro situations these molecules are used to drive 
a monocyte culture to mature into a terminal dendritic cell phenotype, along 
with the addition of LPS and TNFα (Dieu, Vanbervliet et al. 1998).   
 
1.1.1.4 CELLULAR COMPONENTS – GRANULOCYTES 
 
These cells are a subclass of leukocytes that digest microorganisms through 
phagocytosis.  They are a broad subset of cells, encompassing basophils, 
eosinophils and neutrophils (Bochner, Luscinskas et al. 1991).  Basophils are 
the least abundant type of granulocyte; they contain many granules inside the 
cell filled with pro-inflammatory mediators.  Like all granulocytes, basophils 
are able to be recruited to tissues from the circulating blood.   When activated, 
they act to release histamine and leukotrienes and are involved in the IgE 
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response, similar to mast cells (Ochensberger, Daepp et al. 1996).  Neutrophil 
migration is mediated via IL-8.  Microorganisms are attacked by neutrophils, 
leading to phagocytosis and pathogen digestion (Zeilhofer and Schorr 2000; 
Nathan 2006).  Eosinophils are important cellular mediators in the final phase 
of mast cell mediated immune reactions.  They have the ability to secrete 
multiple cytokines such as IFN-γ, IL-5 and IL-10.  They migrate in response to 
eotaxin and IL-5, allowing for a positive feedback loop to be established upon 
contact with foreign parasites (Yamaguchi, Suda et al. 1988).  Eosinophils exert 
their effect through the cationic granules that are present inside the cells 
(Dyer, Percopo et al. 2010).  
 
1.1.1.5 CELLULAR COMPONENTS – NATURAL KILLER CELLS 
 
Natural Killer (NK) cells are lymphocytes that display the CD56 cell surface 
marker (Chan, Sin et al. 1997).  They do not express antigen-specific receptors 
on the cell surface, though they are involved in pathogen immunity through the 
production of cytokines (Cooper, Fehniger et al. 2001).  They are a commonly 
found cell type, accounting for approximately 30% of all cells generated from 
lymphoid progenitors.   They can be found in tissues such as the spleen and 
liver, after maturation in the bone marrow and lymph nodes (Morris and Ley 
2004).  Cell death triggered by the NK cell activation pathway is generally 
mediated through the production of the cytotoxic molecules including perforin 
and granzyme B.  However, activated NK cells can also produce high levels of 
IFN-γ (Trapani 1995).  IFN-γ increases the effector function of macrophages 
and promotes cell mediated immune responses.   
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Major histocompatability complex receptors (MHC) are cell surface proteins 
involved in the presentation of peptide fragments to T-cells.  MHC I inhibitory 
receptors are known to be involved in the immune response, with the 
activation of these receptors triggering secretion of cytokines such as GM-CSF 
and TNF-a, which can lead to the killing of infected cells (Doucey, Scarpellino et 
al. 2004).  In addition, activation of NK cells leads to an increase in IL-12 
production, which is involved in the polarisation of the Th1 lymphocytic 
response (Lawson 2012).   
 
1.1.2 ADAPTIVE IMMUNE SYSTEM 
 
The adaptive, or acquired, immune system’s primary goal is to target and 
destroy invading pathogens that are noxious to the body, as well as being able 
to destroy the harmful products of these pathogens.  The innate and adaptive 
immune systems do not work in isolation; rather, they function alongside one 
another with multiple interactions found between them on a cellular and 
molecular level.  The innate immune system is also known to be able to trigger 
an adaptive immune response.  Immunological memory allows for a rapid 
response of the immune system upon re-exposure to a previously encountered 
antigen (Kurtz 2004).  A multitude of cells are responsible for the immune 
response that is triggered upon exposure to a pathogen, with a summary of the 
main cell types to follow.  Critical to the adaptive immune response are 
lymphocytes, generated from stem cells present in bone marrow.  These cells 
can regulate both humoral and cellular immunity (Morgan, Ruscetti et al. 
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1976).  Broadly, lymphocytes can be split into two distinct categories:  B-
lymphocytes and T-lymphocytes.  These are classified through their 
mechanisms of antigen recognition, as well as effector function.  B-
lymphocytes differentiate into either long lived memory cells, or effector 
plasma cells which secrete antibodies, while T-lymphocytes can differentiate 
into a multitude of different effector cells, whose primary response to 
pathogens is mediated through the large scale production of both pro- and 
anti-inflammatory cytokines. 
T-lymphocytes all express multiple T-cell receptors (TCR) on their surfaces, 
which in turn are responsible for the recognition of different peptide 
fragments presented in the context of MHC molecules (figure 1.1) on antigen 
presenting cells (Hogquist, Jameson et al. 1994).  The resulting TCR–MHC 
interaction leads to clonal expansion and triggering of a highly specific and 
targeted immune response that is able to combat infection. 
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Figure 1.1.  Structure of the MHC displayed on the cell surface.  MHC class I molecules 
present antigens to CD8+ T-lymphocytes.  They are composed of an alpha chain that is 
able to signal intracellularly, as well as a beta-microglobulin to complete the structure.  
MHC class II molecules present antigens to CD4+ T-lymphocytes, which are made of an 
alpha and beta subunit.  
 
1.1.2.1 CELLULAR COMPONENTS – CYTOTOXIC T-LYMPHOCYTES 
 
Cytotoxic T-lymphocytes are primarily CD8+ and are involved in the targeting 
of infected or otherwise damaged cells.  They are activated through a MHC 
class I restricted molecular interaction, which involves the presentation of 
specific antigenic fragments to the T-cell through TCR interactions via MHC 
class I presentation from antigen presenting cells (Norment, Salter et al. 1988).  
They are responsible for the targeting and killing of specific cells through a cell 
death pathway involving cytotoxic molecules including perforin, granzyme B 
 12 
 
and fas ligand, as well as granulysin.  These molecules are released from T-
lymphocytes following antigen stimulation (Kaech, Tan et al. 2003).  Perforin 
elicits its action through binding with granzymes, which form a co-complex on 
the surface of the target cell membrane.  This complex allows increased influx 
of granzyme A and B into the target cell, leading to toxicity (Trapani 1995).  
Granzymes induce programmed cell death following release from cytotoxic T-
cells or NK cells.  They exert their action through caspase activation, in 
addition to increasing the membrane permeability of mitochondria through 
recruitment of signalling molecules Bak and Bax (Wei, Zong et al. 2001).  Fas 
ligand binds to the CD95 fas receptor on the cell membrane.  Binding triggers a 
signalling pathway which results in the activation of the caspase apoptotic cell 
death pathway through caspase-8 activation and signalling to caspase 3 
(Andersen, Schrama et al. 2006).  The effect of granulysin is brought about 
through the up-regulation of lipid-degrading enzymes, which result in the loss 
of structure of cell membranes and the triggering of cell death (Stenger, 
Hanson et al. 1998). 
 
1.1.2.2 CELLULAR COMPONENTS – HELPER T-LYMPHOCYTES 
 
This subset of T-lymphocyte is involved in the activation of immune cells such 
as macrophages and phagocytes.  Once matured, helper T-cells (Th) cells 
express CD4 on their surface which interacts with MHC class II molecules and 
stabilises the APC T-cell interaction during antigen presentation (Snijdewint, 
Kaliński et al. 1993).  Initially present as naïve helper T-cells, these progenitors 
can be activated though antigen exposure to the TCR, with resulting progeny 
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able to become effector, memory or regulatory T-cells, depending on 
conditions.  The differentiation of helper T-lymphocytes occurs through both 
interleukin-2 (proliferation) acting in an autocrine fashion, alongside 
interleukin-4 (polarisation) on the STAT4/STAT6 pathway (Kaplan and Grusby 
1998).  The classic definition of helper T-lymphocytes involves two subsets; 
Th1 and Th2, though newer classifications have been proposed in recent years 
(figure 1.2).   
 
 
Figure 1.2.  Maturation of Naïve T-lymphocytes.  T-cell plasticity can result in a wide 
range of differentiation pathways.  Shown is the differentiation into multiple helper T-
cell subsets, with the master transcription factor for each pathway highlighted.  Primary 
secreted cytokines, as well as effector function are also shown below each helper T-cell 
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pathway.  T-bet (T-box transcription factor), GATA3 (Anti-GABA transporter-3), PU.1 
(Macrophage transcription factor), RORγt (Retinoic acid receptor-related orphan 
nuclear receptor gamma), AhR (Aryl hydrocarbon receptor), Bcl-6 (B-cell lymphoma 6), 
FoxP3 (forkhead box P3). 
 
1.1.2.2.1 Helper T-lymphocytes – Th1 / Th2  
 
Helper T-cells are critical to the continued function of the adaptive immune 
system.  The cytokines they secrete are integral to the production of cytotoxic 
T-cells, as well as humoral responses.  Moreover, Th cells are involved in class 
switching and the production of IgE antibodies from B-cells.   
After initial activation, proliferative T-lymphocytes have been shown to 
polarise into either a Th1 or Th2 subset (Abbas, Murphy et al. 1996).  Th1 are 
traditionally associated with a pro-inflammatory phenotype, with high levels of 
IFN-γ and TNFα secretion.  Differentiation of T-lymphocytes into a Th1 subtype 
is driven by interleukin-12, alongside the transcription factors STAT4 and T-
bet (Szabo, Kim et al. 2000).  Further downstream, the activation of STAT1 
suppresses interleukin-4 production, needed for Th2 differentiation.  It has 
been shown that the immune response to infections, chiefly bacteria and 
protozoa activate a Th2 response.  These bacteria can be killed through the 
action of iNOS – and the resulting free radicals -produced as a result of IFN-γ 
mediated macrophage activation (Mills, Kincaid et al. 2000).  In addition, Th1 
cells promote NK cell and cytotoxic CD8+ T-cell activation linking to the pro-
inflammatory Th1 model (Constant and Bottomly 1997).   Conversely, Th2 cells 
are involved in the immune response that targets threats from extracellular 
pathogens, such as parasitic helminths (Berger 2000).  They are generally 
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considered to be anti-inflammatory, with the cytokines interleukin-5, 
interleukin-13 and TGFβ secreted.  The presence of interleukin-4 is needed for 
Th2 polarisation, driven through the activation of transcription factors STAT6 
and GATA3 (Zheng and Flavell 1997).  In contrast to Th1 cells, Th2 lymphocytes 
are known to recruit eosinophils, mast cells and basophils, as well as acting 
upon B-cells to trigger the secretion of antibodies.    Additionally, Th2 cells 
provide a positive feedback loop for rapid recruitment of these cells following 
antigen stimulation (Bonecchi, Bianchi et al. 1998).  Interleukin-10, another 
cytokine produced from Th2 cells, has been shown to suppress the polarisation 
of naïve Th0 cells into Th1 cells, as well as inhibiting dendritic cell function 
(Steinbrink, Jonuleit et al. 1999). 
This dual classification has been shown to have its limits however.  Interleukin-
10 is also known to suppress both Th1 and Th2 cells, while continuing to 
stimulate antibody production.  The role of regulatory T-lymphocytes are also 
not considered in the suppression and activation of Th1/2 cells, with external 
factors also known to be involved in this regulatory process (Tosolini, 
Kirilovsky et al. 2011). 
Recently, newer subclasses of helper T-lymphocytes have been identified, 
including Tfh, Th9, Th17 and Th22.  These do not fit into the old Th1/Th2 
paradigm, showing that though the Th1/Th2 duality is useful as a base, there is 
a need for greater detail and definition of the roles of these newly discovered 
helper T-lymphocyte subsets.   
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1.1.2.2.2 Helper T-lymphocytes – Tfh / Th9 
 
Follicular helper T-lymphocytes (Tfh) cells are one of the classes that are not 
able to fit into the existing Th1/Th2 paradigm.  They are CD4+ cells expressing 
high levels of CXCR5; a receptor for B cell homing.  They are found in lymphoid 
tissues such as the spleen and lymph nodes (Crotty 2014) and are responsible 
for the production of antibodies through their actions in germinal centres, 
allowing for somatic hypermutation, cell expansion and class switching to 
occur (Fazilleau, Mark et al. 2009).  Effector B cells are produced as a result of 
the action of Tfh cells in the germinal centres.  CD278, encoded by the ICOS 
gene, has been shown to be integral to the development of Tfh cells through 
studies on knockout mice (Akiba, Takeda et al. 2005).  Paracrine activation of 
the CD40 receptor expressed on B cells by Tfh through CD40 ligand binding is 
also critical for the differentiation that occurs in germinal centres (McHeyzer-
Williams, Okitsu et al. 2011).  Their role in the maturation and expansion of 
antibody responses make them integral to the immune responses mounted to 
antigenic challenge.  Additionally, the interplay between interleukin-21 and its 
activation of CD4+ T-cells are dependent on this.  A transcription factor that has 
been identified in the progression of Tfh development is Bcl-6.  Bcl-6 is known 
to be modulated through interleukin-4 dependent STAT activation (Harris, 
Chang et al. 1999; Ichii, Sakamoto et al. 2002). 
Th9 cells were first described in mice.  They secrete interleukin-9 as their 
primary cytokine (Jäger, Dardalhon et al. 2009; Soroosh and Doherty 2009).  In 
contrast to other helper T-lymphocyte subtypes however, these cells do not 
secrete interleukin-10.  Furthermore, regulatory transcription factors that are 
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essential for differentiation into other Th subsets (e.g. T-bet, RORγt and Foxp3) 
are not expressed by Th9 cells (Kaplan 2013).  Interestingly, GATA3 and STAT6 
– responsible for Th2 differentiation – are expressed at low levels, suggesting 
that they are involved in Th9 differentiation (Goswami, Jabeen et al. 2012), 
alongside other cytokines such as interleukin-9 and interferon-α (Schmitt, 
Klein et al. 2014).  Though relatively little is known about their role in humans, 
recent studies have implicated Th9 cells in multiple conditions, such as asthma 
and melanoma (Robinson 2010).  Their primary roles are thought to be the 
recruitment of effector cells such as eosinophils and NK cells, as well as 
promoting the survivability of dendritic cells.  Th9 cells are implicated in 
ulcerative colitis, with a positive feedback loop of interleukin-9 thought to be 
important for increased intestinal permeability mediated by gut bacteria 
(Kaplan, Hufford et al. 2015).  In addition, recent research has outlined a 
potential role for Th9 cells in the progression of skin disease, with pro-
inflammatory and paracrine functions.  Secretion of both TNFα and granzyme 
B were detected from activated Th9 cells, suggesting that they can directly 
induce tissue injury (Schlapbach, Gehad et al. 2014).  
 
1.1.2.2.3 Helper T-lymphocytes – Th17 
 
Th17 cells are responsive to signals from both the IL-1R and IL-23R (Chung, 
Chang et al. 2009).  They are considered highly pro-inflammatory due to their 
large scale production of interleukin-17, TNFα, interferon-γ and MIP-3α 
(Zambrano-Zaragoza, Romo-Martinez et al. 2014).  Primarily involved in 
microbial defence to pathogens, several studies have shown that they are able 
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to trigger neutrophil migration (Pelletier, Maggi et al. 2010).  Also, Th17 cells 
are considered critical in the progression of autoimmune disorders such as 
psoriasis and asthma, as well as certain cutaneous reactions (Singh, Yamamoto 
et al. 2014).  They are found in high concentrations in barrier environments 
such as the mucosa and the skin.  Th17 differentiation from Th0 cells can occur 
through a cocktail of cytokine signalling, comprising of interleukin-1β, 
interleukin-6, interleukin-23 and TGFβ (Harrington, Hatton et al. 2005).  
Interleukin-23, another cytokine secreted from Th17 cells, has been shown to 
be involved in chronic inflammation, as well as tissue damage.  Another 
cytokine produced from Th17 cells, interleukin-21, has been shown to up-
regulate Th17 differentiation in an autocrine and paracrine fashion (Korn, 
Bettelli et al. 2007).  Multiple transcription factors are responsible for the 
differentiation of naïve T-cells into Th17 cells, the two key factors being RORγt 
and STAT3 (Chaudhry, Rudra et al. 2009).  An orphan nuclear receptor; RORγt 
is found in tissues, with promising treatments for the autoimmune disorder 
rheumatoid arthritis focused on inhibiting this transcription factor, halting 
Th17 differentiation (Huang, Xie et al. 2007).  STAT3 activation occurs 
following interleukin-6 exposure.  Nuclear translocation is critical for the 
differentiation of naïve T-cells into Th17 lymphocytes (Stockinger and 
Veldhoen 2007).  Both interleukin-6 and TGFβ are essential for the 
differentiation to occur, with both of these cytokines also shown to be inhibited 
by the presence of Th1 and Th2 cytokines.  Activation of STAT3 triggers the up-
regulation of RORγt which ultimately leads to lineage differentiation into Th17 
cells. 
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Nuclear translocation is involved in the regulation of gene expression.  This is 
key in helper T-cell differentiation through the ability to activate or suppress 
certain transcription factors that mediate differentiation, such as both RORγt 
and STAT3 in the Th17 pathway.  In the case of STAT regulation, tyrosine 
phosphorylation of the proteins allows for direct binding of the molecule to the 
promoter regions of target genes.  This cytokine-mediated regulation is 
dependent on the transfer of STAT molecules between the nucleus and 
cytoplasm; aberration of the cytokine signalling pathway halts STAT 
translocation and gene expression, leading to a termination of the 
differentiation pathway (Meyer and Vinkemeier 2007). 
 
1.1.2.2.4 Helper T-lymphocytes – Th22 
 
In 2009, both Trifari et al. and Duhen et al. independently described a novel 
subset of helper T-lymphocytes that were distinct from the existing groups.  
They were characterised by their secretion of interleukin-22 in the absence of 
interleukin-17, and were so termed Th22 cells (Duhen, Geiger et al. 2009; 
Trifari, Kaplan et al. 2009).  This important distinction showed that Th17 and 
Th22 cells were separate from each other, rather than variants of the same sub 
type (Eyerich, Eyerich et al. 2009).  Th22 cells are relatively poorly understood, 
with little research being conducted exploring their effector function in disease 
conditions.   
Naïve Th differentiation into Th22 cells occurs through the presence of the 
polarising cytokines interleukin-6, as well as TNFα, with further polarisation 
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observed following addition of interleukin-1β (Fujita, Nograles et al. 2009).  In 
contrast, the presence of TGFβ will inhibit Th22 cell differentiation, instead 
driving towards a Th17 phenotype (Bettelli, Carrier et al. 2006).  An integral 
part of Th22 differentiation is the presence of the aryl hydrocarbon receptor, 
with no detectable levels of either RORγt (Th17) or T-bet (Th1) – further 
underlining the evidence for Th22 cells being a distinct subset rather than a 
subset of either Th17 or Th1 cells (Esser, Rannug et al. 2009; Jia and Wu 2014).  
Th22 cells ability to secrete interleukin-22 in the absence of interleukin-17 has 
been previously characterised, though recent studies have shown a propensity 
for these Th22 cells to secrete both interferon-γ alongside interleukin-22 
(Fujita, Nograles et al. 2009).  This could explain the paradoxical nature of the 
responses that are observed following Th22 activation.  For example, Th22 cells 
have been shown to exert both a pro- and anti-inflammatory effect following 
activation and cytokine release.   
The main function of Th22 cells is to protect the host from invasive pathogens.  
In addition to this, epithelial barrier control and airway remodelling have also 
been shown to involve IL-22 (Souwer, Szegedi et al. 2010; Basu, O’Quinn et al. 
2012).  Several pieces of evidence suggest that IL-22 is also involved in 
cutaneous pathological conditions.  First, the interleukin-22 receptor is located 
exclusively on epithelial cells such as keratinocytes (Eyerich, Eyerich et al. 
2009).  Second, Th22 cells have been shown to express high levels of the skin 
homing chemokine receptors CCR4 and CCR10, allowing for migration to sites 
of tissue inflammation (Fujita 2013).  Thirdly, activated Th22 cells secrete 
CCL17, which is a ligand for the CCR10 receptor, suggesting a positive feedback 
mechanism for recruitment and activation (Trifari, Kaplan et al. 2009; Zhang, 
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Li et al. 2011).  Finally, several studies have shown that expression of Th22 
cells is upregulated in disorders such as psoriasis, atopic dermatitis and 
inflammatory bowel disease (Eyerich, Eyerich et al. 2009; Nograles, Zaba et al. 
2009; Kagami, Rizzo et al. 2010; Kagami, Rizzo et al. 2010; Dige, Stoy et al. 
2013). 
 
1.1.2.3 CELLULAR COMPONENTS – REGULATORY T-LYMPHOCYTES 
 
Regulatory T-lymphocytes are characterised as possessing the 
Foxp3+CD25+CD4+ phenotype (Allan, Passerini et al. 2005; Sakaguchi, Ono et al. 
2006).  Their functional role in the body is to modulate and suppress the 
immune system preventing uncontrolled tissue injury.  Suppression of the 
lymphocytic response is driven via cytokine modulation, through the action of 
cytokines such as TGF-β or IL-10 which are known to have a subduing effect on 
the immune system, or through an immunomodulatory receptor pathway via 
CTLA4 signalling (Rubtsov, Rasmussen et al. 2008; Wing, Onishi et al. 2008).  
Regulatory T-cells are an important self-check point for autoimmune 
disorders, as well as tolerance to self-antigens.  TGFβ has been shown to be 
integral in the development of naïve CD4+ T-cells into regulatory T-cells 
(Huber and Schramm 2006; Afzali, Lombardi et al. 2007).  They have been 
shown to express a wide range of TCR with a diverse array of αβTCR present 
on their cell surface.  This is due to their need for recognition of a wide array of 
antigens that are encountered throughout the body. 
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1.1.2.4 CELLULAR COMPONENTS – B-LYMPHOCYTES 
 
CD19+ B-lymphocytes are responsible for both antibody production and 
secretion.  They express immunoglobulins across their cell surfaces, which are 
essential for antigen recognition (Rickert, Rajewsky et al. 1995).  Cross-linking 
of receptors on the cell surface triggers activation and eventual maturation 
into either plasma cells or memory cells as shown in figure 1.3 (LeBien and 
Tedder 2008).  Plasma cells are responsible for antibody secretion and are 
essential for complement fixation and the removal of viral fragments (Pelanda 
and Torres 2012; Nutt, Hodgkin et al. 2015).  They are functionally distinct 
from the other cell type produced following maturation, expressing a 
CD27+CD138+ phenotype (Caraux, Klein et al. 2010).  Memory B cells are long 
lasting, conferring recognition to a previously exposed antigen for years 
without re-challenge.  Upon re-challenge, the memory cells are able to trigger a 
rapid response through polyclonal activation and mediate their response 
through highly precise IgG and IgA immunoglobulins (Kurosaki, Kometani et al. 
2015). 
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Figure 1.3.  The developmental pathway of B cells.  Activation of B cells occurs in two 
ways:   
Thymus-dependant activation (1) involves the recognition of peptide fragments bound to 
MHCII molecules on APC’s by Th cells, leading to the release of cytokines including IL-4, 
activating B cells.  Independent activation (2) can occur through the cross-linking of 
multiple IgM antigen receptors on the cell surface by the antigen itself.  This can occur 
with antigens such as bacterial polysaccharides.  Following B cell activation, clonal 
proliferation occurs, (3) resulting in the differentiation into either plasma cell or 
memory B cells. This proliferation can occur locally, or in the light zones of germinal 
centres located within the lymph nodes.  Activated B cells can undergo somatic 
hypermutation leading to class switching, involving the rearrangement of heavy chain C 
regions of the Ig molecule. Class switching favours IgG, IgA and IgE over IgM and IgD.  
Antigen specificity is retained, allowing for different immunoglobulins to be produced.  
Plasma cells (4) display high Ig secretion, though they no longer respond to specific Th 
signalling.  Memory B cells (5) are the progeny of the cells produced in the germinal 
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centres and are very long lived.  Specificity gained during the differentiation in the 
germinal centres allows the immune response to be triggered quicker and at lower 
antigenic concentrations when compared to the primary response. 
 
 
These immunoglobulins are targeted to a single antigen through hypervariable 
sections located on the antigen binding site (Litman, Rast et al. 1993).  Antigen-
immunoglobulin binding serves either to inactivate the antigen through steric 
hindrance, or allowing the recognition by effector cells to target the antigen 
and mount a suitable immune response.  This is accomplished through 
activation of the complement system, allowing for recognition by target cells 
such as phagocytes through a process known as opsonisation (Ravetch and 
Bolland 2001; Rus, Cudrici et al. 2005).  Figure 1.4 outlines the maturation of 
B-lymphocytes in the germinal centers. 
These antibodies are either soluble in the plasma of the blood, or bound to the 
B-cell membrane in the form of a B-cell receptor (Borghesi and Milcarek 2006).  
These immunoglobulins are found in five classes; IgA (dimer), IgD (trimer), IgE 
(trimer), IgG (trimer) and IgM (pentamer) (Woof and Burton 2004).  IgM and 
IgD are considered part of the primary immune response, as they are found 
expressed as receptors on the surface of naïve B-lymphocytes (Goding 1978). 
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Figure 1.4.   Germinal Center Activation.  Clonal proliferation is typically observed in 
germinal centers (GC) located in the lymph nodes.  These GC are locations of very high B 
cell proliferation.  Within these centres, two distinct regions can be observed; light and 
dark zones, which are located at opposite poles.  These poles contain two different 
populations of the cells:  centrocytes aggregate in the light zone, while centroblasts are 
present in the dark zone.  The maturing B cells in the centroblasts undergo somatic 
recombination responsible for increasing the specificity of the cells to the antigen, along 
with proliferation.  Centrocytes begin to display surface antibodies and are the sub-
populations that eventually mature into the progeny cells, either memory B cells or 
plasma cells.  These are formed through multiple signalling pathways, two of the most 
critical being BLIMP-1 / PAX-5. BLIMP-1 is known to trigger a halt in cellular 
proliferation.  Co-signalling through the up-regulation of CXCR4 causes cellular 
migration from the germinal centres to the surrounding tissues.  
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1.1.3 CUTANEOUS IMMUNE SYSTEM 
 
The cutaneous immune system is able to be considered a distinct arm in the 
host immunity in its own right.  It provides twofold protection; first, the skin 
itself is a physical barrier preventing pathogens from entering the body.  
Second, it houses several cell lineages that are able to counter challenges from 
invading pathogens (Boguniewicz and Leung 2011).  There are large numbers 
of T-cells present in the skin in the absence of pathogenic challenge, showing 
that this is a major site of action for the lymphocyte-driven immune response.  
Studies have estimated the number of T-cells present in the skin to be between 
4 billion and 20 billion.  T-cells primarily have a memory T-lymphocyte 
phenotype illustrating previous encounter with an antigen (Bos, Zonneveld et 
al. 1987; Bos, Hagenaars et al. 1989; Clark, Chong et al. 2006).  Studies have 
shown the upregulation of Th1, Th2 and Th17 lymphocytes in numerous 
inflammatory skin conditions, though little work has been conducted in 
regards to the newer Th9 and Th22 phenotypes (Di Cesare, Di Meglio et al. 
2008; Di Cesare, Di Meglio et al. 2009).  However, there is evidence that 
keratinocytes can produce IL-23, one of the signals required for differentiation 
into a Th17/Th22 phenotype, potentially implicating these subsets in cutaneous 
reactions (Piskin, Sylva-Steenland et al. 2006).     
In the skin, the primary antigen presenting cells are Langerhans cells, which 
are a subset of dendritic cells.  They fulfil the role of antigen presentation in the 
skin, alongside cutaneous dendritic cells.  They are found in the epidermis and 
are characterised by co-expression of CD207 (langerin) and CD1a (Cella, 
Sallusto et al. 1997; Bursch, Wang et al. 2007).  Langerhans cells migrate to the 
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lymph nodes following antigen exposure, allowing for antigen presentation to 
naïve T-lymphocytes.  They express surface molecules involved in T-
lymphocyte recruitment, activation and inhibition, suggesting an ability to also 
regulate unwanted immune responses (von Bubnoff, Bausinger et al. 2004).  
For example, in models of contact hypersensitivity, Langerhans cells have been 
shown to be involved in the suppression of the immune response (Grabbe, 
Steinbrink et al. 1995). 
Key to the cutaneous immune response is the role of resident memory T-
lymphocytes.  These are lymphocytes that are located within tissue and do not 
migrate around the body, as seen with other memory T-lymphocyte subsets 
such as effector memory (Tem) or circulating memory (Tcm) cells (Heath and 
Carbone 2013; Sathaliyawala, Kubota et al. 2013).   
These tissue resident memory T-lymphocytes (Trm) are located in the skin and 
do not migrate to other areas of the body.  They are generated following initial 
antigenic exposure and remain in the affected site for many years following the 
original challenge, conferring immunity at the site (Masopust, Vezys et al. 
2001; Gebhardt, Wakim et al. 2009).  They are characterised through the 
expression of CD103, CD69 and CD8, though CD4 expressing resident memory 
cells have also been reported (Mackay, Rahimpour et al. 2013; Schenkel, Fraser 
et al. 2014).  Studies have also shown that TGFβ is a critical component of 
maturation and residence in the skin, due to its upregulation of the expression 
of CD103 (Casey, Fraser et al. 2012).  These memory lymphocytes allow for 
rapid response to pathogenic exposure without the need for priming and 
activation by antigen presenting cells in the lymph nodes, allowing for direct 
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action at the site of pathogen exposure.  They have also been shown to be able 
to differentiate in an antigen-independent fashion, suggesting that location 
rather than antigenic signalling is a main driving force behind differentiation 
into a Trm phenotype (Casey, Fraser et al. 2012).   
An integral part of cutaneous lymphocytes is the expression of CLA, with over 
85% of cutaneous inflammatory lymphocytes shown to express this compared 
to approximately 5% of circulating lymphocytes (Picker, Michie et al. 1990; 
Picker, Terstappen et al. 1990).  Elegant work by Clark et al. showed that over 
98% of CLA-expressing T-lymphocytes reside in the skin (Clark, Chong et al. 
2006).  This, in addition to other surface molecules such as CCR4 and CCR10 
are indicators of lymphocyte residence or migration to the skin (Campbell, 
Haraldsen et al. 1999).  CCR10 is of particular interest in cutaneous immunity, 
due to the high expression of its ligand, CCL27, by keratinocytes (Morales, 
Homey et al. 1999). 
Keratinocytes are one of the major cell types present in the skin.  They reside 
in the outermost layer of the epidermis, where they respond to PAMP 
signalling.  Keratinocytes express several PRR that help to initiate an immune 
response upon pathogen exposure (Lebre, van der Aar et al. 2007).  They are 
able to secrete multiple cytokines in response to signalling pathways, including 
TNFα, fibroblast growth factor (FGF) and interleukin-6 (Kupper 1990; 
Teunissen, Bos et al. 1998).  The majority of the cytokines secreted by 
keratinocytes are not constitutively expressed and are pro-inflammatory in 
nature.  However, there is also evidence for the secretion of β-defensins by 
keratinocytes that are involved in anti-microbial defence, as well as insulin-like 
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growth factor (IGF-1), responsible for epidermal maintenance (Seo, Ahn et al. 
2001; Edmondson, Thumiger et al. 2003).  These cytokines also have the ability 
to recruit effector cells, such as neutrophils (Reich, Papp et al. 2015).  
Activation of the keratinocytes via surface expressed triggered TLR often 
promotes a strong Th1 response, providing further evidence for their pro-
inflammatory role in cutaneous immunity (Miller and Modlin 2007).  NK cells 
have also been shown to migrate to inflamed skin via chemokine signalling 
from molecules such as CCL5 and CXCL10, both of which are secreted by 
keratinocytes (Ottaviani, Nasorri et al. 2006).   
 
1.1.4 CYTOKINES: PRODUCTION, RECEPTORS AND FUNCTION 
 
Cytokines are small molecular weight proteins that are integral in cell 
signalling, proliferation and maturation of other cells.  They can also act on 
themselves (autocrine signalling) or on cells adjacent to them (paracrine 
signalling), in addition to other more distant locations (Sriuranpong, Park et al. 
2003).  They are produced from a milieu of cell types including both T- and B-
lymphocytes, as well as others such as macrophages and NK cells.  Cytokines 
elicit their function through interaction with receptors located on immune and 
tissue cells (Stamenkovic, Clark et al. 1989; Fiorentino, Zlotnik et al. 1991; 
Street and Mosmann 1991; Fehniger, Shah et al. 1999).   
Th1 cytokines are perceived to be pro-inflammatory in nature and exert their 
effects via the triggering of cellular immune responses.  These cytokines 
include both TNFα and interferon-γ.  Th2 cytokines are more modulatory, with 
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both pro-and anti-inflammatory cytokines found in this class.  They are 
involved in the induction of an antibody-mediated responses and include 
cytokines such as interleukin-4, interleukin-13 and TGFβ (Lucey, Clerici et al. 
1996; Marzi, Vigano et al. 1996; Hoffmann, Cheever et al. 2000). 
There are well over 100 different cytokines that have been characterised – 
though for the remainder of this section two will be focused on for; the pro-
inflammatory cytokine interferon-γ, and the more recently identified 
interleukin-22.  Interferon-γ is classified as a type 2 interferon, sharing little 
structural homology with other interferons, as well as being coded by a 
different chromosomal locus.  It is coded for by the IFNG gene located on 
chromosome 12 (Naylor, Sakaguchi et al. 1983).  Interleukin-22 is part of the 
IL-20 subfamily of cytokines, involved in both pro- and anti-inflammatory 
responses (Sa, Valdez et al. 2007).  These cytokines have been chosen due to 
IFN-γ being the most widely studies pro-inflammatory cytokine produced in 
response to a wide range of stimulation, as well as IL-22 being indicated in 
cutaneous reactions. 
 
1.1.4.1 PRODUCTION 
 
These cytokines are produced from multiple cell types, chiefly in response to 
signals from other cytokines acting upon specific receptors.  Interferon-γ is 
secreted from NK T-lymphocytes, B-lymphocytes and dendritic cells, as well as 
CD4+ and CD8+ T-lymphocytes.  It is produced as a result of cytokines that 
originate from professional antigen presenting cells – chiefly as a result of 
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signalling by interleukin-12 and interleukin-18.  Interleukin-12 is known to 
polarise naïve T-lymphocytes towards the inflammatory Th1 phenotype.  In 
addition, pathogen recognition by macrophages serves to induce a strong IL-12 
secretory response, leading to the recruitment of NK T-lymphocytes and 
interferon-γ secretion.  The active molecule itself is a dimer formed from two 
monomeric structures of the IFN molecule (Ying, Durham et al. 1995; DeMarco, 
Fink et al. 2005; Chan, Crafton et al. 2006).   
Interleukin-22 is secreted from Th17 and Th22 lymphocytes, NK cells and 
fibroblasts (Wolk and Sabat 2006).  Its production is induced by secretion of 
interleukin-23 and interleukin-1β from activated dendritic cells (Satpathy, 
Briseno et al. 2013), as well as through presentation of lipid antigens in the 
skin by Langerhans cells via a CD1a restricted pathway (Colonna 2010).  The 
aryl hydrocarbon receptor, a transcription factor, is integral to the generation 
of interleukin-22 (Esser, Rannug et al. 2009). 
 
1.1.4.2 RECEPTORS 
 
As previously stated, cytokines exert their functions through interactions with 
specific receptors located on target cells.  Cytokine binding induces a 
downstream signalling pathway that triggers altered gene regulation in the 
nucleus of target cells, leading to altered protein synthesis.  Signalling through 
the cytokine receptors occurs through a JAK/STAT mediated pathway, which 
can lead to either genetic regulation directly, or the activation of the caspase 
pathway.  The latter pathway results in activation of the caspase-dependant 
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apoptosis pathway through upregulation of caspase 9 (Darnell, Kerr et al. 
1994; Cardone, Roy et al. 1998; Rawlings, Rosler et al. 2004).   
The interferon-γ receptor is heterodimeric, comprising of two chains involved 
in ligand binding (IFNGR1) and signal transducing (IFNGR2).  The IFNGR2 
chain is constitutively expressed throughout cell phenotypes, with regulation 
of this signalling chain responsible for the modulation of interferon-γ through 
differential expression (Park-Min, Serbina et al. 2007).  Th1 cells have low 
levels of this chain, while Th2 cells express it in large amounts.  However, the 
presence of IFNγ leads to Th1 activation, while conversely inhibiting Th2 cells.  
This explains the pro-inflammatory phenotype shift that is observed in the 
presence of interferon-γ, in addition to providing a positive feedback loop to 
upregulate cytotoxic cell proliferation in response to infection.  Signalling 
occurs through phosphorylation of the JAK1-STAT1 pathway, resulting in the 
binding of STAT1 to promoter genes, regulating IFNγ gene expression (Gough, 
Levy et al. 2008). 
Interleukin-22’s receptor comprised of a heterodimer consisting of an IL22RA1 
and an IL10RB subunit.  Though the IL10RB monomer is found throughout the 
body on a wide range of cell types, the IL22RA1 subunit is only expressed on 
tissues such as the endothelium and skin.  This provides a basis for the 
hypothesis for interleukin-22 to be involved in cutaneous immune responses 
(Kotenko, Izotova et al. 2001).  Interestingly, a soluble inhibitor of interleukin-
22’s function, the IL-22 binding protein (IL-22BP/IL22RA2) has also been 
identified.  It shows homology with the IL22RA1 monomer found in the 
receptor of the cytokine (Kotenko, Izotova et al. 2001).  This homology and 
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opposing effects could explain the paradoxical physiological / toxicological 
actions of interleukin-22.  Similar to interferon-γ, signalling via the IL-22 
receptor occurs through the JAK/STAT pathway, through phosphorylation 
cascades (Lejeune, Dumoutier et al. 2002).  In addition, interleukin-22 also 
triggers ERK and MAPK signalling in endothelial cells (Ouyang, Rutz et al. 
2011).  In contrast to the IFNγ pathway, is the fact that activation of the IL-22 
receptor causes a negative feedback loop to be instigated (Wolk, Witte et al. 
2010).  One of the downstream effects following IL-22 signalling is the 
degradation of the IL22RA1 monomer, preventing a recursive loop of 
activation through reduction of active receptors (Weathington, Snavely et al. 
2014). 
 
1.1.4.3 FUNCTION 
 
Cytokine functions vary from activation of both the innate and adaptive 
immune response, to gene regulation through nuclear receptors.  IFNγ has 
been shown to have both immunomodulatory and stimulatory effects, as well 
as being able to directly act to inhibit viral replication (Flynn, Chan et al. 1993).  
It triggers the upregulation of MHC class I molecules on the surface of antigen 
presenting cells allowing for greater recognition of peptide fragments in 
response to intracellular pathogens (Yang, Xiang et al. 1995).  In addition, IFNγ 
acts to induce the TAP transporter, integral to peptide transport and loading in 
the lumen of the endoplasmic reticulum (York and Rock 1996).  Expression of 
multiple genes are altered by IFNγ, for example CXCL9 (upregulation, T-
lymphocyte chemoattractant), IRF1 (upregulation, apoptosis mediator), PKR 
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(upregulation, anti-viral enzyme) and c-myc (downregulation, cell cycle) 
(Takizawa, Ohashi et al. 1996; Taniguchi, Lamphier et al. 1997; Obaya, Mateyak 
et al. 1999; Gil, Bohn et al. 2001).  The synergistic effect of IL-18 and IL-12 in 
the induction of a Th1 mediated response is integral to its role in the response 
to an intracellular pathogen, and the resulting pro-inflammatory phenotype 
that is observed (Dinarello, Novick et al. 1998). 
The overall function of IL-22 is not fully elucidated.  It is produced primarily 
from T-lymphocytes such as NK cells, as well as both CD4+ and CD8+ T-cells 
(Zheng, Danilenko et al. 2007; Spits, Artis et al. 2013).  Interleukin-22 is 
thought to be involved in the defence against extracellular pathogens, as well 
as maintenance of homeostasis in tissues (Sonnenberg, Fouser et al. 2011; 
Rutz, Eidenschenk et al. 2013; Zenewicz, Yin et al. 2013).  These protective 
functions have been outlined in both the intestine and lungs, though 
expression of the IL-22 receptor suggests this protective function could extend 
to other tissues.  In addition, fibroblasts increase protease production 
following IL-22 stimulation, leading to wound repair (McGee, Schmidt et al. 
2013).  However, studies have also looked at the pathogenic role of 
interleukin-22 in multiple diseases.  Over expression of IL-22 has been 
implicated in conditions such as psoriasis, rheumatoid arthritis and enthesitis 
(Wolk, Haugen et al. 2009; Sherlock, Joyce-Shaikh et al. 2012; Zhang, Li et al. 
2012).  Though there is evidence for the pro-inflammatory nature of 
interleukin-22 signalling, these are predominately tied to pathogenic 
conditions.  The majority of the characterised functions of IL-22 seem to be 
protective in nature, such as the association between IL-22 expression and 
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liver function protection through STAT3 signalling (Hanash, Dudakov et al. 
2012).   
The wide effects of cytokines produced by immune cells are part of complex 
signalling pathways that modulate a variety of downstream effects to promote 
immune responses against invading pathogens.  However, uncontrolled 
cytokine production may promote autoimmune diseases in susceptible 
individuals. 
  
 36 
 
1.2 DRUG METABOLISM 
 
Drug metabolism has been a term used since the 1950’s to describe the 
biomedical modification of xenobiotics by specialised enzyme systems.  Drug 
metabolites are eventually removed from the body through either biliary or 
renal excretion.  Most drugs are highly lipophilic and as such poorly excreted.  
To counteract this, metabolism occurs which transforms the drugs into more 
water soluble compounds allowing for simpler excretion.  The primary site of 
drug metabolism is the liver, evidence for localised metabolism being involved 
in the progression of hypersensitivity reactions has been hypothesised (Ju and 
Uetrecht 1999; Oesch, Fabian et al. 2007).  Metabolism of drugs can lead to the 
formation reactive metabolites that bind covalently to protein to generate the 
antigen which can be recognised by the immune system (Lavergne, Park et al. 
2008). 
Sulfamethoxazole is used to treat infections in patients with cystic fibrosis and 
HIV.  Pichler and Tilch cloned T-cells from SMX hypersensitive patients, with 
the parent drug found to activate both CD4+ and CD8+ proliferative responses 
and cytokine secretion (Pichler and Tilch 2004).  Importantly, PBMC from 
hypersensitive patients are also activated by a metabolite, SMX-NO.  It can 
mimic the action of the parent drug (or vice versa) by binding directly to MHC 
binding peptides to activate CD4+ and CD8+ T-cells (Mauri-Hellweg, Bettens et 
al. 1995; Schnyder, Mauri-Hellweg et al. 1997). 
As a result of the potential involvement of reactive metabolites in drug 
hypersensitivity a number of drugs are withdrawn from use after initial 
greenlighting by the medical community.  Although this may prevent 
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unforeseen harmful side effects and save the pharmaceutical industry 
hundreds of millions of pounds, it prevents a more detailed understanding of 
the role of metabolism in hypersensitivity reactions. 
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1.2.1 DRUG METABOLISING ENZYMES 
 
The majority of drug metabolism (upwards of 95%) occurs in the liver 
(Uetrecht and Naisbitt 2013).  However, other locations are involved in 
metabolism of drugs, including immune cells, which have been shown to 
express low levels of cytochrome P450 enzymes.  Furthermore, skin expresses 
its own compliment of drug metabolising enzymes which can selectively 
metabolise certain drugs (Swanson 2004). 
Enzymes responsible for drug metabolism are classified into two categories: 
microsomal and non-microsomal.  Microsomal enzymes are located in the 
smooth endoplasmic reticulum of tissues, and can be induced by certain drugs, 
such as rifampicin and alcohol (Madan, Graham et al. 2003).  This class of 
enzymes contains the commonly expressed P450 enzymes, as well as others 
such as epoxide hydrolases and uridine diphospho-glucuronosyltransferase.  
Non-microsomal enzymes are located in the cytoplasm.  These are non-
inducible and are generally involved in conjugation reactions, such as in the 
case of esterases.  Metabolism generally occurs in two steps, phase I, followed 
by phase II metabolism.  This sequential metabolism was first put forward in 
1983, and is explained in greater detail below (Neuberger and Smith 1983). 
 
1.2.2 PHASE I METABOLISM 
 
The two most important families of phase I metabolising enzymes are the 
cytochrome P450 enzymes and the flavin-containing monooxygenases (FMO).  
Typically, the end result of phase I metabolism is to attach small functional 
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groups such as sulfhydryls (-SH), hydroxyls (-OH) or carboxyls (-COOH) to the 
parent compound.  These functional groups serve to make the overall structure 
more polar, allowing for conjugation via phase II enzymes (Park, Pirmohamed 
et al. 1992; Pirmohamed, Madden et al. 1996; Stachulski and Lennard 2000). 
Cytochrome P450 enzymes are a large superfamily of enzymes located in the 
endoplasmic reticulum of tissues, predominantly the liver.  This superfamily is 
responsible for three quarters of all metabolism that occurs throughout the 
human body (Berka, Hendrychová et al. 2011).  The primary transformation 
that is catalysed by the P450 family is oxidation (Werck-Reichhart and 
Feyereisen 2000).  Over 50 distinct P450 enzymes have been identified, though 
only a fifth are involved in drug metabolism to any significant degree.  The CYP 
superfamily are polymorphically expressed, with different isoforms of the 
enzymes directly responsible for altered metabolic activity of specific 
compounds.  Examples of this include the CYP2D6 family and their role in 
antipsychotic drug metabolism, as well as CYP3A5 polymorphisms (Gillam, 
Guo et al. 1995; Hustert, Haberl et al. 2001)  Some treatments and drugs are 
contra-indicated in patients known to express certain gene polymorphisms. 
The major CYP superfamily consists of 3 sections, with a total of 8 subclasses 
(CYP1A, CYP1B, CYP2A, CYP2B, CYP2C, CYP2D, CYP2E and CYP3A).  These 
enzyme families account for 95% of all drug metabolism through the CYP 
pathway, with CYP3A4 and CYP2D6 alone responsible for over half of the drug 
metabolism (Wilkinson 2005).   
FMO’s are the other major enzyme involved in phase I metabolism, involved in 
both NADPH-dependent oxidation and reactive intermediate generation.  
There are 5 subclasses of FMO’s, labelled FMO1-5.  They are known to play a 
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role in the metabolism of drugs; FMO1 is involved in sulfamethoxazole 
metabolism and FMO3 is involved in tamoxifen metabolism (Krueger, VanDyke 
et al. 2006; Vyas, Roychowdhury et al. 2006).  Like CYP enzymes, the FMO’s are 
located in the endoplasmic reticulum, and often work in concert with the CYP 
enzymes for drug detoxification.  
 
1.2.3 PHASE II METABOLISM 
 
Phase II metabolism acts upon the newly acquired functional groups that were 
added to drugs during the functionalisation process that occurred through 
phase I metabolism.  The goal of phase II conjugation reactions is to increase 
the molecular weight and assist excretion of the product.  Though the majority 
of compounds undergo both phase I and II metabolism, there are cases where 
conjugation can occur directly without the need for functionalisation 
(Kassahun, Mattiuz et al. 1997).  Typical conjugates include glutathione 
(conjugating with the reactive intermediate NAPQI) or glycine.  A number of 
transferases are involved in the conjugation to less toxic compounds, such as 
the glutathione-s-transferases (Hayes, Flanagan et al. 2005; Perricone, De 
Carolis et al. 2009). 
 
1.2.4 GENETIC POLYMORPHISMS 
 
Allelic variance and single nucleotide polymorphisms lead to inter-individual 
variations in drug metabolism.  Identification of polymorphic enzymes 
involved in the metabolism of drugs associated with hypersensitivity could 
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explain the idiosyncratic nature of the reactions.  Metabolism is rarely either 
‘on’ or ‘off’; rather, a sliding scale of fast and slow metabolisers (Holstein, 
Plaschke et al. 2005; Kirchmair, Williamson et al. 2013).  Despite this, it is still 
unclear how variable metabolic rates impact on the development of 
hypersensitivity.   
As individuals are exposed to different amount of potentially toxic metabolites 
through the metabolic variability, there is the potential for increased danger 
signals to be presented to the immune system.  If an individual was a poor 
metaboliser of an allergenic drug, this would lead to increased T-lymphocyte 
activation due to a more favourable environment for T-cell priming.   
One of the most widely studied compounds in relation to metabolic variability 
is the sulphonamide sulfamethoxazole.  Both the parent compound and the 
metabolite sulfamethoxazole-nitroso are detoxified through the NAT1 and 
NAT2 enzymes.  Poor metabolism of these compounds has been linked with an 
increase in hypersensitivity reactions (Pirmohamed, Alfirevic et al. 2000).  This 
is shown to be directly related to the metabolic activity of the NAT2 enzyme.  
However, no significant associations were found between phenotype and 
hypersensitivity prevalence of the NAT or CYP2C9 (the enzyme involved in the 
formation of SMX-NO) following analysis in a HIV-positive cohort (Rieder, 
Shear et al. 1991; Pirmohamed, Alfirevic et al. 2000).  These data suggest that 
there are multiple determining factors in the development of hypersensitivity.  
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1.3 MECHANISMS OF LYMPHOCYTE ACTIVATION 
 
To understand mechanisms of immune cell activation, a number of terms must 
be defined.  First, an immunogen is any substance that ‘triggers an immune 
response’; secondly, a hapten is ‘a low molecular weight compound capable of 
irreversibly modifying macromolecules’; and finally an antigen is something 
that ‘binds with high affinity to immunological receptors’ (Uetrecht and 
Naisbitt 2013).  These terms are used consistently throughout this thesis. 
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1.3.1 ANTIGENIC STIMULATION OF T-LYMPHOCYTES: TCR ACTIVATION, 
SIGNAL 1, 2, + 3 
 
Activation of T-lymphocytes requires three signals from an antigen presenting 
cell, with the different signals termed 1, 2 and 3.  Firstly, signal 1 is provided 
through the interaction between a peptide-MHC complex and the appropriate 
TCR.  Triggering the TCR is critical for T-cell activation.  However, in the 
absence of other signals the T-cell will be tolerised and become anergic.  Full 
activation only occurs when a co-stimulatory signal, also known as signal 2, is 
present.  Co-stimulatory signals are antigen non-specific, yet are essential for 
full activation.  This involves a complex interplay of co-stimulatory and co-
inhibitory signals, where activation only occurs when the co-stimulatory 
signals predominate.  Signal 3 describes the cytokines released from antigen 
presenting cells following antigen uptake.  Though not essential for T-
lymphocyte activation, signal 3 is critical to fully design the nature of the 
cellular immune response (Curtsinger, Schmidt et al. 1999).   
Displayed on the surface of cells, MHC I and MHC II exist to display peptide 
fragments on the cell surface and allow recognition by T-lymphocytes.  Both 
MHC I and MHC II are similar in structure. However, they differ markedly in the 
pathway of antigen presentation, and the peptides that interact with the 
peptide binding groove.  MHC I molecules are expressed on all nucleated cells 
and serve to present peptides of an intracellular origin to CD8+ T-lymphocytes.  
These MHC class I molecules are assembled through interactions between the 
MHC class I heavy chain (45 kDa) and a chaperone protein calnexin in the 
endoplasmic reticulum.  Further incorporation of β2 microglobulin (12 kDa) 
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leads to the formation of the peptide loading complex (Heemels and Ploegh 
1995).  This can then associate with the proteins TAP1 and TAP2 
(Transporters associated with Antigen Presentation), allowing for 
incorporation of processed peptide fragments (between 8-10 amino acids in 
length) located in the cytosol into the fully formed MHC class I molecule.  These 
TAP proteins are located exclusively in the membrane of the ER and in the cis-
golgi complex, with their main function to transport intracellular peptide 
fragments for antigen presentation.  As members of the ABC transporter 
family, they are activated through ATP-dependent binding (Ortmann, 
Androlewicz et al. 1994).  Once a bound peptide is incorporated into the MHC 
class I molecule located in the membrane of the endoplasmic reticulum (ER), it 
then dissociates from the ER and is transported via the golgi apparatus to the 
surface of the cell for CD8+ T-cell recognition.  Peptide presentation occurs on 
the extracellular portion of the MHC, with the α1 and α2 subunits forming the 
peptide binding site.  This binding site is involved in direct interactions with 
the T-cell receptor, while the α3 subunit interacts with the CD8 molecule that 
is co-expressed on the T-cell.  Multiple pockets are located in the peptide 
binding groove, termed A-F, which can incorporate bulky side chains of certain 
amino acids in the presented peptide fragments.  These pockets also act to 
anchor the peptide in the binding site, through hydrophobic interactions 
between the amino acids on the peptide and the binding groove (Madden, 
Gorga et al. 1992).  Both the A and F pocket are known to show conserved 
structures – 95% of amino acids present in the F pocket are one of 7 different 
AA (Elvin, Potter et al. 1993).   
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Figure 1.5.  Mechanisms of antigen processing and presentation.   
Class I – Intracellular antigens are processed into peptide fragments by the proteasome.  
These fragments are then transported inside the endoplasmic reticulum via the TAP 
transporter, then loaded onto the MHC I molecules present there.  These MHC I molecules 
then is transported via the golgi complex to the cell surface via vesicles, where it is 
expressed and able to interact extracellularly with CD8+ T-lymphocytes. 
Class II – Extracellular antigens are phagocytosed into the cell, then processed in the 
phagosome to form peptide fragments.  These fragments are then carried in the 
endosome to a lysosome.  MHC class II molecules bound to a stabilising Li chain 
dissociate from the endoplasmic reticulum and transport to the lysosomes via the golgi.  
Once in the lysosome, the Li chain is degraded by proteases.  Additionally, the CLiP 
dissociates from the MHC II molecule, allowing for peptide loading and presentation.  
These lysosomes then transport the MHC II molecules to the cell surface for presentation 
to CD4+ T-lymphocytes.  
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MHC II binds to peptides originating from the extracellular environment.  
These peptides are formed through the phagocytosis of extracellular proteins 
through the interaction of lysosomes.  Taken up from the extracellular space, 
antigens are degraded as a result of the vesicle pH.  These lysosomes contain 
enzymes which are involved in the antigen processing pathway.  Vesicles 
containing the processed peptides then fuse with other vesicles containing the 
unbound MHC class II molecules, allowing for antigen binding and migration to 
the surface of the cell.  Antigen binding to the MHC class II molecule is 
mediated through the actions of the Class II associated invariant chain (CLiP) 
peptide.  This peptide is situated in the peptide binding groove, halting other 
peptide presentation.  Removal of the CLiP peptide is regulated through HLA-
DM binding, allowing for exogenous peptide loading and presentation 
(Santambrogio, Sato et al. 1999; Thayer, Ignatowicz et al. 1999).   
Peptides derived from processed proteins eventually activate CD4+ T-
lymphocytes.  MHC II molecules are found on the surface of antigen presenting 
cells and contain two glycoprotein subunits – the α and β chains.  Expression 
can be up-regulated following inflammation and exposure to other co-
stimulatory ligands.  MHC classes are further subdivided, with MHC I 
containing HLA-A, HLA-B and HLA-C structures, while MHC II contains HLA-DP, 
HLA-DQ and HLA-DR (Denzin and Cresswell 1995).  In most cases professional 
antigen presenting cells such as dendritic cells express MHC class I and II and 
are involved in antigen presentation.  Other cells such as B-lymphocytes and 
macrophages also express MHC class I and II.  In contrast, most tissue cells 
express MHC class I – but not MHC class II (Ting and Trowsdale 2002).  MHC 
presentation is summarised in figure 1.5. 
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Antigen presentation can also occur via an alternate mechanism.  Cross-
presentation is integral to the recruitment of CD8+ T-lymphocytes in the 
response to extracellular antigens and involves presentation on MHC I 
molecules via a subclass of dendritic cells (Joffre, Segura et al. 2012). 
While MHC class I are known to present small peptide fragments between 8-10 
amino acids, MHC class II are able to present larger fragments of 12-25.  These 
peptides interact with grooves inside the MHC structure prior to translocation 
of the MHC molecule to the plasma membrane for antigen presentation.  MHC 
binding involves a complex array of Van der Waals interactions as well as 
specific hydrogen bonds.  In the MHC class I, peptide 5 is integral to successful 
binding in the TCR/peptide complex (Rudolph and Wilson 2002).  MHC class II 
binding is less dependent on peptide interactions, with the antigenic binding 
groove more open when compared to MHC class I.  It is because of this that the 
MHC class II are able to present more complex, longer peptide fragments 
(Neefjes and Ovaa 2013). 
Following successful MHC-TCR interactions, downstream signalling is initiated.  
This leads to proliferation of the T-lymphocytes and regulation of cytokine 
secretion.  CD4 / CD8 co-receptors are expressed on the T-cell surface, leading 
to TCR clustering and eventual activation.  TCR phosphorylation by Lck leads to 
the recruitment of Zap-70, the main signalling pathway in T-cell activation.  
This in turn phosphorylates other molecules including LAT, leading to a 
signalling cascade through the LAT signalosome (Smith-Garvin, Koretzky et al. 
2009).   Release of inositol triphosphate (IP3) and diacylglycerol (DAG) follow, 
with resulting MEK/ERK signalling from DAG through the Ras protein leading 
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to CD69 upregulation on the cell surface, a hallmark of cell activation 
(D'Ambrosio, Cantrell et al. 1994).  IP3 signals lead to the release of stored 
Ca2+ from the endoplasmic reticulum.  This influx is critical in the initiation of 
cellular production of interleukin-2, needed for continued lymphocyte survival 
(Liu, Bunnell et al. 1998). 
Co-signalling pathways are also essential for the modulation of T-cell 
activation.  If Signal 1 is present along co-stimulatory signal 2, then activation 
will occur.  However, if a co-inhibitory signal 2 dominates then it will lead to 
cellular anergy and tolerance (Sharpe and Abbas 2006).  In addition, it has 
been shown that co-signalling pathways are able to modulate and even prevent 
the differentiation of T-lymphocytes into subsets, such as Th1 and Th17 (Mizui, 
Shikina et al. 2008). 
A well characterised signal 2 pathway involves the activation CD28, expressed 
on T-lymphocytes, and its ligands CD80 and CD86 expressed on the surface of 
antigen presenting cells.  Early modulation of the signal 2 pathways looked at 
this interaction, with inhibition of CD28 shown to induce T-cell anergy 
(Harding, McArthur et al. 1992).  CD80/CD86 are expressed solely on activated 
antigen presenting cells, providing a checkpoint for autoimmunity (Chen and 
Flies 2013).  This CD28 – CD80/CD86 interaction was shown to be a co-
stimulatory signal, through its activation of phosphokinase C (PKC), triggering 
the production of interleukin-2 through signalling via NFAT (Acuto and Michel 
2003). 
Multiple co-inhibitory signalling pathways have recently been identified. 
Programmed death-1 (PD-1) interacts with its ligand PD-L1 and is a key 
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regulator of T-cell inhibition.  It is widely expressed on a variety of cell types 
and has been shown to regulate autoimmunity (Nishimura, Nose et al. 1999).  
The receptor is only expressed on active cells, with the ligands induced by pro-
inflammatory mediators such as IFNγ and GM-CSF (Keir, Freeman et al. 2007).  
Activation of the receptor leads to the recruitment of SHP-1 and SHP-2 
proteins, which in turn act to dephosphorylate Zap-70, causing inactivation of 
the lymphocyte through a cessation of the signalling pathway (Sheppard, Fitz 
et al. 2004). 
Other co-inhibitory pathways are also beginning to be elucidated, all as a 
component of a complex signalling cascade as outlined in the comprehensive 
review by Chen and Flies (Chen and Flies 2013).  It is important to note that 
the signalling pathways here, such as CTLA4 and TIM-3, work in concert with 
each other to provide an overall response in T-lymphocyte activation or 
inhibition. 
Signal 3 is a much less defined pathway, mediated through the action of 
cytokines released by dendritic cells.  Naïve lymphocytes that are activated in 
the absence of signal 3 cytokines show poor viability and effector function 
(Mescher, Curtsinger et al. 2006).  As the naïve lymphocytes are only 
responding to peptide fragments, rather than the whole antigen itself, it is 
interesting to note that specific antigen targeting responses are mounted by 
the differentiated lymphocytes.  These lymphocytes have never encountered 
the original antigen, so it is reasonable to assume that the final activation 
signal comes from the dendritic cells themselves (Curtsinger and Mescher 
2010).  These polarising signals come in the form of cytokines secreted from 
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the dendritic cells located at the site of antigenic encounter (Kalinski, Hilkens 
et al. 1999).  The full complement of polarising cytokines needed to drive the 
differentiation into effector and helper T-lymphocyte subsets have already 
been explained in section 1.1.2.2, but are also summarised below in figure 1.6. 
 
Naïve T-lymphocyte Polarisation 
Terminal Differentiation Polarising Conditions Transcription Factor 
Th1 IL-2, IL-12 T-bet / STAT4 
Th2 IL-2, IL-4 GATA3 / STAT5 
Th9 TGFβ, IL-4, IL-9 PU.1 
Th17 TGFβ, IL-1β, IL-6, IL-21, RORγt 
Th22 IL-6, TNFα AhR 
Tfh IL-21, CD278 Bcl-6 
 
Figure 1.6  Polarising conditions for naïve T-lymphocyte differentiation.  Different 
helper T-lymphocyte subsets can be polarised based on the cytokine milieu that is 
present signalling to the naïve lymphocytes.  The polarising cytokines are listed for each 
T-helper subset, with the master transcription factor also noted for each case. 
 
1.3.2 HLA POLYMORPHISMS 
 
Human leukocyte antigen (HLA) alleles that code for MHC proteins are a key 
component of variable presentation of peptides to circulating T-lymphocytes.  
These alleles are contained in the HLA gene complex, located on chromosome 
6, with approximately 3x106 base pairs in this region.  It is the most 
polymorphic gene region in the entirety of the human genome (Parham and 
Ohta 1996). 
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These polymorphisms are one of the key driving factors behind the 
development of hypersensitivity reactions to drugs.  This genetic linkage was 
first hypothesised in 1999, with carbamazepine hypersensitivity identified in a 
pair of monozygotic twins (Edwards, Hubbard et al. 1999).   Following on from 
this, other HLA polymorphisms have been associated with drug induced 
hypersensitivity, the most extensively studied being abacavir – HLA-B*5701 
linkage, which now precludes individuals with this HLA phenotype from being 
treated with the compound (Mallal, Nolan et al. 2002; Mallal, Phillips et al. 
2008).  Only in cases where a patient’s genotype is known to be HLA-B*5701 
negative will abacavir treatment be implemented (Martin, Klein et al. 2012). 
Carbamazepine is the only other drug aside from abacavir to require HLA 
genotyping prior to treatment, due to its strong association with HLA-B*1502 
in a Han Chinese population.  Similar to abacavir, it has a strong specificity and 
sensitivity for individuals with this genotype (Chung, Hung et al. 2004).  Both 
carbamazepine and abacavir CD8+ T-cell responses are restricted to the risk 
allele, with no cross-reactivity with other alleles observed. 
Multiple other HLA associations have been reported with different drugs 
(figure 1.7), however their low predictive values make genetic screening for 
these polymorphisms unrealistically expensive to prevent hypersensitivity.  
For example, HLA-B*5701 is also associated with development of flucloxacillin 
hypersensitivity (Daly, Donaldson et al. 2009).  However, only around 1 in 
1000 individuals with this HLA allele will go on to develop flucloxacillin 
hypersensitivity (Andrews, Armstrong et al. 2010).  Additionally, flucloxacillin 
is known to share sequence homology with other HLA alleles, including HLA-
B*5801.  This homology manifests in the ability of flucloxacillin-specific T-
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lymphocytes being restricted primarily to HLA-B*5701, but also HLA-B*5801 
to a lesser degree (Monshi, Faulkner et al. 2013).  Other polymorphisms that 
have been implicated in drug hypersensitivity include lumiracoxib – HLA-
DRB1*1501, allopurinol – HLA-B*5801 and nevirapine – HLA-B*3505 (Chung, 
Hung et al. 2007; Chantarangsu, Mushiroda et al. 2009; Tassaneeyakul, 
Jantararoungtong et al. 2009; Singer, Lewitzky et al. 2010).  Multiple 
mechanisms have been proposed to explain how drugs are able to activate T-
lymphocytes.  These are discussed in greater detail below. 
 
HLA Class Drug Association Adverse Event 
Class I Association 
Abacavir B*57:01 AHS 
Allopurinol B*58:01 HSS / SJS / TEN 
Carbamazepine 
A*31:01 
B*15:02 
SJS / TEN 
Co-Amoxiclav 
A*02:01 
B*07:02 
DILI 
Flucloxacillin B*57:01 DILI 
Nevirapine 
B*35:05 Cutaneous 
Reactions 
Class II 
Association 
Aspirin DPB1*03:01 Asthma 
Co-Amoxiclav 
DRB1*15:01 
DQB1*06:02 
DILI 
Lumiracoxib 
DRB1*15:01 
DQB1*06:02 
DRB5*01:01 
DQA1*01:02 
DILI 
Hepatic Failure 
Nevirapine 
Cw4 Cutaneous 
Reactions 
NSAIDs 
DR11 Cutaneous 
Reactions 
Ximelagatran 
DRB1*07 
DQA1*02 
DILI 
 
Figure 1.7.  Genetic associations with drugs known to cause adverse reactions in 
humans.  Class I and class II associations have been observed in multiple drugs with 
varying odds ratios.  Certain compounds have been shown to have more than one 
association, such as the multiple HLA-D alleles with lumiracoxib, or both class I and II 
associations, such as nevirapine.  Multiple adverse reactions have been reported as a 
result of individuals with these alleles being administered the compound. 
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1.3.3 HAPTEN HYPOTHESIS 
 
The hapten hypothesis originating from the 1930s is the oldest recognised 
model for explaining the chemical basis of drug hypersensitivity.  Landsteiner 
and Jacobs’ seminal work in 1935 utilised the model hapten 
dinitrochlorobenzene (DNCB) to explore the effect of chemical exposure on the 
sensitisation of guinea pigs (Landsteiner and Jacobs 1935).  Their data 
suggested that the chemical reactivity of DNCB and more specifically the 
modification of proteins, via attacking specific nucleophilic amino acid residues 
led to an antigen specific immune response.  Studies conducted in subsequent 
years support the original hapten concept and show that the potential of a 
chemical to activate lymphocytes relates directly to the reactivity of low 
molecular weight compounds (Kitteringham, Maggs et al. 1985; Pickard, Smith 
et al. 2007).  Critical to the hapten hypothesis is the concept that the 
administered chemical itself is initially a non-immunogenic compound – the 
lymphocyte response is only observed once the chemical is bound covalently to 
a protein – this protein conjugate may then be immunogenic, with the ultimate 
antigen being peptides derived from the processed conjugate.  Many drugs are 
administered as inert compounds, which are only able to form protein 
conjugates following metabolism; these compounds are termed pro-haptens 
(Naisbitt, Williams et al. 2001; Posadas and Pichler 2007). 
Investigations into specific locations of protein binding have shown distinct 
areas of interactions, with electrophilic locations on the compounds and 
nucleophilic residues on proteins integral to the lymphocyte activation, 
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confirming Landsteiner’s hypothesis put forward in 1936 (Chipinda, Ajibola et 
al. 2010). 
Work conducted by Weltzien’s group showed that penicilloyl peptide epitopes 
designed to bind to specific MHC class II molecules were able to be recognised 
and trigger an antigen specific response in a classical hapten mechanism from 
antigen-specific T-cells (Padovan, Bauer et al. 1997).  This, as well as the ability 
of metal ions to interact with autologous proteins, was eloquently reviewed by 
Martin, showing that hapten mediated lymphocyte responses were critical to 
allergic diseases caused by low molecular weight compounds (Martin 2004). 
Recent studies using cloned T-lymphocytes reveal that lymphocyte responses 
develop in one of two ways; either through direct modification of peptides 
embedded in surface MHC molecules by the low molecular weight compound 
itself (processing independent) or through the formation of a protein 
conjugate which is encountered, phagocytosed and processed via antigen 
presenting cells, which in turn present the MHC bound peptide antigen to the 
T-lymphocytes (Whitaker, Meng et al. 2011; El-Ghaiesh, Monshi et al. 2012; 
Jenkins, Yaseen et al. 2013; Yaseen, Saide et al. 2015). 
Drug metabolites have been linked to several forms of idiosyncratic drug 
reaction, with an increased level of reactive metabolite thought to correlate 
with increased risk of an adverse drug reaction (ADR) (Nakayama, Atsumi et al. 
2009).  However, other studies have shown that certain drugs are associated 
with a high incidence of ADRs yet no reactive drug metabolites are formed 
during administration, such as in the case of ximelagatran, so the role of 
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reactive drug metabolites in idiosyncratic drug reactions is still not fully 
elucidated (Uetrecht 2008).   
 
1.3.4 ALTERED SELF PEPTIDE REPERTOIRE 
 
Recent research has highlighted the fact that a section of the MHC gene plays a 
major role in the development of drug hypersensitivity.  These human 
leukocyte antigen alleles are highly heterogeneous coding regions involved in 
the presentation to TCR of peptides via the MHC molecules (Madden, Garboczi 
et al. 1993).  A strong association between abacavir and HLA-B*5701 was 
elucidated by Mallal in 2002.  Subsequently, abacavir has been used to study 
drug-specific T-cell responses and the results obtained led to the development 
of the altered self-peptide hypothesis (Mallal, Nolan et al. 2002).  This theory 
works on the basis that abacavir is able to interact at specific locations within 
the antigen binding groove on the MHC molecule.  When present, these drugs 
then alter the self-peptide repertoire that usually interacts at that location.  
The presence of the drug alters the tertiary structure of the MHC molecule, 
leading to antigenic recognition of a normally harmless peptides (Martin, 
Nolan et al. 2004; Chessman, Kostenko et al. 2008; Bharadwaj, Illing et al. 
2012).  Specifically, abacavir interacts non-covalently with the F pocket of the 
antigen binding cleft, but only in cases where the HLA-B*5701 allele is present 
(Illing, Vivian et al. 2012; Norcross, Luo et al. 2012).  This leads to the binding 
of almost 900 novel self-peptides.  It is believed that one or more of these 
peptides trigger an immune response, specifically cytotoxic CD8+ lymphocytes.  
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As a result of this, patients are now screened for the HLA-B*5701 allele before 
the commencement of abacavir therapy.  This is the first case of a genetic test 
being implemented to avoid adverse effects based on known outcomes, 
suggesting that many other drug reactions have the potential to be acting in a 
similar manner.  However, to date abacavir is the only drug that has been 
shown to activate T-cells via this mechanism (Yun, Adam et al. 2012). 
 
1.3.5 PHARMACOLOGICAL INTERACTION OF DRUGS WITH IMMUNE 
RECEPTORS 
 
Chemically inert drugs have been shown to activate lymphocytes through 
mechanisms independent of either processing by antigen presenting cells or 
metabolism.  Multiple drugs have been shown to elicit activation of T-cells 
through this mechanism, including sulfamethoxazole, carbamazepine and 
lamotrigine (Elsheikh, Castrejon et al. 2011).  This direct interaction occurs in a 
reversible interaction between drug and the MHC molecule.  In contrast to the 
hapten hypothesis, this method of activation occurs rapidly, in a matter of 
seconds.  This timeframe suggests that the activation must be occurring 
independently of antigen processing (Schnyder, Burkhart et al. 2000; Pichler, 
Beeler et al. 2006), which requires more time to take place. 
This hypothesis is supported further by the following study results; firstly, 
pulsing experiments that incorporate the drug in question point towards non-
covalent MHC-peptide binding, due to the fact that washed antigen presenting 
cells do not activate T-lymphocyte responses (Schnyder, Mauri-Hellweg et al. 
1997).  This implies that the antigen presenting cells processing machinery is 
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not involved in the presentation of the drug to the TCR.  Secondly, drug 
activation leads to downstream receptor signalling, including Ca2+ release.  
This release is delayed with protein antigens due to the time required for 
processing.  In contrast, drug-specific responses are rapid in nature, which 
precludes the involvement of antigenic processing (Zanni, von Greyerz et al. 
1998).  Finally, antigen presenting cells that are incapable of protein 
processing, such as in the case of fixation via glutaraldehyde, are shown to 
stimulate T-lymphocyte activation in in vitro assays with drugs such as 
lamotrigine, sulfamethoxazole and carbamazepine (Schnyder, Mauri-Hellweg 
et al. 1997; Naisbitt, Farrell et al. 2003; Wu, Sanderson et al. 2006). 
The PI concept is a distinct method of activation from the classical hapten 
hypothesis, though it does not preclude the possibility that a combination of 
both hapten and PI activation might be active in certain drug hypersensitive 
patients.  For example, both sulfamethoxazole and sulfamethoxazole-nitroso 
are capable of activating T-lymphocytes isolated from the skin and blood of 
patients suffering with sulfamethoxazole hypersensitivity (Nassif, Bensussan 
et al. 2002; Farrell, Naisbitt et al. 2003).  The metabolite response is dependent 
on adduct formation and antigen processing.  In contrast, responses to the 
parent drug occur rapidly and are best explained by the PI concept.  The key 
differences between these proposed mechanisms of T-cell activation by drugs 
are highlighted in figure 1.8 and 1.9. 
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Hapten 
Hypothesis 
Direct 
Metabolite 
Binding 
PI Concept 
Altered Peptide 
Concept 
A - Pulsing APC with 
drug antigen    
B - Processing 
Inhibition    
C - Glutathione    
D - Enzyme Inhibition    
E - T-cell activation 
Kinetics 
Delayed Rapid Rapid Delayed 
 
 
Figure 1.8.  Experimental evidence to differentiate between the different pathways of 
drug (metabolite)-specific T-cell activation.   
(A) - Pulsing experiments involve the culture of APC for (1 – 16h) followed by repeated 
washing steps to remove non-covalently bound drug.  The pulsed APC are then used in T-
cell assays as the source of antigen.  (B) - Antigen processing can be blocked via the 
addition of several chemicals to APC.  (C) - Glutathione blocks the protein-reactivity of 
cysteine-reactive drug metabolites.  It can be added to T-cell assays with no known non-
specific effects.  (D) - Enzyme inhibitors can be added to T-cell assays to block drug 
metabolism.  Experiments to date have been limited as it is not known which drugs are 
metabolised in the assay.  (E) - It is possible to monitor the kinetics of T-cell activation by 
measuring internalisation of T-cell receptor expression or T-cell calcium release.  
Antigen processing takes several hours, hence the response is delayed. 
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1.3.6 DANGER HYPOTHESIS 
 
First proposed in 1994, the danger hypothesis was outlined by Matzinger.  It 
states that the immune response can be triggered upon the recognition of 
certain ‘danger signals’ – usually as a result of cellular stress or damage – 
though the lack of these signals can lead to immune tolerance (Matzinger 1994; 
Anderson and Matzinger 2000; Pirmohamed, Naisbitt et al. 2002).  As 
discussed earlier, a full response by the immune system is only triggered with 
the presence of three signals, while activation of the immune cells occurs 
following the recognition of two signals (Curtsinger, Schmidt et al. 1999). 
According to Matzinger, danger signalling through exposure to PAMPs or 
DAMPs will upregulate signal 2 (dendritic cell co-stimulatory interactions) and 
promote a pathogenic response.  Danger signalling was initially discussed in 
terms of drug hypersensitivity in a review by Pirmohamed (Pirmohamed, 
Naisbitt et al. 2002).  This is an attractive proposition as many drug 
metabolites are intrinsically toxic.  Thus, products released by the necrotic 
cells might act as DAMPs and activate dendritic cells.  In support of this 
concept, chemical sensitisers which are directly reactive and damage cells at 
low concentrations upregulate dendritic cell co-stimulatory receptor 
expression and cytokine release.  Sanderson et al showed that metabolism of 
SMX to a nitroso metabolite activates dendritic cells (Sanderson, Naisbitt et al. 
2007).  However, studies with other drugs have not been forthcoming, 
therefore the importance of drug specific dendritic cell signalling remains open 
to debate. 
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Figure 1.9.  Pathways of drug (metabolite)-specific T-cell activation.  Chemically 
reactive metabolites (and directly reactive drugs) activate T-cells via a hapten 
mechanism and through direct modification of MHC or MHC binding peptides.  It 
remains to be determined whether drug metabolite MHC binding can alter the repertoire 
of self-peptides displayed by MHC molecules.  Drugs and stable metabolites activate T-
cells through direct MHC binding. 
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1.4 ADVERSE DRUG REACTIONS 
 
In recent years, there has been a proliferation of drugs used for the treatment 
of a multitude of illnesses and disease.  As a result of this, adverse reactions to 
drugs are becoming more common (Pirmohamed, James et al. 2004).  Due to 
the cost, time and negative treatment opinions, the need for understanding the 
molecular mechanisms of adverse drug reactions is more important than ever.  
The cost of withdrawals of drugs associated with adverse reactions, when 
factoring in research costs can run into hundreds of millions of pounds, so the 
economic reasons for elucidating mechanisms are also clearly relevant.  
Summarised in figure 1.10 are the compounds that have been withdrawn from 
use since 1961.  Genetic polymorphisms, drug composition and structure, 
gender, age, and underlying clinical conditions all contribute towards 
susceptibility to ADRs (Pirmohamed, Breckenridge et al. 1998).  Clinical 
manifestations include the relatively mild skin rashes, urticaria and fixed drug 
eruptions.  A lower number of patients develop serious skin reactions such as 
Stevens-Johnson syndrome and toxic epidermal necrolysis (Lazarou, Pomeranz 
et al. 1998).  Other organs including the liver and kidneys can also be involved 
either in isolation or as a component of a generalised hypersensitivity 
syndrome (Edwards and Aronson 2000; Larrey 2001). 
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1.4.1 ADR - DEFINITION 
 
As defined by the World Health Organization, an adverse drug reaction is ‘a 
response to a drug which is both noxious and unintended, and which occurs at 
doses normally used in man for the prophylaxis, diagnosis, or therapy of 
disease, or for the modifications of physiological function.’ (WHO, 1972).  
While a broad, encompassing statement, there has been controversy regarding 
the wording, with some scientists arguing that it is not accurate enough.  
Edwards and Aronson took issue with the ‘noxious’ part of the definition in 
2000, arguing that it precludes ADR that are not harmful, but merely 
inconvenient (Edwards and Aronson 2000).  In response to this, they proposed 
an alternative definition; ‘an appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of medicinal product, which 
predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product.’  This updated definition is widely accepted, and allows for a broader 
range of symptoms to be included and ultimately defined in the context of ADR. 
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Drug Name Year Identified Clinical Manifestation 
Benfluorex 2009 Pulmonary Hypertension 
Benoxaprofen 1982 DILI 
Clioquinol 1975 Myelo-optic Neuropathy 
Indoprofen 1984 GI Bleeding 
Lumiracoxib 2007 DILI 
Noscapine 1991 Gene Toxicity 
Roziglitazone 2010 Cardiovascular Events 
Suprofen 1987 Renal Dysfunction 
Temafloxacin 1992 Haemolytic Anaemia 
Thalidomide 1961 Teratogenesis 
Ximelagatran 2006 DILI 
Zimeldine 1983 Hypersensitivity 
 
Figure 1.10.  Approved drugs subsequently withdrawn from marker since 1961.  
Selected drugs withdrawn from use since 1961 due to resulting adverse effects.  Adapted 
from Stephen’s detection and evaluation of adverse drug reactions, Talbot et al 2012. 
 
 
1.4.2 ADR - CLASSIFICATION 
 
Adverse drug reactions are normally classified into two distinct types; Type A 
(dose-dependent) and Type B (independent of dose, idiosyncratic).  
Type A reactions are known, predictable responses that develop in response to 
the pharmacological action of the drug in question.  Approximately 85% of 
reported drug reactions are Type A, with the observed responses increasing in 
severity in a dose-dependent manner (Bates, Cullen et al. 1995).  The observed 
symptoms in Type A reactions are usually resolved in response to cessation of 
treatment.  These reactions can be triggered through multiple factors, such as 
intentional overdose, impaired metabolism and drug retention. 
Type B reactions are both unpredictable and not directly dose-dependent, with 
multiple factors influencing their progression (Pirmohamed, Madden et al. 
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1996; Zaccara, Franciotta et al. 2007).  Often referred to as ‘bizarre’, due to 
their idiosyncratic nature, meaning that they are not able to be predictable 
from the known pharmacology of the drug in question.  Typically, Type B 
responses involve the triggering of the hosts immune system, leading to 
reactions commonly being referred to as hypersensitivity reactions.  Both the 
adaptive and innate immune system are implicated in the progression of these 
reactions. 
These classifications are somewhat broad, and by their nature do not take into 
consideration a milieu of different potential influencing factors.  Recent 
discoveries into the linking of certain drug hypersensitivity cases to HLA 
associations, such as in the case of abacavir, allopurinol and carbamazepine, 
mean that these classifications are becoming outdated (Hung, Chung et al. 
2005; Mallal, Phillips et al. 2008; McCormack, Alfirevic et al. 2011).  An ever 
expanding list of HLA-drug associations means that these interactions are 
playing a key role in certain reactions, and as such need to be considered in 
future classifications. 
Edwards and Aronson again attempted to expand the classification with their 
own recommendations, using dose-related (Augmented), non-dose related 
(Bizarre), dose- and time-related (Chronic), time-related (Delayed), 
withdrawal (End of use) and therapy failure (Failure), though these are less 
common than the traditional Type A/B definitions (Edwards and Aronson 
2000). 
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1.4.3 ADR - EPIDEMIOLOGY 
 
Many studies have investigated the relative frequency of drug reactions as a 
cause for hospital admission.  Of these, it is estimated that 6.5% of hospital 
admissions were due to adverse drug reactions, with upwards of 100,000 
annual hospital admissions related in some way to drug exposure (Lazarou, 
Pomeranz et al. 1998; Pirmohamed, James et al. 2004).  It is well known that 
adverse drug reactions can play a major role in overall patient mortality, with 
ADRs listed as the 7th most frequent death contributing factor (Lavergne, Park 
et al. 2008).  However, other studies have investigated this in detail, and have 
found additional contributing factors to the relative abundance of ADR 
mortality.  These factors include race, socio-economic status and age 
(Dormann, Neubert et al. 2004; Shepherd, Mohorn et al. 2012).  In cases where 
a specific predetermining risk factor has been investigated, there have been 
reports suggesting that increased incidences of ADR occur in patients with 
viral infections (Levy 1997; Shiohara, Inaoka et al. 2006), specifically HIV 
(Lucas, Chaisson et al. 1999).  Polypharmacy (van der Ven, Koopmans et al. 
1991; Pirmohamed and Park 2001) might also be a contributing factor in 
chronic conditions such as cystic fibrosis (Whitaker, Naisbitt et al. 2012). 
Recently, investigations into genetic polymorphisms have assisted in our 
understanding of potential mechanisms of ADR.  Mutations in coding genes for 
enzymes involved in drug metabolism can lead to an altering of the function of 
the enzyme.  This alteration can take the form of increased activity (fast-
metaboliser), decreased activity (slow-metaboliser) or even an inactivation of 
the enzyme itself (no metabolism) (Meyer 2000; Pirmohamed and Park 2001).  
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These alterations can lead to cases where a normally therapeutic dose of drug 
can build up and cause ADR when they would not be expected.  This 
differential toxicity has been reported with several drugs (Shenfield 2004; 
Empey 2010).  The cytochrome P450 (CYP) enzymes are well known to be 
highly polymorphic, and as such can show different metabolic activity, 
therefore drug metabolism can differ between otherwise similar individuals 
(Zhou, Liu et al. 2009).    
 
1.4.4 DHR - DEFINITION 
 
As a subset of ADR, drug hypersensitivity reactions (DHR) are defined in 
relation to ADR.  They are defined as ‘an adverse drug reaction with an 
immunological aetiology to an otherwise safe and effective therapeutic agent, 
when administered at recommended doses’.  Drug hypersensitivity reactions 
are complex, immune-mediated reactions with a wide array of symptoms 
ranging from mild to very severe, along with a host of risk factors (Pohl, Satoh 
et al. 1988).   
 
1.4.5 DHR - CLASSIFICATION 
 
The classical definition of drug hypersensitivity reactions was provided in 
1963 by Gell and Coombs, with immune-mediated reactions classified into 4 
distinct categories (Gell and Coombs 1963).  These categories were defined 
primarily through the time of onset of symptoms, with consideration also of 
 67 
 
the underlying mechanistic aspects of the response being observed.  These 
categories were termed I-IV, as discussed below and in figure 1.11. 
Type I:  An immediate response following sensitisation, with IgE the primary 
mediator.  These are caused through antigen cross-linking of receptors on the 
surfaces of immune cells such as mast cells, triggering histamine, cytokine and 
eicosanoid release.  These mediators cause a clinical response, the most severe 
of which is anaphylaxis. 
Type II:  These are cytotoxic reactions, considered semi delayed.  They are 
mediated through natural killer cells along with complement fixation, and are 
triggered through either IgG or IgM antibodies that are produced by B-cells.  
Examples of this type of reaction include haemolytic anaemia and 
thrombocytopenia. 
Type III:  These are also semi-delayed reactions, again triggered through 
either IgG or IgM antibodies.  This time binding to soluble antigens occurs, as 
opposed to cell derived antigens in Type II reactions.  Excess antigen in the 
system causes the development of immune complexes.  These types of 
reactions include vasculitis and lupus. 
Type IV:  These reactions are typically delayed onset reactions, with 
observable symptoms not noticeable until days after initial exposure to the 
antigen.  They are primarily T-lymphocyte mediated.  Both cytokines and 
cytolytic molecules released from the T-lymphocytes are responsible for 
initiating the observed clinical response, with multiple diseases known to be 
triggered in this way, such as drug hypersensitivity syndromes, leishmaniasis, 
urticaria and toxic epidermal necrolysis. 
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Due to the wide range of mediators, as well as the differing effector molecules 
produced, the classic model of Type IV was deemed insufficient, with further 
stratification required to allow for greater understanding of the mechanisms 
involved.  In 2003,   Pichler set out to better define the Type IV reactions, with 
further sub-division into Type IVa-d, utilising the cells involved in different 
conditions (i.e. monocytes, neutrophils, eosinophils and cytotoxic T-
lymphocytes) to establish the classification (Pichler 2003).  The expanded 
classification is summarised in detail in figure 1.12. 
 
 
 Type I Type II Type III Type IV 
General 
Phenotype 
Anaphylaxis Cytotoxicity 
Immune 
Complex 
Delayed 
Initiation 
Time 
<1h <2h 4-8h >48h 
Antibodies IgE IgG, IgM IgG, IgM N/A 
Effector 
Cells 
Basophils, 
Eosinophils 
Antibodies, 
Complement 
Cascade 
Neutrophils, 
Complement 
Cascade 
Lymphocytes 
Drugs Cephalosporin Penicillin Penicillin Piperacillin 
Examples Hay Fever Thrombocytopenia 
Rheumatoid 
Arthritis 
Contact 
Dermatitis 
 
Figure 1.11.  Hypersensitivity classification.  Type I – IV hypersensitivity can be 
distinguished through multiple different parameters, shown on the left of the table.  Key 
to the classification is the time of onset, as well as the effector cells that primarily 
mediate the resulting hypersensitivity. 
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1.4.6 DHR - EPIDEMIOLOGY 
 
Drug hypersensitivity reactions, although relatively rare are of major clinical 
concern, and are responsible for a significant percentage of hospital 
admissions each year (Einarson 1993; Gomes and Demoly 2005).  They belong 
to the Type B styled reactions, where known pharmacology cannot be relied on 
to predict a patient response.  A multi-hospital study conducted in Boston 
reported a hypersensitivity incidence of 6.1% in 4031 patients during a 6-
month period (Bates, Cullen et al. 1995), Koch et al. described a 4.5% incidence 
rate in a cystic fibrosis patient cohort (Koch, Hjelt et al. 1991), with a meta-
analysis performed by Lazarou et al. drawing similar results (Lazarou, 
Pomeranz et al. 1998).  However, recent reviews have stated that the overall 
prevalence of DHR is not fully understood, due to the relative lack of data sets 
available (Gomes and Demoly 2005; Demoly, Viola et al. 2007).  A common 
cause of DHR is the beta-lactam class of antibiotics (Idsoe, Guthe et al. 1968). 
Several studies suggest a DHR incidence rate of between 1-8% to the 
commonly prescribed benzyl-penicillin (Macy and Contreras 2014).  Solensky 
et al. stated that when a patient is shown to be sensitive to one beta-lactam, the 
likelihood of responding to another is increased, making the identification of 
DHR more complicated (Solensky 2003). Multiple drug hypersensitivity is 
becoming a major clinical concern, especially in patients routinely exposed to 
multiple drug regimens (Whitaker, Naisbitt et al. 2012).  
 
 
 
 70 
 
 Effector Cells T-Lymphocyte Secretions 
Type IV a Monocytes IFNγ 
Type IV b Eosinophils IL-4, IL-5 
Type IV c Keratinocytes 
Perforin, Granzyme B, Fas 
Ligand 
Type IV d Neutrophils IL-8 
 
Figure 1.12.  Hypersensitivity Type IV classification.  Type IV hypersensitivity reactions 
have been further classified based on the recommendations set forward by Pichler in 
2000.  These take into consideration the effector cells that mediate the immune response, 
as well as the major secretions from the activated T-lymphocytes. 
 
1.4.7 DHR - DURATION 
 
As previously mentioned, the Gell and Coombs classification system took into 
consideration the relative time of onset of the hypersensitivity in its division of 
DHRs (Gell and Coombs 1963).  These can range from immediate, up to months 
after initial administration.  The majority of T-cell mediated reactions take 
between 1-30 days for symptoms to occur.  Proliferation of T-lymphocytes 
occurs a couple of days after exposure to the antigen, and can continue for 
several weeks.   
 
1.4.8 DHR - DIAGNOSIS 
 
Currently, the diagnosis of DHRs is only able to be confirmed through the use 
of in vivo skin tests.  Well established protocols have been established to carry 
out skin prick, patch and intradermal tests (Brockow, Romano et al. 2002).  
However, in all of these tests there are disadvantages, such as the patient 
compliance due to the invasive nature of the tests, along with the relatively low 
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sensitivity levels, which can sometimes lead to false-negatives being obtained.  
In cases of uncertain response, drug challenge tests can be implemented.  
Challenge tests can lead to the triggering of latent severe symptoms, resulting 
in patient discomfort or even death, and as such are rarely conducted unless 
under strict medical guidelines and supervision (Messaad, Sahla et al. 2004). 
Drug-specific T-lymphocytes can be isolated from peripheral blood, along with 
both blister fluid and inflamed skin samples of patients with suspected DHRs.  
These drug-specific lymphocytes are known to be long lasting, with the 
lymphocytes being able to be detected in patients years after the last 
administration of drug (Bøyum 1976; Dunbar, Ogg et al. 1998). 
Because of this availability of drug-specific lymphocytes from patients, in vitro 
tests provide a potentially valuable way to investigate the pathogenesis and 
mechanisms underlying drug hypersensitivity reactions, with minimal danger 
or discomfort to the patient.  Though better than many clinically used skin 
tests, sensitivity of potential in vitro tests are still not completely 100%, so 
accurate diagnosis is still reliant on patient histories.  The following assays rely 
on isolated PBMC from patients, so their usage is dependent on access to these 
PBMC samples, either fresh or from a cryopreserved sample, in addition to 
having a researcher that is trained in the specific techniques. 
 
1.4.8.1 T-LYMPHOCYTE CLONING 
 
Drug-specific T-lymphocytes often represent a small subset of the total 
lymphocyte population.  Because of this, T-cell cloning allows for the expansion 
of the drug-specific population, eliminating the problems of low cell numbers.  
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T-cell cloning is performed using a standardised procedure that has been 
established for many decades (Lamb, Eckels et al. 1982; Altman, Moss et al. 
1996; El-Ghaiesh, Monshi et al. 2012).  Using the isolated T-lymphocyte clones, 
cellular phenotypes, effector function, proliferative responses and cell surface 
markers can be characterised.  As previously stated, drug-specific T-
lymphocytes are a small proportion of the total lymphocyte population.  For 
this reason the use of T-cell cloning is highly prevalent and important in the 
understanding of the pathomechanisms of drug hypersensitivity reactions. 
 
1.4.8.2 LYMPHOCYTE TRANSFORMATION TEST 
 
The lymphocyte transformation test (LTT) (also known as a lymphocyte 
proliferation assay) is the most widely used in vitro method to diagnose 
potential drug hypersensitivity reactions (Pichler and Tilch 2004).  The test 
works through the measurement of proliferation of T-lymphocytes in response 
to drug exposure over a set time frame, when compared to control samples.  
This is done through the incorporation of radioactive thymidine, which is used 
in DNA synthesis.  Thymidine does not allow additional replication to occur, 
acting as a terminal base, so the assay itself is time sensitive.  LTT’s have a 
broad application domain, with the assays dependent on only T-lymphocytes 
and the drug in question.  Both immediate and delayed-type hypersensitivity 
can be investigated through an LTT, further enhancing its effectiveness 
(Nyfeler and Pichler 1997).  Both sensitivity and specificity in the assay are 
variable, with much depending on the drugs therapeutic dose and potential for 
cross reactivity (for example, piperacillin, a beta-lactam antibiotic does not 
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cross react with other beta-lactams, while flucloxacillin and dicloxacillin have 
been shown to cross react) (Monshi, Faulkner et al. 2013).  Generally, a small 
peripheral blood sample is sufficient to conduct the assay, with peripheral 
blood mononuclear cells isolated and used for analysis.  Cultures with the drug 
are incubated for 96h before thymidine addition, with readouts taken 16h 
later.  A positive result is interpreted with a stimulation index, where control 
proliferation is measured versus antigenic proliferation, with a stimulation 
index (SI) of greater than 2 considered a positive result. 
 
1.4.8.3 FLOW CYTOMETRY 
 
Flow cytometry is a technique that can identify cell surface markers, along with 
the ability to sort cell populations into functionally distinct subsets.  Diagnosis 
of a T-lymphocyte response can occur through the investigation of distinct cell 
surface markers, either from peripheral blood or tissue-specific cells.  These 
markers can also be used to identify antigen-specific T-lymphocyte subsets.   
T-lymphocyte activation can be characterised through the identification of 
activation markers, such as CD69.  Other markers of activation include CD40L 
and CD71 (Simms and Ellis 1996; De Rosa, Herzenberg et al. 2001). 
By utilizing fluorescent antibodies, multiple markers can be investigated 
concurrently, with highly specific sub-populations of cells being able to be 
identified through the relative expressions of each marker. 
A proliferative response can also be studied using the fluorescent biomarker 
carboxyfluorescein diacetate succinimidyl ester.  This biomarker halves its 
intensity upon each subsequent cell division following drug stimulation of 
 74 
 
lymphocytes.  The biomarker itself is incorporated into the cells via 
interactions with intracellular proteins (Lyons and Parish 1994; Lyons 2000). 
 
1.4.8.4 INTRACELLULAR STAINING 
 
A subdivision of flow cytometry, intracellular cytokine staining allows the 
investigation of the cytokine profile of antigen stimulated cells.  Different 
subsets of T-lymphocytes triggered by an antigen are phenotypically similar; 
there are no cell surface markers that can definitively distinguish between a 
Th1 and Th2 lymphocyte response.  However, these cells can be characterised 
through their ability to secrete different cytokine profiles, such as the pro-
inflammatory IFN-γ for Th1 and classically anti-inflammatory IL-4 and IL-13 
for Th2.  Using fluorescent antibodies specific to different cytokines, 
intracellular staining allows the investigation of multiple lymphocyte subsets 
through their cytokine secretion profiles (Scheibenbogen, Letsch et al. 2005; 
Horton, Thomas et al. 2007). 
 
1.4.8.5 ENZYME LINKED IMMUNOSORBENT SPOT ASSAY 
 
An enzyme linked immunosorbent spot (ELISpot) assay is designed to 
characterise cytokine secretion from single cells, both when resting and 
following antigen stimulation.  It is a very quick and easy assay to perform and 
can give highly sensitive and specific readouts.  T-lymphocytes are the primary 
cell type used for this type of investigation, with a large panel of cytokines able 
to be looked at using relatively low cell numbers.  Activated T-lymphocytes will 
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secrete a milieu of both pro- (IFN-γ, TNF, etc.), anti-inflammatory (IL-4, IL-13) 
and regulatory (TGFβ, IL-10) cytokines.  ELISpots allow for detection of low 
frequency cytokine secreting cells to be investigated in a short time frame 
(McCutcheon, Wehner et al. 1997; Crotty, Aubert et al. 2004; Farrell, 
Lichtenfels et al. 2013; Gibson, Ogese et al. 2014). 
In addition, effector molecules such as perforin and granzyme B are also able 
to be detected via ELISpot (Engler, Strasser et al. 2004).  High levels of 
sensitivity are reported with this assay.  Antigen specific IFNγ secreting T-cells 
have recently been detected in greater than 90% of penicillin hypersensitive 
patients using ELISpot (Rozieres, Hennino et al. 2009).  Compared with a 
similarly designed ELISA assay, positive results are able to be detected at levels 
lower than ELISA, though ELISA assays allow for storage of supernatants for 
multiple analysis in the future, whereas ELISpots rely on the availability of 
viable lymphocytes. 
It is important to note that while the ELISpot displays very high sensitivity, it 
does possess a relatively low specificity range.  For instance, limits are present 
in the number of ‘spots’ that are able to be detected following successful assay 
development.  This is dependent on the ability of the image display to discern 
between different unique spots.  For this reason, even the most precise images 
will not be able to detect more than approximately 500 spots per well of an 
ELISpot, despite the presence of many thousands of cells capable of secreting 
cytokines.  The term ‘spot forming unit’ is employed to address this issue, 
where a spot forming unit can potentially be many cells all secreting cytokines 
in the same general location on the ELISpot well, while not being sufficiently 
dispersed to be individually identified by the ELISpot imaging software.  This 
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solves the dichotomy of there being tens of thousands of cells per well, while 
having fewer than 500 ‘spots’. 
T-cell activation requires an interaction with APCs and antigen that provides a 
sufficiently strong signal to activate the T-cell.  The level of antigen presented 
by individual APCs may not be optimal, some of the T-cells may not interact 
with APC (T-cell : APC ratio is 5:1) and the T-cell may not be able to respond; 
all of which can account for the lack of cytokine secretion relative to cell 
numbers.  The ability of the T-cell to respond is also dependent on the cell 
being in the resting stage, or G0, of the cell cycle (Lea, Orr et al. 2003).  The T-
cell clones are not synchronised with respect to the cell cycle during these 
assays, as well as potentially continuing to proliferate in culture due to the 
presence of IL-2.  Thus, the number of cells in G0, and therefore cells that are 
responsive, may be low. 
 
1.4.8.6 MULTIPLEX 
 
A multiplex (Luminex) assay is similar to an ELISpot in many ways.  The 
primary difference is the ability to investigate multiple cytokines in a single 
assay.  The fluorescent beads linked to antibodies are used to allow for 
different spectral characteristics to be incorporated into the assay design.  This 
allows for multiple cytokine readouts from a single cell population.  The assay, 
while functionally superior to the traditional ELISpot, is less widely used due 
to the relative high cost of the assay (Siawaya, Roberts et al. 2008). 
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1.4.9 CUTANEOUS DHR 
 
Hypersensitivity reactions that occur following drug exposure are able to 
target many organs simultaneously.  Common targets of these reactions 
include the liver, kidneys, heart and skin, with the skin reactions being the 
most commonly described (Roujeau 2005).  The skin is the largest organ in the 
human body, so its prevalence in drug hypersensitivity reaction symptoms is 
not surprising.  Approximately 3% of cases of hospital admittance due to drug 
reactions report skin involvement.  The high prevalence of blood vessels in the 
skin means T-cell reactions are more likely to occur here, with relatively easy 
supply to the organ when compared with other organs.  Skin reactions 
themselves can vary greatly, both in appearance and relative severity.  Mild 
cutaneous reactions in the form of maculopapular exanthema and urticaria are 
much less dangerous, as well as much more common.  Though rare, reactions 
such as toxic epidermal necrolysis and Stevens-Johnson syndrome are very 
dangerous, with a high mortality rate observed.  Other reactions can include 
photosensitivity, fixed drug eruptions and urticaria, of differing severity 
(Juhlin, Michaëlsson et al. 1972; Pichler 2003).  Cutaneous reactions can be 
broadly classified into different groups through the cytokines secreted from 
activated T-lymphocytes.  CD4+ lymphocytes are known to be involved in the 
progression of conditions such as maculopapular exanthema; CD8+ 
lymphocytes can be responsible for more serious conditions, due to their 
cytotoxic nature.     
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1.4.9.1 MACULOPAPULAR EXANTHEMA 
 
The most common drug hypersensitivity reaction is the development of 
maculopapular exanthema.  These reactions are seen with beta-lactam 
antibiotics, quinolones and allopurinol, amongst others (Romano, Fonso et al. 
1995).  Following drug administration, reactions are observed after 
approximately a week, with outward symptoms continuing for several days 
following drug cessation, with MPE reported to be responsible for half of all 
cutaneous drug reactions (Bigby 2001; Valeyrie-Allanore, Sassolas et al. 2007).  
MPE is characterised by an increased temperature and itching, as well as the 
hallmarks of the condition, the development of pink macules on the surface of 
the skin, which can develop further into a maculopapular rash.  This response 
is caused through the actions of activated drug-specific CD4+ cells that secrete 
IFNγ and cytolytic molecules (Blanca, Torres et al. 2000; Pichler 2002).  
Additional studies support a role for chemokines such as RANTES, CCL27 and 
eotaxin (Posadas, Padial et al. 2002; Tapia, Padial et al. 2004).    Due to the mild 
severity of the reaction, treatments are fairly standard.  These include the 
cessation of drug, as well as brief courses of antihistamines to counteract more 
severe outbreaks. 
 
1.4.9.2 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 
 
Also called drug hypersensitivity syndrome, drug reaction with eosinophilia 
and systemic symptoms (DRESS) is known to primarily target the liver (though 
kidneys and lungs can also be damaged), and presents with numerous 
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symptoms including a fever, skin rash and eosinophilia (Cacoub, Musette et al. 
2011).  Disease progression is mediated through interleukin-5 secretions from 
activated T-lymphocytes, leading to the recruitment of eosinophils.  Studies 
have shown that a critical checkpoint in the pathogenesis of DRESS involves 
the reactivation of latent human herpes virus 6 + 7 (Descamps, Valance et al. 
2001).  Viral reactivation is also thought to be critical for the clinical 
manifestation of DRESS, with 76% of patients showing viral reactivation in a 
recent study (Picard, Janela et al. 2010).  DRESS is primarily CD8+ T-
lymphocyte mediated, with their role shown to be the targeting of reactivated 
viruses.  Half of investigated CD8+ T-lymphocytes showed a response to EBV 
epitopes, further consolidating their role in the disease.  Though the T-
lymphocyte response is characterised by a classic delayed type IV reaction, the 
actual mechanism is yet to be fully defined.  Multiple drugs have been 
implicated in the development of DRESS.  These include allopurinol, 
carbamazepine and sulfamethoxazole, amongst others.  Withdrawal of the 
offending drug, alongside systemic steroids are the primary treatment method 
of DRESS, which has a reported mortality of 8% (Peyriere, Dereure et al. 2006).  
Interestingly, in contrast to other forms of DHR, reactions continue to develop 
for several weeks after drug cessation.  This is thought to be due to the virus 
specific CD8+ T-cells. 
 
1.4.9.3 STEVENS-JOHNSON SYNDROME 
 
Stevens - Johnson syndrome (SJS) is observed in around 6 cases per million 
people per year, and is a major cause of mortality in cutaneous drug 
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hypersensitivity (Ward, Archambault et al. 2010).  SJS presents with 
keratinocyte cell death, alongside skin detachment.  Diagnostically, between 
10%-30% of total body skin detachment is used to determine a case of SJS.  
Many drugs have been implicated in the pathogenesis of SJS, including 
antibiotics, anti-inflammatories and anti-convulsants (Roujeau, Kelly et al. 
1995; Harr and French 2012).  SJS pathogenesis is poorly understood, with the 
underlying mechanisms not fully elucidated.  Both NK T-lymphocytes and 
cytotoxic T-lymphocytes have been implicated in the condition, leading to 
keratinocyte death.  Two main pathways are responsible for the keratinocyte 
death and resulting clinical symptoms, both mediated through effector 
molecules secreted by activated cytotoxic T-lymphocytes:  the fas ligand 
mediated pathway and the perforin/granzyme B mediated pathway (Abe, 
Shimizu et al. 2003; Chung, Hung et al. 2008).  Granulysin has been shown to 
be present in greater concentrations than other cytotoxic molecules in the 
blister fluid of patients, with blister fluid containing high levels of granulysin 
used to generate SJS-TEN like responses in mice.  In addition, several HLA 
associations have been identified, which can increase the likelihood of the 
hypersensitivity occurring, with the majority of these associations being drug-
specific.  There are few treatments for both SJS and TEN, with primary 
methods of treatment including intravenous Ig, alongside high strength 
corticosteroids, though the efficacy of these are controversial (Faye and 
Roujeau 2005; Teo, Tay et al. 2009).   
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1.4.9.4 TOXIC EPIDERMAL NECROLYSIS 
 
Toxic epidermal necrolysis is reported in 2 cases per million people per year, 
making it a rare form of SJS.  It is also considered a more severe form of SJS, 
with diagnosis occurring when over 30% of total body skin detachment is seen 
(Schwartz, McDonough et al. 2013).  Again, this is accompanied by large scale 
keratinocyte cell death.  In both SJS and TEN, additional symptoms are 
observed, typically multi-organ failure and high fevers.  Similarly, TEN is 
observed with a wide spectrum of drug classes, such as the antibiotics, anti-
convulsants, antifungals and allopurinol which are all known to cause TEN 
(Schwartz, McDonough et al. 2013).  The pathomechanism is not fully 
understood, though recent studies have suggested that the keratinocytes 
themselves play a critical role, with T-lymphocyte activation occurring through 
presentation of the drug via MHC I present on the keratinocyte cell surface 
(Wei, Chung et al. 2012).  Blister fluid analysis from patients with TEN show 
high levels of both NK T-lymphocytes and cytotoxic T-lymphocytes, in addition 
to increased levels of granulysin.    Again, a lack of effective treatments impacts 
on patient prognosis – with mortality of patients reported between 10-50% of 
SJS / TEN cases (Gomes and Demoly 2005; Schneck, Fagot et al. 2008).  
Recently, peptide therapy designed to impact on granulysin using siRNA 
decreased immune responses when targeting CD8+ receptors, suggesting a 
potential novel mechanism to treat cases that do not respond to established 
treatment methods (Wang, Chung et al. 2013). 
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1.5 CYSTIC FIBROSIS 
 
Cystic fibrosis (CF) is a lethal autosomal recessive disease that is typified by 
progressive destruction of the lung tissue leading to respiratory insufficiency 
of the airways.  Impaired mucocilliary clearance leads to chronic infections 
with gram-negative bacteria such as pseudomonas aeruginosa.  Cystic fibrosis 
has an effect on all exocrine glands, including the liver, pancreas and sweat 
glands.  This is a major cause of mortality in patients with cystic fibrosis; liver 
failure as a result of cirrhosis is the second leading cause of death in these 
patients.  It is the most common recessive disease in people with northern 
European descent, and upwards of 4% of that population is thought to be a 
carrier of at least one copy of the mutated CFTR gene (Bobadilla, Macek et al. 
2002).  Normal healthy CFTR genes code for an ion transporter involved in the 
movement of chloride ions across epithelial cells. 
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1.5.1 GENETICS 
 
The condition is caused by mutations in both copies of the cystic fibrosis 
transmembrane conductance regulator gene, which is located on chromosome 
7, specifically in the q31.2 region (Rommens, Iannuzzi et al. 1989).  As CF is a 
recessive disorder, both copies of the gene are required to be mutated, with a 
person with only one mutated copy of the gene showing no symptoms.  There 
is a population split across the globe of relative frequencies of cystic fibrosis, 
with it most commonly seen in northern Caucasian populations, while much 
rarer in sub-Saharan African populations (O'Sullivan and Freedman 2009).   
Over 1500 different mutations have been characterised, though the most 
common is the ΔF508 deletion, which is observed in up to 70% of all cases 
worldwide (Bobadilla, Macek et al. 2002).  This mutation causes a misfolding of 
the protein due to a deletion of the amino acid at position 508 (phenylalanine).  
The misfolded protein is unable to be trafficked to the membrane of the cell 
surface, triggering degradation prior to leaving the endoplasmic reticulum.  
This results in a lack of a CFTR protein at the cell surface, causing multiple 
problems related to chloride ion transport (Dalemans, Barbryt et al. 1991). 
As it is not a sex chromosome-linked disease, CF affects both men and women 
equally.  The high prevalence of the CF mutation suggests some sort of 
heterozygous advantage as a way to explain how a lethal condition could be so 
widespread.  Some studies have shown a link between cholera resistance and 
CF carriage, suggesting a role in water reabsorption as a potential protective 
mechanism in that disease.  Salmonella also requires a healthy working CFTR 
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transporter for successful entry into cells (Pier, Grout et al. 1998; Ma, 
Thiagarajah et al. 2002). 
 
1.5.2 PATHOGENESIS 
 
Though the main site affected in cystic fibrosis is the lungs, additional effects 
can be observed in other locations such as the pancreas and intestines.  
Mutations that occur in the CFTR gene lead to reduced amount of ion transport 
across epithelial membranes.  Alterations in chloride ion transport leads to 
many effects, such as a build up of salt (sodium chloride) outside the cell.  This 
is due to the reduced transport of both chloride and sodium ions to the 
intracellular space, though only in the sweat glands.  In all other cells this 
process is reversed, necessitating the treatment of patients with hypertonic 
saline solutions.  In cases of cystic fibrosis, the faulty CFTR channel prevents 
re-absorption of chloride ions from happening, resulting in the excess amounts 
of salt excreted in sweat.  The salty sweat that is produced is one of the main 
diagnostic tests for CF, excluding a genetic screen (Stern 1997; Mishra, Greaves 
et al. 2005). 
The main adverse effect that is observed in patients with CF is the production 
of thick mucus.  This mucus is formed through abnormally high sodium influx 
in lung epithelial cells from the airway surface liquid due to the defective CFTR 
transporter.  Sodium is able to re-enter the cells through a different 
transporter, meaning its influx is much higher when compared to chloride 
(Welsh 1990; Kibble, Neal et al. 2000).  In turn, this triggers the influx of water 
molecules from the liquid, causing a reduction in the volume of this liquid, 
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making it thicker.  This thick mucus proves an excellent breeding ground for 
opportunistic infections such as pseudomonas., due to the reduction in effective 
ciliary function.  These recurrent infections are often the cause of death in 
patients with CF, due to their recurrent nature and reduced effect of the 
immune system to fight off continual attack.  Colonies of immovable bacteria, 
termed biofilms, exist in the lung and act as the sites of origin for new 
infections.  These biofilms are present due to the idea breeding grounds 
located in the lungs and are typically resistant to multiple antimicrobial agents.  
Biofilms form through structural changes in the bacterium such as 
pseudomonas, with the loss of motility via flagella removal a key component in 
the generation of antimicrobial resistance.   Initially, in early life staphylococcus 
predominates, with pseudomonas present in over 80% of patients once 
reaching adulthood (Oliver, Cantón et al. 2000).  Nasal polyps are also more 
common in patients with CF, resulting in laboured breathing, in addition to the 
respiratory problems caused via mucus build up. 
A common side effect observed in the patients with cystic fibrosis is that of 
pancreatic insufficiency.  This causes a deficiency in digestive enzymes due to 
loss of pancreatic cells leading to malabsorption.  The weight loss that is 
caused by this condition is also a major indicator for a CF diagnosis.  Islets of 
langerhans present in the pancreas are responsible for the production of 
insulin.  Damage to these cells can cause resulting cystic fibrosis-related 
diabetes.  Other conditions that are observed in patients with cystic fibrosis 
include ‘clubbing’ of the fingertips and infertility, with 97% of males infertile.  
This infertility is due to a condition termed ‘congenital absence of the vas 
deferens’ (Borgo, Mastella et al. 1990; McCallum, Milunsky et al. 2000). 
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1.5.3 TREATMENTS 
 
Currently, there is no known cure for cystic fibrosis, so all treatment methods 
come under palliative care, or the treatment of secondary issues that are 
caused as a result of the CF condition.  Patients are often involved in lifelong 
physiotherapy sessions to improve airway function, as the mucus build up 
leads to extreme difficulty breathing if left unchecked.  Lung transplants are 
often a last resort for patients with extensive airway scarring.  A dual lung 
transplant is required to avoid cross-contamination of any bacteria present in 
the host lungs.  Due to the pancreatic damage that is often seen in CF, diabetes 
is common among patients.  As a result, insulin injections are a common 
prescription to allow for stable levels of blood glucose to be maintained 
(Belkin, Henig et al. 2006; Alves Cde, Aguiar et al. 2007; Davies, Alton et al. 
2007). 
A key therapeutic method used in the treatment of patients with cystic fibrosis 
is the inhalation of a hypertonic saline solution (6%).  This inhalation is done 
to improve mucus clearance from the airways of people with cystic fibrosis, 
countering the thickened mucus found as a result of the defective CFTR 
transporters triggering excessive water reabsorption from the airway surface 
liquid.  Application of a hypertonic saline solution increases the salt content of 
the airway surface liquid, leading to an increase in osmosis to rehydrate the 
liquid.  This decreases mucus viscosity as well as improving ciliary function for 
an increase in mucus removal. 
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Aerobic fitness is also considered to be an important factor in patient outlook.  
It is measured through VO2 peak values, with a markedly increased survival 
rate in patients with cystic fibrosis where their aerobic fitness was maintained. 
The recurrent infections that are present throughout a patient’s life mean that 
people with CF are usually on at least one course of antibiotics.  This is done to 
hopefully not allow the bacterial colony to get a foothold in the airways, though 
the presence of biofilm colonies of infections such as pseudomonas in cystic 
fibrosis means that patients are never considered to be fully free from 
infections (Lyczak, Cannon et al. 2002; Flume, O'Sullivan et al. 2007).  
Treatment methods utilising aerosolised antibiotics such as Aztreonam, 
levofloxacin and tobramycin are employed to improve lung function in cases of 
chronic infections.  This treatment does have side effects however.  In patients 
with CF, there is a much higher reported incidence of allergy to beta-lactam 
antibiotics.  One in 3 patients are known to be allergic to at least one drug, with 
20% showing multiple beta-lactam hypersensitivity.  This compares to an 
incidence rate of approximately 2% in the general population (Whitaker, 
Naisbitt et al. 2012).   
Doring et al. stated that based on current study evidence, ‘prophylactic 
treatment with anti-pseudomonal antibiotics are not recommended to prevent P. 
aeruginosa infections in patients with cystic fibrosis’, though they do go on to 
state that the use of early antibiotic eradication therapy in the treatment of 
pseudomonas shows beneficial effects (Doring, Flume et al. 2012).  In a study 
investigating the incidence of piperacillin hypersensitivity, between 26-50% of 
CF patients were shown to be hypersensitive to the drug.  Careful management 
of the antibiotic courses is often required, as certain commonly prescribed 
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antibiotics can have long term side effects, such as kidney damage with 
tobramycin (Hoffmann, Rubin et al. 2002).  In addition to this, prophylactic 
treatment with multiple courses of antibiotics greatly increases the chance of 
antibiotic resistance.  Increasingly, combination therapies are being used to 
counter this threat of resistance.  One such example of combination therapy is 
the co-administration of piperacillin and tazobactam in targeting p. aeruginosa.  
Piperacillin is a powerful broad-spectrum antibiotic used to treat gram-
negative infections which exerts its mechanism of action through the inhibition 
of bacterial cell wall synthesis.  Tazobactam is prescribed alongside this 
compound due to its synergistic mechanism of action.  It is a β-lactamase 
inhibitor, acting to prevent the breakdown of piperacillin by enzymes 
produced by gram-positive bacteria.  This confers additional activity to the 
piperacillin compound.  This resistance is of paramount concern for clinicians 
to consider, as antibiotic resistance is increasingly becoming the major barrier 
for the treatment of illnesses, due to the relative scarcity of new drug classes 
currently in development. 
Research has been implemented to develop new compounds that are able to 
treat cystic fibrosis in novel ways.  One such compound is the new lumacaftor / 
ivacaftor combination therapy.  The two different drugs work in synergy with 
each other via different mechanisms of action.  Lumacaftor acts as a chaperone 
during protein folding, increasing the transport of CFTR proteins to the 
membrane surface (Kuk and Taylor-Cousar 2015).  This counters the defect 
observed in the Δ508 deletion, where proteins are not transported to the 
surface.  Additionally, ivacaftor acts upon CFTR transporters present on the 
membrane surface by binding to the ion channel itself, increasing chloride 
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transport by increasing the probability of the ion channel being open (McPhail 
and Clancy 2013).  Though this combination therapy has shown to be 
potentially life changing in its effects, its prohibitive cost (>£250,000 / year) 
means that the treatment is not widely available in the UK, depending on the 
health care systems. 
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1.6 BETA LACTAM ANTIBIOTICS 
 
Antibiotics are among the most widely prescribed medications around the 
world.  Antibiotics fall into several classes, with one of the most popular being 
the beta-lactam class (Elander 2003).  These drugs are characterised by their 
common beta lactam ring, alongside different side chains.  They exert their 
action through the inhibition of cell wall synthesis in bacteria, via the 
interaction with the penicillin binding proteins.  These proteins catalyse the 
cross linking of the bacteria cell wall, meaning that the bacteria are unable to 
generate a solid continual cellular outer layer once exposed to the beta-lactam.  
They are bactericidal, and irreversibly bind with the serine residue 403 at the 
active site of the penicillin binding protein (Waxman and Strominger 1983; 
Fisher, Meroueh et al. 2005).   
Due to the widespread use of beta-lactam antibiotics, resistance has begun to 
become to represent an important clinical problem.  Bacterial methods of 
resistance occur either through utilising altered penicillin binding proteins to 
synthesise their cell walls, such as in the case of MRSA, or through the 
production of the beta-lactamase enzyme.  This enzyme hydrolyses the active 
beta-lactam ring of the antibiotic and renders it inactive (Drawz and Bonomo 
2010).  Newer treatment methods counteract this through co-administration 
with a beta-lactamase inhibitor such as clavulanic acid, but resistance is still of 
major concern to treatment regimens. 
One such antibiotic that is used in treatment of bacterial infections is 
piperacillin.  Usually co-administered with the beta-lactamase inhibitor 
tazobactam, piperacillin is a broad spectrum beta-lactam antibiotic used in the 
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treatment of a range of infections, most notably in pseudomonas related 
conditions.  An intravenous antibiotic, approximately 30% of piperacillin is 
bound to serum proteins.  It undergoes renal excretion, with a short half-life in 
plasma of around 1h (Sorgel and Kinzig 1994).  It is excreted largely 
unmetabolised, though a minor desethyl metabolite is formed through N-
dealkylation in the liver (Ghibellini, Bridges et al. 2007). 
Drug-proteins adducts have been implicated in the development of beta-lactam 
hypersensitivity reactions (Park and Kitteringham 1990; Evans, Watt et al. 
2004; Pichler, Naisbitt et al. 2011).  Piperacillin binds selectively to lysine 
residues on proteins.  In in vitro assays, piperacillin binds to human serum 
albumin, with the resulting adducts able to activate patient T-cells (El-Ghaiesh, 
Monshi et al. 2012). Furthermore, piperacillin albumin adducts have been 
identified in the blood of patients following a 14 day treatment course.  
Typically, piperacillin hypersensitivity is reported in patients with underlying 
medical conditions such as cystic fibrosis, or those who show hypersensitivity 
to other drugs in the beta-lactam class (Weiss and Adkinson 1988; Koch, Hjelt 
et al. 1991; El-Ghaiesh, Monshi et al. 2012).  Symptoms of piperacillin 
hypersensitivity include maculopapular exanthemas, fever and other mild 
cutaneous reactions.  Reactions have a delayed onset, with the mean time to 
the development of clinical symptoms reported to be 9.1days, though 
alternative studies have reported high frequency of immediate reactions, 
suggesting alternative mechanisms of action (Whitaker, Naisbitt et al. 2012; 
Roehmel, Schwarz et al. 2014).  Although comparatively rare, immediate 
hypersensitivity is also observed in multiple beta-lactams.  These are a Type I 
reaction mediated through the IgE molecule, and can range in severity from 
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mild urticarial rashes to life-threatening anaphylaxis.  The hypersensitivity 
reaction subsides upon cessation of drug.  Studies have shown that 
piperacillin-specific Th2 lymphocytes can be isolated from the blood of patients 
with piperacillin hypersensitivity (El-Ghaiesh, Monshi et al. 2012). 
Investigations have been conducted into the cross-reactivity that is observed 
with the beta-lactam class of antibiotics.  The beta-lactams are a broad class, 
consisting of penicillins, cephalosporins, carbapenems and monobactams.  
Cross reactivity is reported between different compounds in the same class, as 
well as between classes.   
The principle site of immunogenicity in these compounds are the beta-lactam 
ring, the thiazolidine or dihydrothiazolidine ring and the side chains.  Studies 
highlight that cross-reactivity is dependent on similar side chains between 
compounds.  This theory is further enhanced by the fact that penicillins that 
share a common group in their side chain are often seen to cross react with one 
another.  
In studies comparing responses between penicillins and cephalosporins, low 
cross-reactivity is observed.  Independent groups reported the incidence rate 
of cross-reactivity at around 10%, though this is reduced when comparing 
responses to the newer generation of cephalosporins.  For example, Buonomo 
et al. showed an 18.5% incidence of cross-reactivity with cephalosporins when 
investigating patients with confirmed ampicillin hypersensitivity (Romano, 
Gue ant-Rodriguez et al. 2004; Antunez, Blanca-Lopez et al. 2006; Buonomo, 
Nucera et al. 2014). 
In contrast to this, a comparison between penicillins and carbapenems showed 
little to no cross-reactivity, with work performed by Romano’s group showing 
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an incidence rate of approximately 1% (Romano, Gaeta et al. 2010).  The 
cephalosporins are split into two sub classes; the methoxyimino R1 side chains 
and the aminocephalosporins.  Structural similarity at the R1 side chain 
position is critical for cross-reactivity in these compounds, with no cross-
reactivity reported between the two sub-classes.  However, it is important to 
note that the incidence of cross-reactivity is dependent on multiple factors 
which are still not fully elucidated.  For example, amoxicillin and cefadroxil are 
different compounds which share the same side chain, yet only have a reported 
cross-reactivity of 40% (Miranda, Blanca et al. 1996).  
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1.7 THESIS OUTLINE 
 
The aims of this thesis were to investigate the role of both pro-and anti-
inflammatory cytokines in the progression of piperacillin hypersensitivity in 
patients with cystic fibrosis.  To fully understand the pathomechanisms that 
were involved, a number of analytical, biological and functional experiments 
were designed, using blood samples from both healthy volunteers and cystic 
fibrosis patients.  Also, inflamed skin samples were obtained from the 
hypersensitive patients with cystic fibrosis. 
Specific aims of this thesis include: 
 Investigation of the feasibility of priming naïve T-cells to piperacillin. 
 Exploration of the phenotype and cytokine secretion from piperacillin 
primed T-cells. 
 Characterisation of the phenotype and function of drug-specific T-cells 
isolated from the blood and inflamed skin of hypersensitive patients. 
 Delineate if a typical Th1 of Th2 response is observed. 
 Investigation of the COX-2 selective NSAID lumiracoxib and its role in 
drug hypersensitivity. 
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2.1 REAGENTS AND MATERIALS 
 
2.1.1 REAGENTS 
 
Lymphoprep was purchased through Axis-Shield (Dundee, United Kingdom).  
[3H]-methyl tritiated thymidine was from Moravek (California, United States).  
Recombinant interleukin-2 was purchased from Peprotech (London, UK).  Both 
protein standards as well as readymade Bradford reagent was purchased from 
Bio-Rad Laboratories (Hemel-Hempstead, UK).  Propan-2-ol was purchased 
from Fischer Scientific (Loughborough, UK).  Dimethyl sulfoxide was 
purchased from Sigma Aldrich (Dorset, UK).  Western blot developing and 
fixation solutions were purchased from Kodak (Watford, UK).  Meropenem, 
sulfamethoxazole-nitroso and piperacillin were obtained from AstraZeneca 
(Luton, UK), Dalton Pharma Solutions (Toronto, Canada) and Wockhardt 
Limited (Wrexham, UK).  Lumiracoxib and its metabolites were a gift from 
Novartis (Surrey, UK).  Cyclosporin-A was purchased from Fluka Analytical 
(Dorset, UK).  Pooled human serum was bought from Innovative Research 
(Michigan, USA), while foetal bovine serum was bought from Invitrogen 
(Paisley, UK).  Tetanus toxoid (pure) was purchased from Statens Serum 
Institut (Copenhagen, Denmark).  All fluorescent antibodies purchased for flow 
cytometry analysis were from either BD Biosciences (Oxford, UK) or R&D 
Systems (Minnesota, USA).  All chemokine antibodies were purchased from 
eBioscience (Ireland, UK). 
Any other solvents, reagents and supplies were purchased from Sigma-Aldrich 
(Dorset, UK) unless otherwise mentioned. 
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2.1.2 MATERIALS 
 
All ELISpot kits and developing substrates were purchased from Mabtech 
(Stockholm, Sweden), with the exception of fas ligand, which was from AbCam 
(Cambridge, UK).  The trial kits of interleukin-22 ELISpots were a gift from 
Niklas Ahlborg of Mabtech.  Multi-screen ELISpot assay plates were bought 
from Millipore (Watford, UK).  Interleukin-22 ELISA kits were purchased from 
eBioscience (Ireland, UK).  Melt-on wax scintillator sheets, glass fibre filter 
mats and plastic sample wallets were purchased from Perkin-Elmer Life 
Sciences (Massachusetts, USA).  Magnetic bead separation kits were bought 
from Miltenyi Biotech (Surrey, UK).  Cell culture plates, flasks and dishes were 
purchased from Thermo Scientific (Hemel-Hempstead, UK).  Western blot 
nitrocellulose membranes and Hyperfilm ECL were purchased from GE 
Healthcare Life (Buckinghamshire, UK).   
Any other solvents, reagents and supplies were purchased from Sigma-Aldrich 
(Dorset, UK) unless otherwise mentioned. 
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2.2 CELL CULTURE MEDIUM 
 
T-lymphocyte culture medium contained RPMI-1640, supplemented with 10% 
human antibody serum, penicillin (100U/ml), streptomycin (0.1mg/ml), 
transferrin (25µg/ml), L-glutamine (2mM) and HEPES buffer (25mM).  All 
assays were cultured in media absent of both penicillin and streptomycin, 
though media that contains this combination is also suitable for use.  Normally, 
work with beta-lactams is conducted in the absence of both penicillin and 
streptomycin.   
Antigen presenting cells in the form of Epstein-Barr transformed B-lymphocyte 
lines were cultured in media containing RMPI-1640, supplemented with 10% 
foetal bovine serum, penicillin (100U/ml), streptomycin (0.1mg/ml), L-
glutamine (2mM) and HEPES buffer (25mM). 
Chemotaxis buffer contained RPMI-1640 supplemented with 0.5% bovine 
serum albumin. 
Cells were frozen for long term storage using a freezing medium containing 
80% foetal bovine serum and 20% DMSO.  This freezing medium was then 
combined in a 1:1 ratio with standard lymphocyte culture medium to a volume 
of 1ml prior to freezing and storage. 
Flow cytometry medium (FACS Buffer) contained Hanks balanced salt solution, 
supplemented with 10% foetal bovine serum and 0.03% sodium azide (NaN3).   
Magnetic cell separation medium (MACS buffer) contained 2.5g BSA, 2mL 
EDTA (500mM), 48mL HBSS for a 10x strength stock solution.  Dilution to 1x 
strength was done via 1:10 dilution with HBSS.  
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2.3 INSTRUMENTATION 
 
Assays incorporating radioactive [3H]-thymidine were harvested using a cell 
harvester (TomTec, USA) and analysed via the Micro Beta Trilux Counter 
(Perkin Elmer, Cambridge, UK).  ELISpot assays were read using an AID 
ELISpot Reader (Cadama Medical, Stourbridge, UK).  ELISA plates were read 
using an MRX plate reader (Dynex, Lincoln, UK).  Flow cytometry readings 
were taken using a BD FACS Canto II flow cytometer (BD Biosciences, Oxford, 
UK) and analysed using a combination of Cyflogic (CyFlo Ltd.) and Flowing 2 
(Turku University, Finland).  Bradford assays were read using an MRX plate 
reader (Dynex, Lincoln, UK).  All columns and magnets used for the magnetic 
cell separations were purchased from Miltenyi Biotech (Surrey, UK).  All 
statistical analysis was performed using SigmaPlot 13 software (SyStat 
Software Inc.). 
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2.4 SAMPLE RECRUITMENT 
 
All patient samples were screened prior to being taken.  Cystic fibrosis samples 
were taken from patients of known allergic status to drugs, through the 
Regional Adult Cystic Fibrosis Unit in St James’ Hospital in Leeds.  Healthy 
volunteer samples were used for naïve controls.  These people have previously 
not been exposed to the drug in question, to the best of their knowledge.  All 
patients agreed with the written informed consent provided.  The research 
study was approved through the local research ethics committees.  Patient 
samples were collected after study approval from the East Leeds Ethics 
Committee.  Healthy volunteer samples were approved by the Liverpool Local 
Research Ethics Committee.   
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2.5 METHODS 
 
2.5.1 PERIPHERAL BLOOD MONONUCLEAR CELL ISOLATION 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood 
samples obtained from either volunteers or patients.  Peripheral blood was 
obtained via a trained phlebotomist in heparinised vacutainer vessels.  In a 
50ml tube, 25ml of lymphoprep was added, with blood carefully layered on top 
using a syringe and quill.  Erythrocytes were separated through density 
centrifugation (400g, 25min, 17°C, no brake).  A buffy coat layer was generated 
which contained the required PBMCs.  This layer was carefully extracted into a 
fresh tube using a pasteur pipette.  Two further washes using 50ml of Hank’s 
balanced salt solution were performed to ensure all remaining lymphoprep 
was removed.  PBMCs were then counted via trypan blue exclusion, with 10µl 
of cell suspension added to an equal volume of trypan blue (0.2% w/v) and 
counter via a haemocytometer, using a Lecia DME light microscope (Lecia 
Microsystems, Milton Keynes, UK).  The total cell number of viable cells was 
recorded as follows:  observable viable cells * magnification factor * dilution 
factor.  Percentage viability from initial blood separations was regularly >98%.   
Isolated PBMC were frozen and stored for further analysis.  The PBMC were 
frozen in a freezing mixture (80% FBS, 20% DMSO) and equal parts cell culture 
medium at a density of 1x107 cells/ml.  These were stored in cryovials and 
placed into a Mr Frosty container for 24h at -80°C.  Once frozen, the cells were 
then transferred into either a -150°C freezer or a liquid nitrogen tank for long 
term storage.  In cases when cells were used immediately, cells were 
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transferred into the appropriate media for experimental conditions, stated as 
appropriate. 
 
2.5.2 MAGNETIC SEPARATION OF CELL SUBSETS 
 
Following on from PBMC isolation, cell subsets are able to be magnetically 
separated in order to be used in multiple assays.  First, the PBMCs were re-
suspended in MACS buffer (800µl / 1x108 cells).  CD14 microbeads were then 
added (200µl per 1x108 cells), mixed and incubated in the dark for 15min, 4°C.  
Additional MACS buffer was then added (15ml per 1x108 cells) to wash cells 
which were then re-suspended in MACS buffer (500µl per 1x108 cells) and 
passed through a magnet holding an LS column.  The column was washed using 
additional MACS buffer for a total flow through of 15ml.  Cells that flow 
through are CD14- and were used for the next stage, while a plunger was used 
on the column to elute the CD14+ cells.  Columns were pre-wet with 3ml of 
MACS buffer prior to sample addition. 
Next, the CD14- cells were re-suspended in MACS buffer (400µl per 1x108 cells) 
and Pan-T biotinylated antibody cocktail was added (100µl per 1x108 cells).  
These cells were mixed and incubated in the dark for 15min, 4°C.  Next, MACS 
buffer (300µl per 1x108 cells) and anti-biotin microbeads (200µl per 1x108 
cells) were added and incubated for 15 min, 4°C.  Cells were then washed with 
MACS buffer (15mL per 1x108 cells) and passed through another LS magnetic 
column.  The flow through are CD3 positive cells, while a plunger was used to 
elute the remaining CD3 negative cells in the column. 
 103 
 
Regulatory T-lymphocytes and memory T-lymphocytes were removed from 
the CD3+ cells using positive selection with CD25 and CD45RO microbeads.  
The isolated CD25+ (regulatory T-lymphocytes), CD45RO+ (memory T-
lymphocytes) and CD45RO- (naïve T-lymphocytes) were then able to be used 
in future assays.  All cells were able to be incorporated into assays directly 
following separation, or could be frozen down (1x107 per ml) for storage and 
future analysis. 
 
2.5.3 PROLIFERATION ASSAY 
 
Immune responses are able to be easily measured through the use of a 
proliferation assay.  T-lymphocyte clones (5x104, 50µl) were cultured in a 96-
well U-bottomed cell culture plate, with antigen presenting cells in the form of 
irradiated autologous cells (1x104, 50µl).  The remainder of the well volume 
was made up of either drug at differing concentrations, cell media alone 
(negative control) or PHA (5µg/ml, positive control) (all 100µl).  Cells were 
then incubated at 37°C, 5% CO2 for 3 days, with tritiated [3H]-thymidine 
(0.5µCi/well) added for the last 16h of culture.  Cells were then harvested onto 
a printed filter mat, sealed with wax and contained in a scintillation sheet.  The 
readouts were measured on a MicroBeta Trilux counter through scintillation 
counts, with readouts displayed in the form of CPM.  An SI of greater than 2 
was considered a positive result.   
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2.5.4 LYMPHOCYTE TRANSFORMATION TEST 
 
Lymphocyte Transformation Tests (LTTs) were performed on PBMC isolated 
from patient’s blood samples.  The LTT was used to investigate the presence of 
memory T-lymphocytes that showed drug-specific reactivity, as described 
elsewhere (Pichler and Tilch 2004).  Briefly, PBMCs (1.5x105/well, 100µl) were 
cultured with drug (differing concentrations, 100µl) in a 96-well U-bottomed 
cell culture plate, in triplicate.  A range of drug concentrations were used to 
establish an optimal response range.  Tetanus toxoid (0.5µg/ ml, 100µl) was 
used as a positive control, with culture media alone as a negative control.  Once 
all conditions were added, plates were incubated for 6 days at 37°C, 5% CO2.  
Sixteen hours prior to the end of the incubation, tritiated [3H]-thymidine was 
incorporated into the assay (0.5µl/well).  Upon the end of the incubation plates 
were harvested using a MicroBeta Trilux counter, as described previously. 
 
2.5.5 ELISA 
 
ELISA stands for enzyme-linked immunosorbent assay, and is used in the 
quantification of a substance – typically an antigen or cytokine – present within 
a solution.  In our work the solutions that were tested were supernatants taken 
from the wells of conducted assays, aiming to measure the total amount of 
interleukin-22 that had been produced.  Briefly, a capture antibody 
(100µl/well, 10µg/ml) was coated onto the wells of a 96-well flat bottomed 
plate, diluted in coating buffer (HBSS containing 0.5% FBS), and then left 
overnight at 4°C.  The wells were then washed (250µl/well, 5x, PBS), and assay 
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diluent added to each well for 1h.  The wells were then washed (250µl/well, 
5x, PBS) and samples are added (100µl/well).  The plate was then incubated 
for 2h at 17°C.  Plates were then washed again, and detection antibody 
(100µl/well, 1µg/ml) added to each well diluted in assay diluent for 1h.  Wells 
were then washed and streptavidin-HRP (100µl/well, 1µg/ml) added to each 
well for 30min.  Wells were then washed and substrate solution (TMB, 
100µl/well) added to each well for 15min.  Finally, the stop solution (1N NaOH, 
50µl/well) was added to halt the reaction and the resultant colour changes 
were read at 450nm.   
 
2.5.6 BRADFORD ASSAY 
 
The Bradford Assay is a simple, quick assay used to measure protein 
concentrations.  This is generally performed prior to an ELISA or Western blot, 
in order to establish a concentration curve through known quantities of a 
protein - typically BSA - allowing the identification of an unknown sample.  
Unknown protein concentration samples were then compared against a known 
protein concentration curve to obtain total protein values, through the use of a 
spectrophotometer.  Once all standards (5µl/well, 1.25µg/ml – 10µg/ml) and 
unknowns (5µl/well) were set up in triplicate, coomassie stain (150µl) was 
added to each well, with the resultant colour change read off at 595nm.  Values 
obtained were then analysed with the known protein concentrations used to 
generate a dilution dependant concentration curve.  This curve was then used 
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to read off the unknown spectrophotometric values, giving a reading for 
protein concentration. 
 
2.5.7 ELISpot 
 
The enzyme-linked immunosorbent spot assay (ELISpot) is similar in design to 
the ELISA, however it allows for the characterisation of low levels of cytokine 
secretions from T-lymphocytes themselves, without the need for supernatants 
(Engler, Strasser et al. 2004; Zhang and Lehmann 2012).  ELISpot assays were 
used to quantify the number of IFN-gamma and interleukin-22 secreting cells, 
in addition to other cytokines.  Briefly, Multi-screen HTS filter plates were pre-
wet with 100µl of activation mix (70% EtOH, 30% d.H20), then washed with 
d.H20 (5x, 200µl), coated with a capture antibody (15-60µg/ml, 100µl) and 
stored overnight at 4°C.  Next, the wells were washed of capture antibody using 
sterile PBS (250µl, 5x) and then blocked for 2h with standard cell culture 
medium (250µl).  This media was then removed, and T-lymphocytes (5x104, 
50µl), irradiated autologous antigen-presenting cells (1x104, 50µl) and the 
appropriate culture condition (positive control, negative control, drug, 100µl) 
were added to the well.  Cell culture medium alone was used for a negative 
control, with PHA (5µg/ml) used for a positive control.  The plates were then 
incubated at 37°C, 5% CO2 for 48h.  After incubation, the cells were discarded 
and the wells washed with PBS (250µl, 5x).  Biotinylated antibodies to specific 
cytokines were then added to each well (1µg/ml, 100µl) in a solution of PBS 
containing 0.5% FBS.  This was then incubated at room temperature for 2h, 
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and then the wells were washed with PBS (250µl, 5x).  Streptavidin-ALP was 
then diluted in the PBS containing 0.5% FBS and added to each well for 1h 
(1µg/ml, 100µl).  The liquid was then discarded and the wells washed with PBS 
(250µl, 5x).  A solution of BCIP/NBT substrate (100µl) was added to each well 
for 15min for spot formation to occur.  The reaction was then halted using slow 
running tap water, with the wells left overnight to dry prior to being read on an 
AID plate reader. 
 
2.5.8 FLOW CYTOMETRY 
 
Flow cytometry was used to investigate the cell surface phenotype and 
function of T-lymphocytes.  Cells (1x105, 200µl) were incubated with 
antibodies conjugates to different fluorochromes (5µl) in FACS buffer for 
25min, 4°C in the dark.  For example: CD3-APC, CD4-PE, CCR7-FITC, CXCR1-
APC.  These cells were then washed and re-suspended in either fresh FACS 
buffer (200µl) or para-formaldehyde (4% v/v, 200µl).  Fresh FACS buffer was 
used to re-suspend cells for same day analysis, with para-formaldehyde used in 
cases where analysis was planned on future days.  Cell data was analysed using 
a FACS Canto II machine.  A minimum of 1x104 events were used for analysis 
acquisition. 
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2.5.9 T-LYMPHOCYTE CLONING 
 
T-lymphocyte cloning uses small initial amounts of lymphocytes to generate a 
large population of clones for analysis and comparison assays.  This is done 
through a serial dilution method, with each individual clone that is generated 
comprising of a population of identical cells generated from an initial single 
cell precursor. 
Briefly, PBMCs from either patient or volunteers, in addition to isolated skin 
lymphocytes (1x106, 500µl) were cultured with drug (500µl) at optimal 
concentration in a 48-well plate for 2 weeks.  On days 6 and 9 the wells were 
supplemented with interleukin-2 (200U/ml) to induced T-lymphocyte 
expansion.   
On day 14, the cells were then harvested and used for a serial dilution.  Cells 
were plated out into 96-well U-bottomed cell culture plates at concentrations 
of 0.3, 1, 3 and 10 cells per well.  They were then re-stimulated with allogeneic 
irradiated PBMC (5x104/well), PHA (2µg/ml) and interleukin-2 (75U/ml).  
These cells were fed every 2 days using cell culture media supplemented with 
interleukin-2 (75U/ml).  Wells that contained clones that were growing well 
were placed into a fresh 96-well cell culture plate and allowed to expand, 
through splitting the well as required.  This was determined through a large 
confluent pellet being present in the bottom in the well, in addition to the 
medium beginning to turn yellow in between normal feeding schedules.  
Specificity to the cultured antigen was assessed using a standard proliferation 
assay performed in duplicate wells. 
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Once antigen-specific T-lymphocytes were identified, they were re-stimulated 
every 3 weeks to maintain a sufficient level of proliferation with allogeneic 
irradiated PBMC (5x104/well), PHA (2µg/ml) and interleukin-2 (75U/ml). 
 
2.5.10 EBV GENERATION 
 
Epstein-Barr virus transformed B-cell lines were used throughout the work 
conducted as autologous antigen-presenting cells in multiple assays.  These 
were generated through the following method.  First, PBMCs (2-4x106) from a 
donor were incubated in supernatant taken from the B9.58 cell line.  The 
supernatant (10ml) was filtered through a 0.45µm filter attached to a syringe 
prior to addition to the PBMC, in order to remove any of the cell line from the 
suspension.  Cyclosporin A (1µg/ml) was added to the supernatant to inhibit T-
lymphocyte proliferation.  The PBMC were then incubated overnight at 37°C, 
5%C02.  Next, the cells were washed and re-suspended in antigen-presenting 
cell medium containing cyclosporin A (1µg/ml) and plated into a 24 well plate 
at a final volume of 2ml.  These plates were then incubated for 2 weeks, with 
fresh antigen-presenting cell media containing CSA added every 3 days.  After 2 
weeks, antigen-presenting cell media without CSA was used to feed the cells, in 
order to allow for expansion.  When sufficient expansion had occurred, cells 
were transferred into a free-standing cell flask, and fresh media was used to 
maintain healthy cells and continued to be grown as necessary, normally being 
fed twice a week. 
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2.5.11 ANTIGEN PULSING ASSAYS 
 
Antigen-pulsing assays are used to look at drug-protein binding and to assess 
the requirement for antigen processing that may be used in the lymphocytes.  
Epstein-Barr virus transformed B-cells were cultured with drug for 16h, then 
washed with HBSS in order to remove any free drug.  These antigen-presenting 
cells were then included in assays in the place of non-antigen pulsed cells, in 
order to investigate if presentation occurs.  Generally, T-lymphocytes 
(5x104/well, 50µl) and irradiated drug-pulsed antigen-presenting cells 
(1x104/well, 50µl) were cultured with T-lymphocyte medium (100µl).  Soluble 
drug at optimal concentration is included as a positive control in place of T-
lymphocyte medium alone (Yaseen, Saide et al. 2015).    
 
2.5.12 WESTERN BLOT ANALYSIS 
 
Protein samples isolated from previous cell culture assays were harvested 
from the supernatants were aliquoted out (10µl) were loaded into the 
appropriate wells on a 10% SDS-polyacrylamide gel for electrophoresis (1h, 
300V, 60mA).  The separated proteins were transferred from the gel to a 
nitrocellulose membrane (1h, 300V, 250mA).  Blocking for non-specific binding 
was performed through the use of 2% non-fat powdered milk in TST buffer 
(Tris-HCl 10mM, NaCl 150mM, Tween-20 0.05%; pH 8.0) for 2h at 17°C.  The 
presence of drug-protein adducts was detected through the addition of 
primary antibody (mouse anti-penicillin, 1:20,000) diluted in 2% milk / TST 
overnight at 4°C.  The following day, unbound antibody was washed from the 
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sample using PBS-Tween-20 (5x wash).  A secondary antibody (goat anti-
mouse HRP, 1:1,000) was then diluted in milk / TST and added to the 
membrane for 2h at 17°C.  Unbound antibody was then again washed off using 
PBS-Tween-20 (5x wash).  Membrane bound signals were then detected 
through ECL and developed using standard radiography film in a dark room for 
differing times (up to 30s) before images were taken. 
 
2.5.13 MHC RESTRICTION ASSAY 
 
Anti-human HLA-A, B and C antibodies (MHC class I) and anti-human HLA-DP, 
DQ and DR antibodies (MHC class II) were utilised in some reactions to block 
MHC class I and II interactions (5µg/ml, 100µl/well).  Briefly, autologous EBVs 
were incubated with either the class I or II blocking antibodies (1x104/well, 
50µl) for 30min, then cultured with generated T-lymphocyte clones.  
Proliferation readouts as well as ELISpot analysis was performed following a 
48h incubation at 37°C, 5% CO2.   
 
2.5.14 T-LYMPHOCYTE PRIMING ASSAY 
 
Using a recently established method (Faulkner, Martinsson et al. 2012) it is 
possible to prime naïve t-lymphocytes to respond to certain compounds, using 
autologous dendritic cells as the primary source of antigen presentation.  By 
using this assay we were able to investigate potential lymphocytic responses 
without the need for patient samples. 
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CD14+ cells are cultured in the presence of GM-CSF (800U/ml) and IL-4 
(50µg/ml) for 6 days.  On day 6, TNF-α (50µg/ml, 3µl/ml) and LPS (1mg/ml, 
6µl/ml) were added to induce maturation into mature dendritic cells.  These 
cells (2x104/well) are then incubated with autologous naïve T-lymphocytes 
(2.5x106 per well) in a 48-well cell culture plate containing the drug aiming to 
be primed to at optimal concentration.  The drugs used in this assay were 
piperacillin, sulfamethoxazole-nitroso, lumiracoxib and its minor metabolites 
(concentrations given in chapters).  Sulfamethoxazole-nitroso was included in 
all assays as a positive control, as 9 out of 10 samples are known to be 
successfully primed to that compound (personal communication).  These 
plates were then incubated for 7 days at 37°C, 5%CO2.  After the 7 days, freshly 
matured dendritic cells (1x104 per well) are added to the now primed T-
lymphocytes (1x105 per well) after all cells are washed.  Positive controls are 
obtained using PHA (5µg/ml), negative controls with both media alone and 
wells lacking fresh dendritic cells. 
 
2.5.15 MEMORY T-LYMPHOCYTE ASSAY 
 
Memory T-lymphocytes allow the investigation of patient responses to 
previously exposed compounds.  Simply, a 48-well cell culture plate was coated 
with a CD-3 antibody (10µg/ml) overnight at 4°C.  The following day, the plates 
were washed with HBSS (200µl, 5x) and memory T-lymphocytes from healthy 
volunteers (1x106) were added to the wells, in addition to polarising cytokines 
(Th1, Th2, Th17 Th22) as shown in figure 2.1 and antigen presenting cells in the 
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form of EBV (4x104).  CD28 antibody and medium alone were also run for 
comparisons.  Following incubation of the cells for 6 days at 37°C 5%CO2, the 
cytokine secretion of cells were then used in an ELISpot readout (1x105 
cells/well, 100µl) alongside medium alone (100µl). 
 
Figure 2.1.  Culture conditions for lymphocyte polarisation 
Th1 IL-12 (25ng/ml), Anti IL-4 (5µg/ml) 
Th2 IL-4 (25ng/ml), Anti IL-12 (5µg/ml), Anti IFN-γ (200ng/ml) 
Th17 
IL-1β (20ng/ml), IL-6 (20ng/ml), IL-23 (20ng/ml), TGFβ 
(5ng/ml) 
Th22 TNF-α (50ng/ml), IL-6 (20ng/ml) 
 
 
2.5.16 CHEMOTAXIS ASSAY 
 
The chemotaxis assay is designed to measure the ability of cells to migrate 
across a semi-permeable membrane in response to certain chemokines, 
depending on whether the cells display the appropriate chemokine receptors.  
First, chemotaxis buffer containing the desired chemokine(s) (5-25ng/ml) was 
placed into the bottom half of a trans-well plate (500µl).  The clones 
(generated from patient blood and skin, as well as priming assay generated 
clones) were then re-suspended in chemotaxis buffer (1x105/ml, 100µl) and 
placed into the bottom half of the plate.  Time points were chosen for cell count 
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measurement (0h, 1h, 4h, 24h) and cell counts were taken from the bottom 
half of the trans-well plate (10µl), measuring the total amount of migration 
across the semi-permeable membrane.  Results were recorded as percentage 
total migration.  
 
2.5.17 SKIN LYMPHOCYTE ISOLATIONS 
 
All skin biopsies were obtained following a positive skin patch test to 
piperacillin.  The samples were taken by a trained clinician under sterile 
conditions at St James’ Hospital, Leeds.  The skin biopsy (2mm) was placed into 
standard lymphocyte culture medium and supplemented with interleukin-2 
(75U/ml) for transportation to the laboratory.  The sample was then placed 
into a sterile petri dish and finely minced with a scalpel, then re-suspended in 
cell culture medium with interleukin-2 (75U/ml, 9ml).  This volume was then 
split into 3 wells of a 12-well plate, and incubated for 5 days at 37°C, 5% CO2.  
After the allotted time, the suspension was then passed through a cell strainer 
(0.45µm) and rinsed into a 50ml tube.  The cell suspension was then placed 
into a 48-well plate, where it was supplemented with irradiated PBMC 
(1.5x104/well), PHA (5µg/ml) and interleukin-2 (75U/ml) for 14 days.  
Following day 14, normal T-lymphocyte cloning was undertaken, as explained 
earlier. 
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3.1 INTRODUCTION 
 
Beta-lactam antibiotics are one of the most widely prescribed drugs across the 
world, with approximately half of all antibiotics prescribed estimated to be 
from the beta-lactam family (Elander 2003).  They all share a common 
structure, with side chains conferring differential activity centred on the beta-
lactam ring which gives them their name.  The beta-lactam family of drugs are 
used in the treatment of bacterial infections.  They exert their pharmacological 
action through the inhibition of cell wall synthesis in the invading bacteria 
(Waxman and Strominger 1983).  This class of antibiotics are extensively 
prescribed for the treatment of patients with recurrent infections, such as is 
seen in patients with cystic fibrosis.  The fibrosis of the lungs, as well as the 
increased production of thick mucus that is hard to remove provides an ideal 
breeding ground for multiple opportunistic bacteria, such as pseudomonas 
aeruginosa (Isles, Maclusky et al. 1984; Oliver, Cantón et al. 2000). 
Unfortunately, a much higher incidence of beta-lactam hypersensitivity is 
observed in patients with cystic fibrosis when compared to the general 
population.  It is not understood why this is, though genetics, overall drug 
burden and the prophylactic nature of the treatment in these cases are all 
suggested to play a role.  As a result of this, many patients with cystic fibrosis 
are unable to be treated with conventional beta-lactam antibiotics, resulting in 
a worsening prognosis.  This represents a major clinical concern since the 
primary cause of mortality in cystic fibrosis is as a result of complications due 
to infections present in the lung (O'Sullivan and Freedman 2009). 
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Piperacillin, a powerful broad-spectrum antibiotic, is often contra-indicated in 
patients with cystic fibrosis, with studies putting the prevalence of 
hypersensitivity between 26-50% (Koch, Hjelt et al. 1991; Pleasants, Walker et 
al. 1994; Burrows, Nissen et al. 2007).  Patients typically present with 
maculopapular exanthema, with a cutaneous aetiology the primary 
manifestation of the delayed type reaction, with the mean time of onset of 
symptoms after initial administration put at 9.1 days.  Because of the delayed 
onset of clinical symptoms, T-lymphocytes are thought to be the primary 
drivers of tissue injury.  Investigating the role of lymphocytes in the 
progression of piperacillin hypersensitivity would greatly enhance the 
understanding of the disease pathology. 
In the general population, piperacillin is well tolerated, with incidences of 
adverse reactions reported in the region of 2%.  Classical research defining the 
hapten hypothesis suggests that the T-lymphocytes need to be presented with 
a drug modified peptide antigen before a response can occur (Landsteiner and 
Jacobs 1935; Uetrecht 1997; Park, Pirmohamed et al. 1998; Naisbitt, Gordon et 
al. 2000).  In the case of piperacillin, it is thought that the hapten hypothesis is 
the primary mechanism for lymphocyte activation.  A previously established 
protocol outlined a way to prime naïve T-lymphocytes to drug derived 
antigens (Faulkner, Martinsson et al. 2012).  This assay utilises naïve T-
lymphocytes taken from the peripheral blood.  These cells are unique in that 
they have not been exposed to any form of antigen.  In this assay, ‘priming’ of 
these naïve T-lymphocytes allows us to study cells that would otherwise be 
tolerant to the antigen.  Thus, it is possible to study the origin of the drug-
specific T-cell response and factors associated with T-cell activation and 
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polarisation.  Dendritic cells are the key antigen presenting cells used for T-
lymphocyte priming.  They are generated from CD14+ monocytes and matured 
into dendritic cells through a culture cocktail of both GM-CSF and IL-4, as well 
as LPS and TNF-α as a final maturation step (Dauer, Obermaier et al. 2003).  
This maturation step is essential for the development of dendritic cells, with 
the machinery to successfully present antigenic determinants.  In contrast, 
immature dendritic cells are less suited to lymphocyte activation; their main 
role involves pathogen recognition via TLR signalling and antigen uptake 
(Mahnke, Schmitt et al. 2002).  The structural differences of immature and 
mature dendritic cells are highlighted in figure 3.1. 
Multiple studies have highlighted the role of interleukin-17, as well as a newly 
identified Th17 class of helper T-lymphocytes in hypersensitivity reactions 
(van Beelen, Teunissen et al. 2007; Joshi, Fong et al. 2009; Peiser 2013).  
However, previous work in patients with drug hypersensitivity has not studied 
the Th17 response in any detail.  Moreover, one of the cytokines secreted from 
Th17 cells, interleukin-22, represents a promising candidate for further study.  
Its receptor is a heterodimer comprised of one unit of both the interleukin-10 
receptor 2 and the interleukin-22 receptor 1 (Jones, Logsdon et al. 2008).  This 
interleukin-22 receptor is present in all tissues, such as the skin in high 
quantity, though is absent on immune cells (Wolk and Sabat 2006).  
Interleukin-22 is known to be involved in the response to bacterial pathogens, 
and is produced by both activated T-lymphocytes and to a lesser extent 
dendritic cells (Zheng, Valdez et al. 2008). 
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Figure 3.1.  CD14+ cells cultured in a 24-well plate, both pre- and post- maturation via 
the addition of LPS and TNF-α.  The un-matured CD14+ monocytes (left) are shown after 
6 days of dendritic cell polarisation using GM-CSF and interleukin-4.  These cells are 
immature and lack confluence.  In the CD14+ cells (right) there is clear clumping of the 
now matured dendritic cells, as highlighted by several arrows on the image.  These 
dendritic cells are not uniform in shape and have a tendency to stick to plates after 
culture and maturation, requiring scraping from the plate surface to acquire them.   
 
 
Drug-specific T-lymphocytes are able to secrete both pro- and anti-
inflammatory cytokines in response to stimulation with the appropriate drug-
derived antigen (Monshi, Faulkner et al. 2013).  In fact, Pichler recently devised 
a revised classification of delayed type drug hypersensitivity based on the 
Th1/Th2 cytokines secreted from drug specific T-lymphocytes (Pichler 2003).  
However, relatively little work has been done to characterise the complete 
profile of cytokines secreted by T-lymphocytes and their overall role in disease 
progression.  
  
 120 
 
3.2 AIMS AND HYPOTHESIS 
 
Investigation into the mechanisms of T-lymphocyte activation in patients with 
drug hypersensitivity is accomplished through characterisation of the 
phenotype and function of antigen-specific T-cells isolated from PBMC.  Beta-
lactam antibiotics are known to have a high incidence of hypersensitivity 
reactions and as such the T-cell response has been studied extensively.  The 
generation of T-cell clones responsive to the drugs has enabled researchers to 
define the way in which the drug activates T-cell and the nature of the induced 
response.  However, these patient studies tell us little about the processes 
involved in the activation of naïve T-cells as this occurs in patients prior to the 
appearance of hypersensitivity. 
Thus, this chapter focuses on healthy volunteer samples, and the responses 
that can be generated in response to piperacillin challenge.  A dendritic cell co-
culture T-cell assay was employed to prime naïve T-cells from donors that had 
never previously been exposed to the drug.  Successful priming allowed us to 
generate T-lymphocyte clones for further phenotypic analysis and functional 
characterisation.   
The working hypothesis was that: 
‘Drug-specific T-lymphocytes could be generated in naïve lymphocyte 
samples following priming using autologous dendritic cells, with the 
resulting primed lymphocytes able to give an insight into the T-
lymphocyte response observed in hypersensitive patients’. 
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3.3 METHODS 
 
All experimental methods used in this chapter are explained in greater detail in 
Materials and Methods Chapter 2.  They include: 
 Peripheral blood mononuclear cell isolation (2.5.1) 
 Magnetic separation of cell subsets (2.5.2) 
 Proliferation assay (2.5.3) 
 ELISpot (2.5.7) 
 Flow cytometry (2.5.8) 
 T-lymphocyte cloning (2.5.9) 
 EBV generation (2.5.10) 
 T-lymphocyte priming assay (2.5.14) 
 Memory T-lymphocyte priming assay (2.5.15) 
 Chemotaxis assay (2.5.16) 
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3.4 RESULTS 
 
3.4.1 Healthy volunteer PBMC do not respond to piperacillin exposure in vitro 
 
In order to fully understand the underlying mechanisms in piperacillin 
hypersensitivity, our first experiments focused on looking at healthy volunteer 
samples and if the interaction of T-cells with piperacillin resulted in a 
detectable proliferative response.  Four volunteers were selected, and PBMC 
were isolated from each individual using a standard protocol.  PBMC were used 
in a lymphocyte transformation test, with differing concentrations of 
piperacillin up to a maximal dose of 2mM.  PHA at a concentration of 5µg/ml 
was used as a positive control.  Proliferative responses to piperacillin were not 
observed with any concentration of the drug (SI<2).  In contrast, lymphocyte 
proliferative responses above control values were detected in PHA treated 
wells (SI>2).  These results ensured that the samples being used for further 
analysis did not harbour piperacillin responsive T-cells (figure 3.2).  Potential 
T-cell responses to other antibiotics (such as flucloxacillin or meropenem) 
were not investigated.  This was not considered to be relevant, as previous 
work has shown that piperacillin does not exhibit cross-reactivity to other 
beta-lactam antibiotics (El-Ghaiesh, Monshi et al. 2012; Yaseen, Saide et al. 
2015). 
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Figure 3.2.  Proliferative responses from 4 healthy volunteers assumed to be naïve to the 
beta-lactam antibiotic piperacillin.  PBMCs (1x104, 100µl) were cultured for 5 days in 
either T-lymphocyte culture media alone, differing concentrations of piperacillin up to a 
maximal 2mM, or PHA (5µg/ml) as a positive control.  Readouts were measured as CPM 
via [3H]-thymidine incorporation for the final 16h of the experiments.  Statistical analysis 
was performed via a one way ANOVA, compared to the control media well. (P=0.05 *, 
P=0.005 **, P= <0.001 ***). 
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3.4.2 T-lymphocyte cytokine secretion is dependent on the local micro-
environment 
 
In order to gain a greater understanding of T-lymphocyte polarisation and the 
role of the microenvironment, memory T-lymphocytes isolated from healthy 
volunteers were studies using a simple ELISpot assay.  Plates were pre-coated 
with CD3 antibody.  Cells were then cultured in the presence of polarising 
cytokines for 6 days (Th1 – IL-12 25ng/ml, Anti IL-4 100ng/ml; Th2 – IL-4 
25ng/ml, Anti IL-12 100ng/ml; Th17 – IL-1β 20ng/ml, IL-6 20ng/ml, IL-23 
20ng/ml, TGFβ 5ng/ml; Th22 – TNFα 50ng/ml, IL-6 20ng/ml).  After 
development of the assay, lymphocytes exposed to different polarising 
cocktails were shown to secrete different profiles of cytokines.  Th1 polarised 
cells secreted high levels of interferon-gamma, Th2 polarised cells secreted 
large amounts of the interleukin-13, Th17 polarised cells secreted interferon-
gamma, interleukin-17A, and interleukin-22 and the Th22 polarised cells 
secreted high levels of interleukin-22 in the absence of interleukin-17A (figure 
3.3).  This assay was repeated on several occasions with similar results.  The 
plasticity that is shown by T-lymphocytes is shown clearly in this assay, which 
demonstrates that polyclonal T-cell populations can initiate divergent T-cell 
responses when required.  These responses are at least partly determined by 
the microenvironment at the time of antigen exposure.  In addition, the cells 
require external stimuli in order to both survive and proliferate.  Shown in 
figure 3.4 are two well images taken from the same healthy donor.  In the well 
where medium alone is present, the lymphocytes are shown to be sparse and 
poorly viable.  In cells treated with anti CD3 and anti CD28 antibodies, large 
aggregation and expansion can be observed.   
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Figure 3.3.  ELISpot well images showing the differing cytokine secretions from a 
population of memory T-lymphocytes following culture in media containing polarising 
cytokines.  High levels of interferon-gamma are seen in Th1 cultures while high 
interleukin-13 is seen in Th2.  Th17 cultures display large secretions of interleukin-17A, 
with additional interferon-gamma and interleukin-22.  Th22 cultures display interleukin-
22 secretions in the absence of interleukin-17A, with low levels of both interferon-
gamma and interleukin-13 also detected. 
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Figure 3.4  Two representative wells containing memory T-lymphocytes in the absence 
(left) and presence (right) of external stimuli.  In cases where external stimuli are not 
present, lymphocytes are poorly viable and show little to no proliferative activity.  
However, when external stimuli such as the presence of anti CD3 and anti CD28 
antibodies are present, lymphocytes become highly proliferative and aggregate together 
in response to the stimuli. 
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3.4.3 Priming of healthy volunteer naïve T-lymphocytes to piperacillin using an 
autologous dendritic cell co-culture T-cell assay 
 
Following the results showing that the PBMC from volunteers are not 
responsive to piperacillin, a priming assay was designed utilising autologous 
dendritic cells and naïve T-cells.  First, cells were magnetically separated, then 
naïve T-lymphocytes were co-cultured with either piperacillin or 
sulfamethoxazole-nitroso (for a positive control comparison) for two weeks in 
order to generate a colony of primed T-lymphocytes.  Secondly, the primed T-
cells were re-stimulated with an additional batch of dendritic cells and drug for 
72h, then proliferative responses and cytokine release was measured.  In all 
samples, successful priming was observed to both piperacillin and 
sulfamethoxazole-nitroso (figure 3.5).  Proliferative responses were analysed, 
with an SI greater than 2 considered a positive result.  Responses to 
piperacillin and sulfamethoxazole nitroso were shown to be drug 
concentration dependant.  In some cases, the lowest concentration of tested 
drug (12.5µm SMX-NO, 0.5mM pip) did not show significant responses, but 
maximal drug concentrations all expressed highly significant priming for both 
tested drugs.  Moreover, the primed T-cells were not activated with the 
alternative drug, which confirms antigen specificity (results not shown).  
Combined results from the four donors are shown in figure 3.6.  In addition, 
cytokine secretion from these primed cells was analysed via ELISpot, with 
secretions of multiple cytokines observed in response to drug challenge 
(figure 3.7, figure 3.8).  Maximal cytokine secretion was observed at optimal 
drug concentration (50µM SMX-NO, 2mM pip).  PHA was included as a positive 
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control to measure total potential secretory ability.  Dose dependant secretion 
of IFNγ, IL-13 and IL-22 was observed in both sulfamethoxazole-nitroso and 
piperacillin primed conditions.  Interleukin-17A was not observed in any 
condition.  An additional condition was tested investigating the response in the 
absence of T-cells.  In these wells, cytokine secretion was abrogated, showing 
that the cytokines were being produced from the T-lymphocytes.  Finally, when 
compared together, both the sulfamethoxazole-nitroso and the piperacillin 
primed lymphocytes were shown to have significant dose-dependent 
responses to differing concentrations of drug challenge (figure 3.6).   
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Figure 3.5.  Recall proliferative responses of naïve T-lymphocytes after priming against 
either sulfamethoxazole-nitroso or piperacillin.  In each case, proliferation was analysed 
through the culture of T-lymphocytes (1x105/well, 100µl), antigen presenting cells 
(2x104/well, 50µl) and the appropriate culture condition (50µl) to a final well volume of 
200µl.  Statistical analysis was performed using a one way ANOVA to compare to the 
control and test wells.  All drug treated samples showed a significant increase in 
proliferation when compared to control wells.  (P=0.05 *, P=0.005 **, P= <0.001 ***).  
 
 
 
 
 
 
 
Figure 3.6.  Combined results displaying the proliferative response of primed T-cells 
from 4 donors following re-stimulation with either piperacillin or sulfamethoxazole-
nitroso.  With both drugs, T-cells from all individuals were combined and the 
appropriate statistical analysis was performed (one way ANOVA compared to control 
well).  These results mirror the individual proliferation results from the volunteers, with 
maximal proliferation observed to PHA.  In both cases, a dose-dependent response is 
observed to increasing drug concentrations, with the highest response observed at 
maximal concentrations of the drug.  
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Figure 3.7.  ELISpot analysis of newly primed T-lymphocytes to sulfamethoxazole-
nitroso.  ELISpot wells containing T-lymphocytes (1x105, 100µl), antigen presenting cells 
(2x104, 50µl) and the stated culture condition (µM) to a final volume of 200µl per well.  
Analysis was performed using an AID ELISpot reader.  Displayed are the results obtained 
from volunteer 2. Increasing concentrations of drug correlate with a clear dose-
dependent response observed in newly primed T-lymphocytes.   
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Figure 3.8.  ELISpot analysis of newly primed T-lymphocytes to piperacillin.  ELISpot 
wells containing T-lymphocytes (1x105, 100µl), antigen presenting cells (2x104, 50µl) 
and the stated culture condition (µM) to a final volume of 200µl per well.  Analysis was 
performed using an AID ELISpot reader.  Displayed are the results obtained from 
volunteer 2. Increasing concentrations of drug correlate with a clear dose-dependent 
response observed in newly primed T-lymphocytes.   
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3.4.4 T-lymphocyte clones generated from priming assays secrete IFNγ and IL-
13 alongside IL-22 
 
Following the successful T-lymphocyte priming observed in 3.4.3., the newly 
primed lymphocytes were used to generate T-lymphocyte clones specific to 
piperacillin.  Alongside this, EBV-transformed B-cell lines were generated from 
all volunteers and used as a ready supply of autologous antigen presenting 
cells.   Five hundred and twenty six clones were generated from the 4 donors.  
Of these, 64 were activated to proliferate to piperacillin (figure 3.9).  Clones 
were initially tested using duplicate control and piperacillin-treated (2mM) 
wells.  A stimulation index value of greater than 2 was taken as a positive 
result.  A predominantly CD8+ phenotype was observed in the drug-specific 
clones, which is the opposite of what is seen in hypersensitive patients (see 
other chapter results).  Across all 4 volunteer samples, similar numbers of both 
total tested clones and resulting drug-specific clones were observed, with 
between 117-150 total tested clones and 14-19 drug-specific clones generated.  
The average percentage generation of drug-specific clones was 12.1% (9.3% - 
15.7%).  From the drug-specific clones generated (n=64), 49 were shown to be 
CD8+, giving a CD8+ phenotype percentage of 76.6%.   
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ID Type # Tested # Specific % CD4+ % CD8+ 
Volunteer 1 Primed T 150 14 36 64 
Volunteer 2 Primed T 121 19 37 63 
Volunteer 3 Primed T 138 16 6 94 
Volunteer 4 Primed T 117 15 13 87 
 
Figure 3.9.  A table showing the generation of clones from 4 volunteers that had 
previously been primed to piperacillin.  A total of 64 drug-specific clones were generated 
from 526 tested individual clones. 
 
 
From the drug-specific T-lymphocyte clones generated, 10 clones per 
volunteer were chosen and expanded by repetitive mitogen stimulation for 
further investigation.  The clones were chosen though a combination of initial 
proliferative values, in addition to overall cell numbers available for analysis.  
Moreover, CD4+ and CD8+ clones from each volunteer was selected.  Clones 
were found to proliferate in the presence of piperacillin in a dose-dependent 
manner, with a drug concentration of 1-2mM stimulating maximal responses.  
Therefore, 2mM was used in ELISpot experiments to profile the cytokines 
secreted from the piperacillin-specific clones.  Multiple cytokines were 
measured for each drug specific clones; namely interferon-gamma, interleukin-
13, interleukin-17A and interleukin-22.  Experiments were conducted 
according to the methods stated in Materials and Methods Chapter 2, as well as 
following manufacturer’s instructions.  For all clones tested, secretion of 
interferon-gamma and interleukin-13 was observed when compared to control 
wells.  Approximately half of all tested clones secreted interleukin-22 at 
differing levels.  In contrast, no interleukin-17A secretion was observed (figure 
3.10, figure 3.11).  
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Figure 3.10.  Cytokine secretion from piperacillin-specific T-lymphocyte clones that have 
been generated from previously primed naïve T-lymphocytes.  T-cells (1x105, 100µl) 
were stimulated with autologous dendritic cells (2x104, 50µl) and culture condition 
(either culture media alone or piperacillin at 2mM, 50µl) and cytokine secretions then 
measured by ELISpot.  This analysis was undertaken on all clones.  Clones selected show 
secretion of interferon-gamma and interleukin-13, as well as differing levels of 
interleukin-22.  No clones secreted interleukin-17A.   
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Figure 3.11.  Cytokine secretion from piperacillin-specific T-lymphocyte clones that have 
been generated from previously primed naïve T-lymphocytes.  T-cells (1x105, 100µl) 
were stimulated with autologous dendritic cells (2x104, 50µl) and culture condition 
(either culture media alone or piperacillin at 2mM, 50µl) and cytokine secretions then 
measured by ELISpot.  This analysis was undertaken on all clones.  Clones selected show 
secretion of interferon-gamma and interleukin-13, as well as differing levels of 
interleukin-22.  No clones secreted interleukin-17A.   
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3.4.5 Chemotaxis to ligands occurs in response to chemokine receptors 
differentially expressed on clones 
 
Further investigations were undertaken to characterise the phenotype of cell 
surface chemokine receptors that were expressed on the T-lymphocyte clones.  
A panel of chemokine receptors, listed in figure 3.12 were investigated.  
Analysis of the data was conducted through a combination of Cyflogic and 
Flowing software.  First, the clones were gated using forward and side scatter 
(FSC / SSC) as shown in figure 3.13.   
 
Tube Number PE APC FITC 
1 Unstained Unstained Unstained 
2 CCR1 CCR2 CLA 
3 CCR4 CCR6 CD69 
4 CCR8 CCR9 CCR5 
5 CCR10 CXCR3 CCR3 
6 E-Cadherin CXCR6 Blank 
 
Figure 3.12.  Table displaying the layout for chemokine receptor staining that was used 
for all analyses.  In each tube, 1x105 cells were re-suspended in MACS buffer (200µl) and 
ran through a FACS Canto II machine to acquire readouts for receptor expression.  4µl of 
fluorochrome antibodies were added per condition to each well.   
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Figure 3.13.  Screenshots of the flow cytometry analysis conducted using Flowing 
Software.  In this image, initial whole event captures are displayed on the left image.  
The highlighted red area shows where the viable lymphocyte population is located.  
Gating on this area allows for removal of the background undesirable cells and cell 
fragments (shown on right).  This allows for investigations into only the desired 
populations through relative fluorochrome expressions on the X and Y axis (example 
shown is a control unstained sample top, with CD4-PE expressing clones shown on the 
bottom). 
 
All chemokine receptor analysis was performed through comparing the MFI 
(mean fluorescent intensity) of expressed fluorochromes on clones when 
compared to control samples stained with a relevant isotype control (figure 
3.14).  
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Receptor Volunteer 1 Volunteer 2 Volunteer 3 Volunteer 4 
CCR1 ✓✓ ✓✓ ✓✓ ✓✓✓ 
CCR2 ✓✓ ✓✓ ✓✓ ✓✓ 
CCR3 X X X X 
CCR4 ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ 
CCR5 ✓✓ ✓✓ ✓✓ ✓✓ 
CCR6 X X X X 
CCR8 ✓✓ ✓✓ ✓✓ ✓✓ 
CCR9 ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ 
CCR10 ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ 
CXCR3 ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ 
CXCR6 ✓ ✓ ✓ ✓ 
CD69 ✓✓✓ ✓✓✓ ✓✓✓ ✓✓✓ 
CLA X X X X 
E-Cadherin ✓ ✓ ✓ ✓ 
 
Figure 3.14.  Table showing the relative expression of different chemokine receptors in 
relation to control samples as a comparison of MFI.  (✓= MFI difference 1.5-2, ✓✓= MFI 
difference 2-2.5, ✓✓✓ = MFI difference 2.5+). 
 
 
Although clones across volunteers expressed the same chemokine receptors 
(figure 3.14), individual clones were shown to express differing levels of each 
receptor. 
The functional consequence of receptor expression was investigated using a 
chemotaxis assay containing chemokine ligands to respective receptors.  
Lymphocyte migration was expressed as percentage migration, with receptor 
expression-dependent migration observed across clones.  A total of 12 clones 
were investigated (3 per volunteer) and analysis performed in the presence of 
RANTES, CCL2, CCL4, CCL17, CCL25, CCL27, CXCL9 and CXCL16, ligands to 
CCR1, CCR2, CCR5, CCR4, CCR9, CCR10, CXCR3 and CXCR6 respectively at a 
number of time points (0h, 1h, 2h, 24h) to measure percentage migration 
(figure 3.15).  Migration by clones was observed in both a time and receptor 
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expression dependant manner, with highly expressed receptors correlating 
with maximal percentage migration.   
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Figure 3.15.  Time dependant chemotaxis of T-cell clones towards individual 
chemokines.  A total of 12 clones were investigated (3 per volunteer) over multiple time 
points (0h, 1h, 2h, 24h).  Percentage migration was obtained through cell counts 
performed at the allotted time points, with total cell number minus cells counted used to 
work out percentages. 
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3.5 DISCUSSION 
 
The method of antigenic recognition in patients with beta-lactam 
hypersensitivity is hypothesised to involve the binding of the beta-lactam ring 
to exposed lysine residues on host proteins.  In agreement with this 
hypothesis, sophisticated mass spectromic methods have been used to 
characterise the site selective binding of various beta-lactam antibiotics to the 
protein human serum albumin (Jenkins, Meng et al. 2009; Whitaker, Meng et al. 
2011).  The derived protein adducts are thought to be taken up by antigen 
presenting cells and processed to liberate a range of peptides, some of which 
contain the drug bound to lysine.  Although the precise nature of antigenic 
peptides is yet to be defined, research conducted prior to commencement of 
these studies revealed that albumin adduct active T-cells from hypersensitive 
patients and fixation of APC which blocks protein processing inhibits the T-cell 
response (El-Ghaiesh, Monshi et al. 2012).  At the St. James’ Hospital regional 
adult cystic fibrosis centre, the majority of patients that are treated there 
develop hypersensitivity to at least one antibiotic, with multiple drug 
hypersensitivity a common occurrence.  While hypersensitivity reactions in the 
healthy population are relatively uncommon, it is much higher in patients who 
are suffering with cystic fibrosis, and as such are exposed to greater and more 
frequent antibiotic dosing regimens (Parmar and Nasser 2005).   
Previous studies have shown that PBMC’s from both drug tolerant patients and 
naïve donors do not respond in a lymphocyte transformation test when 
stimulated with allergenic drugs at optimal concentrations.  Figure 3.2 shows 
similar findings with piperacillin.  Proliferation of lymphocytes cultured with 
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piperacillin was not observed.  These data show that the volunteer samples 
used in subsequent investigations throughout the chapter would not respond 
to the beta-lactam antibiotic piperacillin under normal culture conditions using 
methods to characterise T-cell responses in drug hypersensitive patients. 
The polarisation of helper T-lymphocytes has been extensively reported in 
multiple studies (Romagnani 1997; Sallusto, Lanzavecchia et al. 1998; Kidd 
2003).  While the classical Th1 / Th2 distinction has been the mainstream 
profiling conducted for multiple years, recent advances into the lymphocytic 
phenotypes have led to the discovery of newer subtypes, such as Th9, Th17 and 
Th22 (Eyerich, Eyerich et al. 2009; Korn, Bettelli et al. 2009; Schlapbach, Gehad 
et al. 2014).  Th1 cells are considered to be pro-inflammatory, with interferon-
gamma the main cytokine secreted from these cells.  Other pro-inflammatory 
cytokines are known to be secreted from these cell types, alongside cytolytic 
molecules such as fas ligand and granzyme B.  In contrast, the Th2 class of 
lymphocytes display a more anti-inflammatory phenotype, with low levels of 
interferon-gamma and higher levels of cytokines such as interleukin-5 and 
interleukin-13 (Berger 2000).  The pro- and anti-inflammatory nature of these 
two classes are typified though the perception that Th1 cells are involved in 
and promote MHC class I driven  cytotoxic T-cell responses, with Th2 secreting 
cells linked to the promotion of B-cell responses and antibody production.  It 
should however be noted that that separation of T-cells into a Th1/Th2 
phenotype is not universal.  Many antigens stimulate human T-cells to secrete 
both Th1 and Th2 cytokines. 
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The perception that Th1/Th2 polarised signalling describes all forms of 
immune response is now outdated.  It fails to take into account the newer 
cytokines identified that have integral roles in lymphocyte responses, such as 
interleukin-17A and interleukin-22.  For example, the highly pro-inflammatory 
interleukin-17A is secreted from Th17 cells (Miossec, Korn et al. 2009), 
alongside high levels of interferon-gamma and interleukin-22.  Th22 cells also 
secrete interleukin-22, but in the absence of interleukin-17A.  Interleukin-22 
can be considered both pro- and anti-inflammatory depending on the other 
cytokines being secreted from T-cells, as well as the location of cytokine 
secretion (Duhen, Geiger et al. 2009).  This plasticity of helper T-lymphocytes 
is demonstrated further in figure 3.3.  Completely different cytokine secretion 
profiles are displayed with memory T-lymphocytes when the cells are cultured 
for 6 days in different cytokine micro-environments.  In cases of chronic 
pathology where tissue microenvironments could contain multiple cytokines, 
the plasticity of these cells and their potential involvement in hypersensitivity 
cannot be understated.   
An initial investigation into priming naïve T-lymphocytes with autologous 
dendritic cells and sulfamethoxazole-nitroso was conducted to establish the 
assay conditions and to serve as a positive control.  Sulfamethoxazole-nitroso 
is considered a ‘model hapten’ due to its propensity to stimulate T-cells from 
hypersensitive patients (Castrejon, Berry et al. 2010), as well as in animal 
models of immunogenicity (Naisbitt, Williams et al. 2001).  Moreover, SMX-NO 
has previously been shown to activate T-cells from healthy drug naïve donors 
using a range of culture conditions (Pichler 2003; Faulkner, Martinsson et al. 
2012).  In cases where the underlying mechanisms of sensitisation and 
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resulting hypersensitivity is unclear, this novel method of using cells from 
healthy donors could help to elucidate pathways of drug-specific T-cell 
activation.  The work undertaken in this chapter was to explore the activation 
of naïve T-cells to the beta-lactam piperacillin, which is known to form 
penicilloyl protein conjugates as a result of the opening of the beta-lactam ring 
(Weltzien and Padovan 1998; Whitaker, Meng et al. 2011).  Successful priming 
of purified naïve T-cells was observed in 4 volunteers to both 
sulfamethoxazole-nitroso and piperacillin as shown in figure 3.5 and figure 
3.6.  Statistically significant priming (P= <0.001) was seen at optimal 
concentrations of both the nitroso metabolite (at 50µM) and piperacillin (at 
2mM).  The strength of the induced response to SMX-NO and piperacillin was 
higher than that observed with 7 other drugs studied in Liverpool (Monshi, 
Faulkner et al. 2013; Gibson, Ogese et al. 2014; Yaseen, Saide et al. 
2015)(unpublished data).  This could be due to multiple factors, chief of which 
would be the simple fact that priming to non-reactive drugs is more difficult, 
with lower proliferation values observed across the board for compounds 
activating T-cells via a PI mechanism involving the direct binding of the drug to 
MHC molecules.   
Previous studies have shown that both Th1 and Th2 cytokines are secreted 
from T-cells from beta-lactam hypersensitive patients (Whitaker, Meng et al. 
2011).  In the original dendritic priming investigation, both pro- and anti-
inflammatory cytokines were also found to be secreted from SMX-NO specific 
T-cells following successful priming (Faulkner, Martinsson et al. 2012).  In 
agreement with this, figure 3.6 shows that both IFNγ and IL-13 are secreted 
following re-stimulation of piperacillin naïve T-cells.  Furthermore, T-cells 
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secreted interleukin-22 following piperacillin and SMX-NO treatment.  In 
contrast, IL-17A secretion was not detected.  These data prompted us to 
investigate the functionality of the drug specific T-cells in greater detail. 
Many studies have shown the value of the lymphocyte serial dilution assays for 
the generation of drug-specific T-lymphocyte clones (Naisbitt, Britschgi et al. 
2003; Farrell, Lichtenfels et al. 2013).  Previous work in our department have 
shown that beta-lactam drug-specific clones are able to be generated, with 
piperacillin clones displaying a predominantly CD4+ phenotype.  Figure 3.9 
shows that successful generation of drug-specific T-lymphocyte clones is 
possible after naïve lymphocyte priming.  Of the total 526 clones tested, 64 
were shown to have a SI greater than 2 indicating drug specificity for a 
percentage generation of 12.2%.  In contrast to previously reported data, the 
majority of clones generated were of a CD8+ phenotype, although CD4+ clones 
were also present.  This dichotomy of results is difficult to reconcile, though 
the in vitro assay and the ‘forced’ priming of naïve lymphocytes to a specific 
compound might explain the disparity.   
Clones were shown to secrete both pro- and anti-inflammatory cytokines, 
though again no interleukin-17A was detected from the clones.  While 
extensive studies have characterised Th1, Th2 and Th17 lymphocytes, no sub-
class of cells fully marry up with the cytokine secretion profiles observed in 
piperacillin specific clones (Zhu and Paul 2008).  The presence of interleukin-
22 in the absence of interleukin-17A suggests a different sub-class of helper T-
lymphocytes, such as the Th22 class (Akdis, Palomares et al. 2012).  This 
suggestion can be further backed up due to the cutaneous nature of 
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interleukin-22’s physiological action, and its dual pro- and anti-inflammatorial 
nature (Boniface, Guignouard et al. 2007). 
In order to further understand the profile of drug-specific lymphocytes present 
in piperacillin hypersensitivity reactions, an investigation into chemokine 
receptor expression was undertaken.  Previous studies have highlighted the 
ability to select lymphocytes from a whole population of cells and cell 
fragments (Pechhold, Pohl et al. 1994).  Viable lymphocytes could be identified 
through a CD3+ phenotype, with the resulting cells stained with multiple 
markers of cell surface receptors to a host of chemokines.  Of particular 
interest are the receptors CCR1, CCR4, CXCR3 and CCR10.  CCR1 is involved in 
both lymphocyte recruitment and activation, as well as having a link to both 
innate and adaptive immunity (Weber, Weber et al. 2001).  CCR4 is linked to 
cutaneous trafficking of lymphocytes, suggesting a key role in cutaneous 
hypersensitivity syndromes.  CXCR3 is found in numerous inflamed tissues, as 
well as integrin activation (Qin, Rottman et al. 1998).  CCR10 is expressed on 
multiple lymphocytes and its interaction with CCL27 is heavily implicated in T-
lymphocyte mediated cutaneous inflammation, again suggesting an important 
role for the hypersensitivity commonly observed to beta-lactam antibiotics 
(Soler, Humphreys et al. 2003). 
A selection of 10 clones per volunteer were chosen for chemokine analysis, 
with the resultant expressions recorded as MFI increase above a baseline.  Of 
the receptors that were investigated as shown in figure 3.14, some were 
expressed constitutively across all clones, such as CD69.  This is not 
unexpected, due to the fact that it is a marker of activation which would be 
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present on dividing lymphocytes such as the tested clones(Cambiaggi, Scupoli 
et al. 1992). 
Significant increases in expression were observed in chemokine receptors, 
including CCR1, CCR4, CCR10 and CXCR3.  These were elevated compared to 
controls, suggesting a high level of expression across all drug-specific clones.  
These receptors are all implicated in either lymphocyte trafficking or 
cutaneous migration which, when taken in tandem with the clones ability to 
secrete the tissue specific cytokine interleukin-22, suggests that these cells are 
important mediators of piperacillin hypersensitivity. 
Though these clones have been shown to have the potential to migrate in 
response to chemokines, due to their high receptor expressions proof of 
migratory ability is required.  To accomplish this, chemotaxis assays were 
employed.  The assay used assesses the ability of clones to migrate across a 
semi-permeable barrier in the presence of differing concentrations 
chemokines (Gibson, Ogese et al. 2014).  Migration in response to ligands was 
matched to receptors expressed on the cell surfaces.  Figure 3.15 shows that 
time-dependent migration occurred in response to chemokine ligand presence. 
Taken in totality, the naïve T-lymphocytes were successfully primed to 
piperacillin and elicited responses typical of a hypersensitivity reaction.  These 
primed drug responsive lymphocytes were cloned and expanded.  The cloned 
cells displayed a interleukin-22+ cytotoxic CD8+ phenotype.  In addition, the 
drug-specific lymphocytes expressed receptors, and were able to migrate in 
response to chemokines that are implicated in cellular trafficking to inflamed 
sites, as well as the skin.  These data suggest that piperacillin-specific T-
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lymphocytes play an integral role in the progression of hypersensitivity.  
Though this work has only been conducted on volunteer samples, the value of 
this data cannot be understated and the impetus to investigate the role of drug-
specific T-lymphocytes in patients with piperacillin hypersensitivity is now 
clear.  The role of interleukin-22 also seems to be important and this is studied 
in much more detail in other chapters. 
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4.1 INTRODUCTION 
 
Cystic fibrosis is a lethal autosomal recessive disorder which is one of the most 
common conditions across the globe, especially in western Caucasian 
populations (Cutting, Curristin et al. 1992).  It is estimated that 4% of the 
population of the United Kingdom are recessive carriers of the gene 
responsible, with approximately 10,000 people thought to have the condition 
in the country as of 2014 (www.cysticfibrosis.org.uk).  Cystic fibrosis is caused 
through a mutation of the cystic fibrosis transmembrane conductance 
regulator protein, which is coded for through the CFTR gene located at position 
q31.2 on the long arm of chromosome 7 (Rommens, Iannuzzi et al. 1989).  This 
is a highly polymorphic region of coding DNA, which is responsible for the 
mutations resulting in the condition.  Over 1500 individual mutations have 
been observed, though by far the most common is the ΔF508 deletion (Kerem, 
Rommens et al. 1989; Bobadilla, Macek et al. 2002).  In the case of ΔF508, the 
deletion of the phenylalanine causes a premature stop codon to exist, resulting 
in an incorrect tertiary structure of the resultant protein.  This misshapen 
protein is not able to translocate to the cell membrane, and as a result ion 
transport is halted (Welsh and Smith 1993).  The fully functional protein is 
involved in the transport of chloride ions across cell membranes in the 
epithelium, through a cAMP- activated ATP anion gated channel (Dalemans, 
Barbryt et al. 1991).  Mutations in the CFTR gene can result in numerous 
problems, such as insufficient ion transport, complete inactivity of the ion gate 
or inability of the freshly synthesised protein to translocate to the cell 
membrane.  In cystic fibrosis, the secretion of chloride is reduced, with a 
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resultant increase in sodium absorption (Sheppard and Welsh 1999).  This 
leads to reduced liquid in the airways, as well as defective ciliary function.  A 
hallmark of cystic fibrosis and a long used diagnostic test involves the 
investigation of patient sweat, as the excessively salty sweat caused through 
this ion imbalance is a characteristic of the condition (Mishra, Greaves et al. 
2005).   
Due to decreased liquid in the airways, patients with cystic fibrosis are known 
for exhibiting excessively viscous mucus.  This is a major impediment to 
patient quality of life, with repeated physiotherapeutic treatments required to 
allow for improvement of patient prognosis through mucus removal (Govan 
and Deretic 1996).  This thick mucus is a location where opportunistic 
infections and bacteria are known to frequent, with the conditions optimal for 
their survival and growth (Lyczak, Cannon et al. 2002).  The effect of these 
opportunistic pathogens in the airways results in the eventual mortality of 
over 80% of patients with cystic fibrosis (Turcios 2005; O'Sullivan and 
Freedman 2009).   
Treatment of these infections usually consists of a combination treatment of 
beta-lactam antibiotic and aminoglycoside (as well as a beta-lactamase 
inhibitor in some cases).  However, a barrier to this treatment regimen exists 
in the fact that patients with cystic fibrosis exhibit a markedly higher incidence 
of beta-lactam hypersensitivity when compared with the healthy population 
(Parmar and Nasser 2005; Burrows, Nissen et al. 2007).  As a result of this, 
treatment regimens are often unsuitable for the patients, resulting in the 
development of resistant bacteria and the quick exhaustion of traditional 
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treatment options.  Studies have shown that in cases where patients with cystic 
fibrosis exhibit hypersensitivity to at least one antibiotic, there is a 1 in 5 
chance that they will exhibit multiple drug hypersensitivity (Whitaker, Naisbitt 
et al. 2012).  Though reactions to beta-lactam antibiotics are typically delayed-
type in nature and therefore mediated through T-lymphocytes and their 
secretions, immediate hypersensitivity is observed in a small number of cases.  
In cases of delayed-type piperacillin hypersensitivity, the mean time of onset of 
symptoms following drug administration is 9.1 days (Whitaker, Meng et al. 
2011).  Interestingly, severe forms of skin eruption (e.g. Stevens-Johnson 
syndrome), as well as internal organ damage are rarely seen in the 
hypersensitive patients. 
Multiple drug hypersensitivity is a major clinical concern, as treatment options 
soon become exhausted.  Multiple hypersensitivity is where reactions are 
observed in at least 2 drugs of a different chemical class (Gex-Collet, Helbling et 
al. 2005; Pichler, Adam et al. 2010).  Due to the high frequency of this condition 
in patients with cystic fibrosis, more radical treatment methods, such as dual 
lung transplants, are considered as a last line of treatment.  Single lung 
transplants are often the only available treatment in patients, meaning that 
lung conditions are often critical to cystic fibrosis patient’s prognosis.  
However, even single lung transplants are considered highly dangerous, due to 
the risk of a bacterial colony that is present in the un-transplanted lung 
infecting the newly acquired lung and being unable to be treated (Belkin, Henig 
et al. 2006).   
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Cross-reactivity between beta-lactam antibiotics is reportedly low, with few 
compounds implicated in truly allergic cross reactivity.  Aztreonam and 
penicillins were safely tolerated in 95% of patients in a study (Moss 1991), 
with others reporting no cross-reactivity observed in piperacillin treated 
patients (Romano, Gue ant-Rodriguez et al. 2004).  However, though cross-
reactivity is a minor concern, patients often are shown to be sensitised to 
another compound upon withdrawal of the initial antibiotic, further clouding 
the treatment options (Atanaskovic-Markovic, Gaeta et al. 2008).   
Previous studies in our lab have shown that piperacillin-specific T-lymphocyte 
clones generated from patients with cystic fibrosis secreted pro-inflammatory 
cytokines in response to drug challenge, as well as highly significant 
proliferative responses (Monshi, Faulkner et al. 2013; Yaseen, Saide et al. 
2015).  The ability to use these clones for further mechanistic studies allows 
for a greater potential understanding of the underlying mechanism of the 
hypersensitive response.  The observed pro-inflammatory cytokines that were 
secreted suggested a Th1 response, though no studies in cystic fibrosis patients 
have taken into consideration the potential role of newer classes of helper T-
lymphocytes, such as Th17 and its hallmark, interleukin-17A as well as the 
poorly understood Th22 class of cells, with its high levels of interleukin-22 
secretion.  Interleukin-17, in contrast to interleukin-22, is known to be a highly 
pro-inflammatory cytokine that has been shown to exert its effect through the 
mediation of certain chemokines implicated in inflammatory conditions 
(Onishi and Gaffen 2010).  It has been shown to be strongly involved in 
autoimmune disorders, as well as skin conditions such as psoriasis (van 
Beelen, Teunissen et al. 2007).  Integral to its involvement in the inflammatory 
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response is the triggering of neutrophil and macrophage recruitment, which is 
a key part of the immune cascade observed in the presence of interleukin-17 
(Linden, Hoshino et al. 2000; Sergejeva, Ivanov et al. 2005). 
As the receptor for interleukin-22 is located exclusively on tissues such as the 
skin (Wolk, Kunz et al. 2004), the potential role for interleukin-22 in the 
progression of cutaneous reactions cannot be overlooked.  It can be considered 
both a pro- and anti-inflammatory cytokine, depending on the poorly defined 
conditions in which it is generated.  In addition, studies have reported that 
interleukin-22 is critical in bacterial pathogen defence, alongside epithelial 
remodelling (Sonnenberg, Fouser et al. 2010).  Due to these conditions, a 
potential role for interleukin-17 and interleukin-22 in the progression of the 
cutaneous symptoms observed in beta-lactam hypersensitivity in cystic 
fibrosis is a realistic possibility.   
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4.2 AIMS AND HYPOTHESIS 
 
The high incidence of drug hypersensitivity observed in patients with cystic 
fibrosis treated with beta-lactam antibiotics is an important clinical concern, 
yet the underlying pathomechanism that drives this reaction is not yet 
understood.  Through our collaboration with the cystic fibrosis centre at St. 
James’ hospital we had access to patients with cystic fibrosis who were willing 
to donate samples for research into this iatrogenic disease. 
Through the generation of piperacillin-responsive T-lymphocyte clones it was 
possible to enhance our understanding of the immune pathophysiology that 
was associated with drug treatment.  Since interleukin-17 and interleukin-22 
are implicated in other forms of cutaneous disease, alongside the fact that 
receptors for both cytokines are located in tissues such as the skin, our 
research focused on the potential role that interleukin-17 and interleukin-22 
could play in driving the hypersensitivity reaction.  We proposed the following 
hypothesis: 
‘Drug-specific T-lymphocytes isolated from patient PBMC secrete tissue-
specific cytokines that are responsible for driving observed 
hypersensitivity reactions.’ 
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4.3 METHODS 
 
All experiments described in this chapter were performed using methods 
explained in greater detail in Materials and Methods Chapter 2.  These include: 
 Peripheral blood mononuclear cell isolation (2.5.1) 
 Proliferation assay (2.5.3) 
 Lymphocyte transformation test (2.5.4) 
 ELISA (2.5.5) 
 Bradford assay (2.5.6) 
 ELISpot (2.5.7) 
 Flow cytometry (2.5.8) 
 T-lymphocyte cloning (2.5.9) 
 EBV generation (2.5.10) 
 MHC restriction assay (2.5.13) 
 Chemotaxis assay (2.5.16) 
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4.4 RESULTS 
 
4.4.1 PBMC isolated from hypersensitive patients proliferate in vitro in the 
presence of piperacillin 
 
Lymphocyte transformation tests (LTTs) were performed on PBMC isolated 
from four piperacillin hypersensitive patients with cystic fibrosis.  
Hypersensitivity to piperacillin had previously been diagnosed, according to 
clinical criteria.  Patients had not been exposed to the drug for several years.  
T-lymphocytes (1.5x105 / well, 100µl) were cultured in the presence of 
different concentrations of piperacillin, up to a maximal 2mM concentration 
(100µl).  After the addition of [3H]-thymidine for the final 16h of the assay (as 
outlined in 2.5.4), readings were taken as CPM, with a positive result 
considered to be a SI greater than 2.  All four patients showed significant dose-
dependent proliferative responses in the presence of piperacillin.  In certain 
circumstances the response observed with piperacillin was above the positive 
control (tetanus toxoid, 10µg/ml).  Figure 4.1 shows the dose-response graphs 
for four donors whose samples were used throughout this work.  An optimal 
concentration of 2mM of piperacillin was identified, due to the resulting drop 
in proliferative response observed at a higher 4mM concentration.  This drop 
off was assumed to be due to toxicity, with the drug causing cell death rather 
than proliferation.  PBMC from four tolerant controls, along with healthy 
donors, were not activated following culture with piperacillin.  Proliferative 
responses were seen in tetanus toxoid treated cells (data not shown).   
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Figure 4.1.  Lymphocytes from hypersensitive patients proliferate in vitro in the 
presence of piperacillin.  PBMC were isolated and cultured with increasing 
concentrations of piperacillin (0.25mM – 4mM), or tetanus toxoid (positive control) for 5 
days.  [3H]-thymidine incorporation was used to detect antigen-specific T-lymphocyte 
responses.  Readings were taken in triplicate, with statistical analysis performed via one-
way ANOVA compared to the negative control.  ** - P=0.005, *** - P=<0.001. 
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4.4.2 PBMC isolated from hypersensitive patients secrete interferon-gamma, 
interleukin-13 and interleukin-22 in response to piperacillin  
 
After positive lymphocyte proliferative responses to piperacillin were 
detected, further investigations were performed to assess the profile of 
cytokines secreted.  Lymphocytes (1x105 / well) were cultured with media 
alone, piperacillin (at an optimal concentration of 2mM), or PHA (5µg/ml) in 
order to elicit cytokine release.  A range of cytokines were investigated, to 
obtain an overview of the potential for PBMC to secrete Th1, Th2, Th17 and/or 
Th22 cytokines.  All four hypersensitive patients were investigated, with the 
results from donors 1 and 4 displayed in figure 4.2.  In a resting state when 
PBMC were cultured with media alone, all donors displayed a low level of 
interferon-gamma secretion, with no other cytokines detected.  Challenge with 
piperacillin elicited strong cytokine responses, with interferon-gamma, 
interleukin-13 and interleukin-22 detected from all donors.  Interleukin-17A 
secretion was not detected from piperacillin treated PBMC.  Interestingly, 
interleukin-17A was detected when the PBMC were exposed to the positive 
control PHA, showing that the cells had the potential to secrete interleukin-
17A.  Secretion of both interferon-gamma and interleukin-22 in drug and PHA 
stimulated wells were compared and no significant difference was observed 
(P>0.05), which suggests drug challenge elicited a near maximal interferon-
gamma and interleukin-22 response. 
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Figure 4.2.  Cytokine secretion from hypersensitive patient PBMC in response to 
piperacillin.  PBMC (1x106, 200µl) were cultured with piperacillin or PHA as a positive 
control for 48h at 37°C, 5% CO2.  The secretion of cytokines were visualised via ELISpot 
using commercially available kits.   Exposure of PBMC to piperacillin resulted in the 
secretion of interferon-gamma, interleukin-13 and interleukin-22.  Interleukin-17A was 
not observed from drug-stimulated wells.  Figure shows representative images from two 
patients.  Other patient responses were comparable.   
  
 163 
 
4.4.3 Quantification of interleukin-22 secretion from patient PBMC and memory 
T-lymphocyte cultures 
 
Though ELISpot analysis is useful for low level quantification of cytokine 
secretions, spot-forming units do not allow for accurate quantification of total 
cytokine levels.  In order to address this, supernatants were harvested from T-
lymphocyte cultures following drug exposure for 2 days and assessed for the 
presence of interleukin-22 via ELISA.  PBMC and magnetically separated 
memory T-lymphocytes from 4 hypersensitive patients were used for this 
analysis, under different cytokine polarising conditions (see figure 2.1 – 
Chapter 2).  Similar levels of interleukin-22 were detected following 
piperacillin exposure to PBMC and memory cell lines exposed to the control 
CD28 in the absence of polarising conditions.  Exposure to Th1/Th2 polarising 
conditions significantly reduced the levels of interleukin-22 from piperacillin 
treated PBMC and memory T-cells (figure 4.3).  In contrast, a significant 
increase in interleukin-22 was detected with memory T-lymphocytes exposed 
to piperacillin under Th17 and Th22 polarising conditions.  Negligible levels 
were observed in the medium control for both cell types.  High levels 
(1500pg+) of interleukin-22 were detectable in both the Th17 and Th22 
conditions.  Though secretion levels were similar, higher interleukin-22 levels 
where seen from the memory T-lymphocytes. 
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Figure 4.3.  Quantification of interleukin-22 secretion from hypersensitive patient PBMC 
and memory T-lymphocytes following exposure to piperacillin under polarising 
conditions.  Interleukin-22 was measured after 2 days in culture supernatants via ELISA.  
Interleukin-22 in media control wells in the absence of piperacillin (not shown) was 
subtracted from the drug-treated wells.  CD28 stimulation was used as a positive control.  
Statistical analysis was performed via Students’ T-test comparing CD28 positive control 
values to differing polarising conditions (** = P> 0.005, *** = P>0.001). 
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4.4.4 Drug-specific T-lymphocyte clones generated from patient PBMC mainly 
express a CD4+ phenotype 
 
PBMC isolated from patients hypersensitive to piperacillin were cultured for 
14 days in the presence of piperacillin (2mM), with the resulting T-lymphocyte 
lines serially diluted to generate individual clones.  Clones that expanded to 
approximately 1x106 cells were tested for piperacillin specificity, with a SI 
greater than 2 considered a positive response when tested with 2mM 
piperacillin (cpm drug-treated / cpm control) (figure 4.4).  
In total, 1440 clones were generated from the four hypersensitive patients.  
Following specificity testing, 570 clones produced a stimulation index of 2 or 
greater; hence, an antigen-specific generation rate of 39.6%.  It should be noted 
that the majority (361) of these piperacillin specific clones were from a single 
donor (figure 4.5). 
All piperacillin specific clones were phenotyped by flow cytometry.  Four 
hundred and ninety four were shown to be CD4+, with 77 recorded as CD8+.  Of 
these clones, the majority were frozen down and stored in liquid nitrogen for 
potential future analysis, with 40 well growing clones selected for expansion 
and further analysis. 
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Figure 4.4.  Piperacillin specific proliferative responses of clones generated from 
hypersensitive patients.  A stimulation index of greater than 2 was considered to be a 
positive result (shown on the graph as the horizontal line).  All piperacillin responsive 
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clones were further expanded for analysis. 
 
Figure 4.4.  Piperacillin specific proliferative responses of clones generated from 
hypersensitive patients.  A stimulation index of greater than 2 was considered to be a 
positive result (shown on the graph as the horizontal line).  All piperacillin responsive 
clones were further expanded for analysis. 
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ID Type # Tested # Specific % CD4+ % CD8+ 
Donor 1 Blood 768 361 87 13 
Donor 2 Blood 104 34 84 16 
Donor 3 Blood 376 134 89 11 
Donor 4 Blood 192 41 77 23 
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Figure 4.5.  (Top) Table showing the generation of piperacillin-specific T-lymphocyte 
clones from hypersensitive patient PBMCs.  A total of 1440 clones were generated from 
four patients, with 570 piperacillin-specific clones detected.  Clones (5x104 cells/well) 
were cultured with autologous EBV (5x103/well) in the presence of piperacillin for 48h, 
with [3H]-thymine (0.5µCi/well) added 16h prior to finishing.  Specific clones were 
determined via a SI of greater than 2.  CD phenotyping was conducted via flow cytometry 
to all piperacillin specific clones.  (Middle) Flow cytometry trace showing phenotyping 
of tested clones.  A minimum of 5x105 events were used for CD phenotyping, with an 
either/or gating mechanism employed.  PE-CD4 and APC-CD8 antibodies were used to 
phenotype clones.  (Bottom) Dose-dependent proliferative responses of 4 representative 
piperacillin-specific clones following exposure to piperacillin.  Clones (5x104 cells/well) 
were cultured with autologous EBV (5x103/well) in the presence of differing piperacillin 
concentrations (0.5-4mM) for 48h, with [3H]-thymine (0.5µCi/well) added 16h prior to 
finishing.  Maximal responses were observed at 2mM, with toxicity observed at 4mM. 
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4.4.5 Drug-specific T-lymphocyte clones show a pro-inflammatory cytokine 
secretion profile, including high levels of interleukin-22 
 
Following the successful generation of antigen-specific clones, 10 clones from 
each patient were expanded in order to investigate the cytokines secreted.  A 
panel of both CD4+ and CD8+ clones were selected for analysis.  Representative 
ELISpot images are shown in figure 4.6.  High levels of interferon-gamma and 
interleukin-13 were secreted from all piperacillin treated clones.  Interleukin-
22 was detected in over 60% of tested piperacillin-specific CD4+ and CD8+ 
clones.  Piperacillin specific activation of the clones did not result in the 
secretion of interleukin-17A.  Further investigations were conducted to assess 
the secretion of cytotoxic molecules perforin, granzyme B and fas ligand.  
These were performed via ELISpot using the same clones discussed above, 
with representative results shown in figure 4.7.  Again, drug specific responses 
were detected in all tested clones, though the levels of cytolytic molecules 
secreted varied with different clones.  Both CD4+ and CD8+ clones secreted high 
levels of granzyme B.  Perforin and fas ligand were secreted in lower levels 
than granzyme B in response to drug challenge (figure 4.8).  
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Figure 4.6.  Piperacillin specific cytokine secretion from hypersensitive patient clones.  
Six representative clones are displayed, 10 clones per donor were investigated.  T-
lymphocyte clones (1x105/well, 100µl), autologous EBVs (2x104/well, 50µl) and culture 
condition (culture media alone / piperacillin 2mM, 50µl) were incubated for 48h at 37°C, 
5% CO2.  Spot forming units were measured via ELISpot.  Visual comparison was 
conducted through an AID plate reader.  High levels of interferon-gamma, interleukin-13 
and interleukin-22 were observed in both CD4+ and CD8+ clones following piperacillin 
exposure. 
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Figure 4.7.  Piperacillin specific secretion of cytolytic molecules from hypersensitive 
patient clones.  Six representative clones are displayed, 10 clones per donor were 
investigated.  T-lymphocyte clones (1x105/well, 100µl), autologous EBVs (2x104/well, 
50µl) and culture condition (culture media alone / piperacillin 2mM, 50µl) were 
incubated for 48h at 37°C, 5% CO2.  Spot forming units were measured via ELISpot.  
Visual comparison was conducted through an AID plate reader.  Detectable amounts of 
perforin, granzyme B and fas ligand were observed in both CD4+ and CD8+ clones 
following piperacillin exposure. 
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Figure 4.8.  Cytotoxic molecules secreted from piperacillin-specific clones from 
hypersensitive patients.  Results displayed from 24 clones across 3 donors.  T-lymphocyte 
clones (1x105/well, 100µl), autologous EBVs (2x104/well, 50µl) and culture condition 
(culture media alone / piperacillin 2mM, 50µl) were incubated for 48h at 37°C, 5% CO2.  
Visual comparison was conducted through an AID plate reader, with SFU recorded.  CD4+ 
and CD8+ clones are shown in white and black circles respectively. 
 
 
The total spot forming units (SFU) in drug treated and control wells were then 
counted across all clones and compared.  These comparisons are shown in 
figure 4.9.  Statistical analysis was performed using a Student’s T-test.  A 
significant increase in cytokine secretion was observed between control and 
drug-treated wells for interferon-gamma, interleukin-13, interleukin-22, 
granzyme B and fas ligand (p=<0.001), as well as perforin (p=0.005). 
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Figure 4.9.  Cytokine and cytolytic molecule secretion from piperacillin-specific clones.  
Values were compared group-wise across both culture conditions, with significant 
secretion differences noted in all tested secretory molecules, with the exception of 
interleukin-17A.  (n=30, Students’ T-test, * - p=0.05, ** - p=0.005, *** - p=<0.001).  Visible 
spots were identified using an ELISpot reader and expressed as SFU. 
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4.4.6 Drug-specific T-lymphocyte clones express multiple chemokine receptors 
on their surface, and migrate in response to specific ligands in a dose- and 
time-dependent manner 
 
Further investigations were conducted on piperacillin specific and non-drug 
specific clones isolated from the same patients in order to characterise 
chemokine receptor expression on the cell surface.  Due to limited cell 
numbers, receptor expression was only measured on clones from 3 of the 
patients.  The results (figure 4.10) show significant differences between 
piperacillin specific and non-specific clones.  CCR1, CCR9, CCR10 and CD69 
were expressed at significantly higher levels on drug-specific clones, while 
CCR2, CCR3, CXCR1 and E-cadherin were expressed at higher levels on the 
non-drug specific clones.   
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Figure 4.10.  Chemokine receptor expression on piperacillin-specific T-cell clones 
derived from blood of hypersensitive patients.  Piperacillin-specific and piperacillin non-
specific T-cell clones (SI< 2) derived from the blood of hypersensitive patients (n=36 per 
group) were analysed for chemokine receptor expression using flow cytometry.  
Expression is recorded as fold expression above isotype control.  Statistical analysis 
performed via Student’s T-test (* - p=0.05, ** - p=0.005, *** - p=<0.001). 
 
A chemotaxis assay was designed and used to investigate the ability of clones 
to migrate in response to exposure of specific ligands that are known to bind to 
different receptors.  The experimental conditions described in chapter 3 were 
used to measure percentage migration across a semi-permeable membrane.  
Migration of greater than 20% of each clone was observed with ligands for 
CCR1, CCR4, CCR9 and CCR10.  The movement of cells was time dependant, 
with the greatest effect noticed after 24h (figure 4.11).  These data align with 
the relatively high expression of receptors on the cell surface. 
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Figure 4.11.  Migration of clones in response to specific chemokines.  1x105 cells were 
placed in the top of a trans-well plate, with chemokines in the lower half.  Migration was 
measured as percentage total migration across the membrane at specific time points, 
with percentages worked out through visual analysis through counting using a 
haemocytometer.  Above each graph the respective ligand-receptor combination is 
detailed. 
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4.5 DISCUSSION 
 
Cystic fibrosis is the most common lethal autosomal recessive disorder, which 
is responsible for a high incidence of mortality across the western world.  The 
opportunistic infections that are the by-product of the condition contribute to 
the patient mortality, with over 80% of cases reported to end with infection-
related mortality (O'Sullivan and Freedman 2009).  To combat these recurrent 
infections, there is widespread prescription of prophylactic antibiotic 
treatments, foremost amongst which are the beta-lactam and aminoglycoside 
classes which are sometimes inhaled to reach the site of infection (Hansen, 
Pressler et al. 2005; McCoy, Quittner et al. 2008).  In the general population, 
these compounds are well tolerated, with low incidences of adverse events or 
hypersensitivity reported.  However, in patients with cystic fibrosis, the 
incidences of adverse effects are vastly increased (Allan, Moss et al. 1975; 
Wills, Henry et al. 1998; Ogese, Saide et al. 2015).  This increase may be due to 
the widespread use, with patients treated with multiple antibiotics to combat 
the infections (Chmiel, Aksamit et al. 2014).  The development of adverse 
reactions often precludes treatment options, thereby greatly complicating 
patient management.  In one study, the incidence of hypersensitivity to at least 
one beta-lactam antibiotic was put at one in three, compared to approximately 
2% in the general population (Whitaker, Naisbitt et al. 2012).  In order to 
obtain a greater understanding of the underlying mechanisms involved in the 
hypersensitivity reactions, in vitro assays have been developed to characterise 
the phenotype and function of drug specific immune cells from hypersensitive 
patients.   
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It has been reported that PBMC isolated from the peripheral blood of patients 
with cystic fibrosis show a positive proliferative response to a range of 
antibacterial agents in a lymphocyte transformation test (Lavergne, Whitaker 
et al. 2010; El-Ghaiesh, Monshi et al. 2012; Jenkins, Yaseen et al. 2013; Naisbitt, 
Nattrass et al. 2014).  This assay involves culturing patient PBMC with the 
suspect drug for 6 days and then analysis of proliferation through the 
incorporation of [3H]-thymidine.  The positive lymphocyte transformation test 
results have been replicated with the current patient cohort (results shown in 
figure 4.1).  PBMC from all hypersensitive patients demonstrated a significant 
proliferative response to the drug piperacillin above control values, with a 
maximal response observed at 2mM piperacillin.  Interestingly, the response of 
piperacillin was higher than that of the positive control tetanus toxoid 
response in several patients.    Stimulation index values were not shown, but 
ranged from 19 – 62 at 2mM piperacillin.  Piperacillin tolerant and healthy 
volunteer PBMC from 4 donors were also tested using the lymphocyte 
transformation test (LTT), with no significant lymphocyte proliferation to 
piperacillin detected.  In contrast, a significant response to tetanus toxoid was 
observed.   These data confirm that the LTT is both a sensitive and specific in 
vitro assay for the diagnosis of piperacillin hypersensitivity in patients with 
cystic fibrosis. 
Cytokine secretion from PBMC was investigated following piperacillin 
stimulation, with the mitogen PHA used as a positive control.  Multiple studies 
have shown that both pro- and anti-inflammatory cytokines can be secreted 
from PBMC of beta-lactam hypersensitive patients (Brander, Mauri-Hellweg et 
al. 1995; Rodriguez-Pena, Lopez et al. 2006; Lochmatter, Beeler et al. 2009; 
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Torres, Mayorga et al. 2014).  This is mirrored in the results that were 
generated in this chapter, with high levels of interferon-gamma and 
interleukin-13 observed following drug stimulation of hypersensitive patient 
PBMC.  The primary objective of this chapter was to establish whether 
interleukin-17 and interleukin-22 are also secreted by drug-responsive T-
lymphocytes.  PBMC from all patients secreted interleukin-22 following 
piperacillin stimulation (figure 4.2).  However, interleukin-17A secretion was 
not detected.  PBMC from the same patients were shown to secrete interleukin-
17A (alongside other cytokines) in PHA-treated wells; thus confirming that the 
lack if IL-17 in piperacillin wells was not due to a technical deficiency.  
Interleukin-17A is an integral cytokine secreted by Th17 lymphocytes 
(Annunziato, Cosmi et al. 2007; Korn, Bettelli et al. 2009; Waite and Skokos 
2012).  The absence of this cytokine in drug-treated PBMC wells suggests that 
this subclass of lymphocytes is not involved in piperacillin hypersensitivity.  
Th22 secreting lymphocytes on the other hand show a strong interferon-
gamma+ interleukin-22+ phenotype (Duhen, Geiger et al. 2009), which is 
observed in the ELISpot results, suggesting that these lymphocytes may be 
driving the hypersensitivity response.   
Interleukin-22 has been implicated in the progression of cutaneous disorders, 
primarily due to the fact that the heterodimeric interleukin-22 receptor is 
expressed at high levels exclusively in tissues such as the skin (Logsdon, Jones 
et al. 2002; Wolk, Kunz et al. 2004).  In order to investigate IL-22 secretion in 
greater detail, supernatants isolated from piperacillin treated cells were 
assessed using an interleukin-22 ELISA.  Since the positive LTT data are 
observed several years after the hypersensitivity reaction, it is likely that the 
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drug-specific IL-22 is being secreted from memory T-lymphocytes.  To 
investigate this, whole PBMC, as well as magnetically separated memory T-
lymphocytes, were cultured with piperacillin.  In both cases, high levels of 
interleukin-22 were quantified via ELISA (figure 4.3).  When the experiments 
were repeated under Th17 and Th22 polarising conditions, higher levels of 
interleukin-22 secretion was detected in the drug treated culture supernatants.  
These data confirm that piperacillin specific interleukin-22+ memory T-
lymphocytes circulate in the peripheral blood of hypersensitive patients 
several years after clinical symptoms subside.  Somewhat surprisingly, both 
Th1 and Th2 culture conditions reduced the level of interleukin-22 in the 
supernatant of piperacillin stimulated cells.  Collectively, these data suggest 
that a Th22 polarising condition likely dominates in hypersensitive patients at 
the time of drug treatment. 
Clonal expansion following serial dilution is an important technique used for 
the investigation of typically low abundance antigen specific lymphocytes 
(Engler, Strasser et al. 2004; Wu, Farrell et al. 2007; Ko and Chen 2012).  For 
example, functional analysis of drug-specific PBMC by flow cytometry is almost 
impossible, due to the low frequency of antigen specific lymphocytes – 
reportedly less than 1:10,000.  The availability of clones allows a detailed 
analysis of cellular phenotype and function of individual cells.  PBMC from the 
four hypersensitive patients described in the LTT experiments were used in 
the cloning procedure.  In total, 1440 clones were expanded from the serial 
dilution plates across the 4 donors, with 570 clones shown to be responsive to 
piperacillin (i.e. with a stimulation index of greater than 2 (figure 4.5)).  These 
clones were shown to be primarily CD4+, with 494 clones displaying this 
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phenotype.  However, a small percentage of clones were CD8+.  These cells 
were used alongside the CD4+ cells for a more detailed functional analysis.  The 
detection of a dominant CD4 phenotype on drug responsive clones is in 
agreement with previous studies (Hertl, Bohlen et al. 1993; Pichler, Zanni et al. 
1997; Wu, Farrell et al. 2007; Monshi, Faulkner et al. 2013).  These data 
contrast with the CD8+ clones generated in chapter 3 from healthy volunteers 
following priming.  This disconnect between observed results shows that the 
priming assay is not completely mimicking the observed patient data.  Despite 
these differences, assessment of the phenotype and function of T-lymphocytes 
specific to piperacillin from patients and healthy volunteers represents a useful 
comparative tool.  The difference between patients and volunteers likely 
relates to the different routes of drug antigen exposure.  In vitro piperacillin 
binds almost exclusively to HSA (Jenkins, Yaseen et al. 2013), forming an 
adduct and possibly a hapteneic antigen.  However, it should be noted at high 
concentrations, the drug also likely binds directly to the surface MHC 
molecules.  In contrast, in patients, cells are exposed to much lower drug 
concentrations where the piperacillin hapten might modify specific proteins to 
generate an antigen for T-lymphocytes. 
Subsets of clones from each patient (i.e. 10 per patient) were chosen based on 
replication rate and CD phenotype for further analysis.  These clones were then 
placed into an ELISpot assay to assess drug specific cytokine secretion 
phenotypes.  Th1, Th2, Th17 and Th22 cytokines were investigated in order to 
define the Th phenotype that was displayed by individual drug-specific clones.   
Other investigations have shown that high levels of interferon-gamma are 
secreted by beta-lactam specific T-lymphocyte clones (Lochmatter, Beeler et al. 
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2009; Torres, Mayorga et al. 2009), which is in agreement with the data that 
was generated in these experiments (figure 4.6).  In addition, high levels of 
interleukin-13 were secreted from all clones.  Several clones secreted IL-13 in 
the absence of drug treatment, suggesting that this cytokine can be 
constitutively expressed under standard cell culture conditions.  Clones from 
hypersensitive patients also secreted high levels of interleukin-22.  A similar 
profile of cytokines was secreted from clones isolated from healthy volunteers.  
The lack of interleukin-17A secretion from T-cell clones from hypersensitive 
patients and volunteers agrees with the PBMC ELISpot data (figure 4.2), which 
showed that although the PBMC have the ability to secrete interleukin-17A (as 
shown by the PBMC wells stimulated with PHA), no drug response was 
detected.  The absence of interleukin-17 from drug-treated PBMC and clones 
suggests that piperacillin specific IL-17 secreting T-lymphocytes do not 
circulate in the blood of hypersensitive patients.  Collectively, the data shows 
that drug treatment of CD4+ T-cells in the presence of autologous antigen 
presenting cells is associated with the secretion of Th1 (IFN-γhigh), Th2 (IL-
13high) or Th1/2 (IFN-γhigh, IL-13high) cytokines.  IL-22 secretion was seen with 
piperacillin-stimulated Th1, Th2 and Th1/2 clones, whereas IL-17 was not 
detected.   
In addition to the assessment of cytokines, specific cytotoxic molecules were 
investigated, in order to determine whether drug-specific clones have the 
potential to damage target cells.  It has been shown previously that perforin 
and fas ligand are both secreted by cytotoxic CD8+ T-lymphocytes recruited to 
the skin of patients with a variety of inflammatory conditions (Kehren, 
Desvignes et al. 1999; Nassif, Bensussan et al. 2002; Kish, Gorbachev et al. 
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2012).  Therefore, if drug-specific clones secrete these markers, it would 
provide a potential mechanism for the observed tissue injury.  Perforin 
(Voskoboinik, Smyth et al. 2006), granzyme B (Trapani and Smyth 2002) and 
fas ligand (Waring and Mullbacher 1999) are all known to mediate targeted 
cell killing, through various apoptotic pathways.   
Perforin, granzyme B and fas ligand were all secreted from drug stimulated 
clones.  In cases where perforin and granzyme B was secreted, detectable 
levels were also seen in control wells, while fas ligand was only detected in 
wells treated with the drug (figure 4.7).  Two distinct phenotypes were 
observed, a perforin+granzyme B-fas ligand+ and a perforin-granzyme B+fas 
ligand- phenotype.  These phenotypes were detected in IL-22 secreting and IL-
22 negative clones.  The differing phenotypes were also observed when CD4+ 
and CD8+ clones were analysed (figure 4.8).   
Previous studies have shown that multiple chemokine receptors are expressed 
on the cell surface of drug-specific lymphocytes (Schaerli, Britschgi et al. 2004; 
Gibson, Ogese et al. 2014), with differing phenotypes expressing a wide variety 
of potential chemokine receptors.  Peripheral circulating lymphocytes have the 
ability to migrate in response to chemotactic signalling (Sallusto, Lenig et al. 
1999; Zlotnik and Yoshie 2000).  Specific  chemokine receptors are implicated 
in homing, such as CCR9 and gut homing (Pabst, Ohl et al. 2004), as well as the 
role of CCR4 and CCR10 in skin homing (Soler, Humphreys et al. 2003; 
Fujimoto, Uratsuji et al. 2008).  Based on these findings, a number of 
chemokine receptors expressed on drug specific and non-specific clones were 
profiled and compared.   
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A number of significant differences were observed between the drug specific 
and non-specific clones (figure 4.10).  Of particular interest was the low 
expression of CCR3 on the drug specific clones, a receptor involved in 
eosinophil recruitment (Forssmann, Uguccioni et al. 1997).  Eosinophils are 
rarely found in inflamed skin of beta-lactam hypersensitive patients.  In 
addition, high expression of CCR10 and CD69 expression suggest that the drug-
specific clones are both active and have the capacity to migrate towards skin 
(Moretta, Poggi et al. 1991; Homey, Alenius et al. 2002).  Overall the expression 
pattern suggests that drug-specific blood derived lymphocytes have the ability 
to migrate to the skin of hypersensitive patients.   
A chemotaxis assay was performed (figure 4.11) to investigate the migratory 
potential of the drug specific clones.  Similar responses to previous chapter 
work were observed - with migration occurring in a time- and expression-
dependent manner.  In cases where no significant increase in receptor 
expression was observed, such as in the case of CCR2 (a monocyte chemotaxis 
receptor) (Han, Tangirala et al. 1998) and CXCR3 (involved in integrin 
activation) (Rottman, Smith et al. 2001), little migration was observed.  CCL17 
and CCL27, ligands involved in the homing of leukocytes towards skin both 
promoted migration of the clones (Campbell, O'Connell et al. 2007).   
These data taken together show that a T-lymphocyte response is generated 
following drug exposure in cases of piperacillin hypersensitivity.  These T-
lymphocytes show a Th22 phenotype, with high levels of interferon-gamma 
and interleukin-22 secreted in the absence of interleukin-17A.  In addition, 
multiple cytotoxic markers are secreted from the drug-specific lymphocytes 
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upon challenge in vitro.  These drug-specific lymphocytes thus have both the 
potential to migrate to the primary site of beta-lactam hypersensitivity (i.e. the 
skin), as well as the ability to recruit other cell types to the location and cause 
tissue injury (Aberer, Bircher et al. 2003; Torres, Blanca et al. 2003; Romano, 
Blanca et al. 2004; Blanca, Romano et al. 2009).  It has been recently shown 
that for every blood derived antigen specific T-lymphocyte there is an identical 
cell that resides in the tissue at the site of inflammation.  Moreover, authors of 
the paper propose that the tissue resident cells respond rapidly following 
repeated antigen exposure whereas the circulating cells are recruited to the 
tissue to enhance the duration of the response (Gaide, Emerson et al. 2015; 
Watanabe, Gehad et al. 2015).  Thus, the final step of the thesis was to 
investigate the cells present at the site of the reaction; i.e. lymphocytes that are 
derived from inflamed skin, and to compare the phenotype, function and 
migratory capacity of drug specific blood and skin derived cells.   
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CHAPTER 5 – CHARACTERISATION OF THE DRUG-
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5.1 INTRODUCTION 
 
Previous work characterising the cellular pathophysiology of drug 
hypersensitivity has focused on investigating lymphocytes extracted from 
peripheral blood; these PBMC are not the best way to investigate these 
reactions.  Increasingly, tissue samples and lymphocytes extracted from the 
site of the reaction are becoming the gold standard for mechanistic 
investigations.  In cases of beta-lactam hypersensitivity, where cutaneous 
symptoms are highly common, this means being able to sample from the site of 
rash or pathology present on the skin of the patient as a result of the 
hypersensitive response.   
In tissues such as the skin, different cells exist in their own 
microenvironments.  Studies have reported that tissue-resident cells are 
located in these areas, and therefore are highly likely to be involved in immune 
responses mounted against invasive pathogens.  These tissue resident cells are 
not present in the circulation, and as such do not normally respond to 
circulating antigens that are solely located in the periphery (Clark, Chong et al. 
2006; Clark 2010; Heath and Carbone 2013; Mueller, Gebhardt et al. 2013).   
In general, three types of memory T-lymphocytes are involved in immune 
regulation throughout the body; central memory T-lymphocytes, effector 
memory T-lymphocytes and resident memory T-lymphocytes (Sallusto, 
Geginat et al. 2004; Sathaliyawala, Kubota et al. 2013).  While the first two 
populations are present throughout the circulation, the resident memory T-
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lymphocytes are solely located in their specific tissues, and do not show 
migratory ability.   
In addition to these tissue specific lymphocyte sub-populations, there are also 
resident antigen presenting cells located in specific tissues (Constant, Brogdon 
et al. 2002; Winau, Hegasy et al. 2007).  Normally, dendritic cells present 
antigens via MHC to the T-lymphocytes (Lanzavecchia and Sallusto 2001).  
However, in places such as the skin, cells like langerhans cells take up this role 
and become the primary route through which antigens are presented (Romani, 
Koide et al. 1989; Merad, Ginhoux et al. 2008).  As such, the complex 
interaction between these specialised antigen presenting cells and the resident 
T-lymphocytes could provide an insight into the progression of 
hypersensitivity in cases where a cutaneous aetiology is present. 
Recent work has demonstrated that T-lymphocyte mediated cell death of 
keratinocytes can be brought about in a model of allergic contact dermatitis 
(Pennino, Eyerich et al. 2010).  These skin resident T-cells were responsible for 
the antigen non-specific killing of keratinocytes through secretion of pro-
inflammatory cytokines, directly contributing to the observable disease 
phenotype. 
It has been documented that lymphocytes express multiple cell surface 
receptors (Valiante, Uhrberg et al. 1997; Baecher-Allan, Brown et al. 2001; 
Brigl and Brenner 2004).  These range from the receptors that are present on 
all lymphocytes, such as the CD3 molecule, to the highly specialised markers 
like CD64 on monocytes (and, by extension, macrophages) and specific 
keratins in keratinocytes (such as keratin-1) (Krüger, Büning et al. 2001; 
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Murphy and Reiner 2002; Roth, Kumar et al. 2012).  Chemokines that can be 
secreted in response to antigenic challenge have been shown to induce 
chemotaxis of lymphocytes in simple chemotaxis assays (Ogese, Saide et al. 
2015).  Based on this, there is the potential of circulating systemic lymphocytes 
being recruited to areas normally reserved for localised lymphocytes, such as 
the tissue resident memory T-lymphocytes (Cinamon, Grabovsky et al. 2001; 
Stein and Nombela-Arrieta 2005). 
Specific chemokines have been shown to be involved in this ability for 
chemotactic migration to occur.  In the case of lymphocytes, these chemokines 
include RANTES, CCL2 and CCL25 (Utsunomiya, Tani et al. 1997; Uehara, Song 
et al. 2002).  Of these the most interesting for further study is CCL27, due to the 
specific implication of its ability to trigger migration to cutaneous locations 
(Homey, Alenius et al. 2002; Soler, Humphreys et al. 2003).  This potential 
ability for migration, in addition to the ability of T-cells to secrete interleukin-
22 would provide strong support for the role of these mediators in cutaneous 
hypersensitivity reactions to drugs.   
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5.2 AIMS AND HYPOTHESIS 
 
Due to the fact that the primary response observed in patients exhibiting 
hypersensitivity to piperacillin is cutaneous in nature, it is critical to 
investigate the cytokine, lymphocytic and pathophysiological micro-
environment at the site of reaction, namely in the skin.  To do this, skin 
biopsies were obtained from patients following a positive skin test to allow for 
characterisation of the lymphocytes in inflamed skin. 
The cytokines interleukin-17A and interleukin-22 are both implicated in pro-
inflammatory conditions related to the skin.  However, our previous work 
suggested that interleukin-22 is secreted from drug specific T-cells in the 
absence of interleukin-17A.  Thus, a Th22 rather than a Th17 response may be 
dominant in hypersensitive patients.   
Therefore, the aim of this chapter was to characterise the T-lymphocyte 
response in inflamed skin of piperacillin hypersensitive patients.  Our 
hypothesis was that;  
‘Drug-specific T-lymphocytes present in the inflamed skin of piperacillin-
hypersensitive cystic fibrosis patients would show a Th22 phenotype, and 
respond to drug challenge’. 
  
 197 
 
5.3 METHODS 
 
All experimental methods mentioned in this chapter are explained in greater 
detail in Materials and Methods Chapter 2.  These include: 
 Peripheral blood mononuclear cell isolation (2.5.1) 
 Magnetic separation of cell subsets (2.5.2) 
 Proliferation assay (2.5.3) 
 Lymphocyte transformation test (2.5.4) 
 Bradford assay (2.5.6) 
 ELISpot (2.5.7) 
 Flow cytometry (2.5.8) 
 T-lymphocyte cloning (2.5.9) 
 EBV generation (2.5.10) 
 Western blot analysis (2.5.12) 
 Chemotaxis assay (2.5.16) 
 Skin lymphocyte isolations (2.5.17) 
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5.4 RESULTS 
 
5.4.1 Isolation of T-lymphocytes from inflamed skin of hypersensitive patients 
with cystic fibrosis 
 
Critical to the understanding of the lymphocytic response occurring in skin is 
the ability to isolate and culture antigen-specific lymphocytes from the tissue.  
Previous studies have outlined a method for this extraction, utilising both 
expansion and magnetic bead separations of a small skin biopsy obtained 
following a skin test.  Briefly, skin was mechanically dissected and incubated in 
medium containing interleukin-2 to allow the T-cells to migrate out of the 
tissue.  After 5 days T-cells were expanded with the mitogen PHA.  On day 14, 
an aliquot of the cells were cultured with titrated concentration of piperacillin 
and irradiated autologous EBV transformed B-cells as antigen presenting cells.  
After a further 14 days, [3H]-thymidine was added and proliferative responses 
measured 16h later.  The cells proliferated in response to drug exposure in a 
dose-dependent manner, as show in figure 5.1.  The observed responses from 
these assays mirror responses shown in chapter 4 with PBMC from the same 
hypersensitive patients.   
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Figure 5.1.  Proliferation of T-cell lines from skin of hypersensitive patients following 
challenge with different concentrations of piperacillin, with medium alone as a negative 
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control, as well as PHA (5μg/ml) as a maximal stimulation positive control.  
Lymphocytes were isolated from 2 skin samples from 2 patients. 1.5x105 cells were 
cultured per well in a 96-well plate with piperacillin and antigen presenting cells.  3[H]-
thymidine was added after 5 days with the assay harvested 16h later.  Results were 
obtained via beta-counter analysis, with CPM as the readout value.  Significant 
stimulation is shown in all drug-treated wells above control.  Significance was obtained 
through one-way ANOVA analysis versus the control samples.  ** - P = 0.005, *** - P = 
<0.001. 
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5.4.2 Keratinocytes isolated from inflamed skin samples do not present modified 
piperacillin to resident lymphocytes 
 
Keratinocytes could present piperacillin protein adducts to T-cells to trigger an 
immune response.  To investigate this, a simple western blot assay was 
conducted with differing concentrations of both piperacillin and primary 
human keratinocytes isolated from the skin biopsy taken from hypersensitive 
patients, to see if protein adducts with piperacillin were observed.   
Keratinocytes were cultured for 5 days in the presence of piperacillin.   After 5 
days, culture supernatants were collected and analysed.  Upon analysis, no 
modifications of the serum proteins were observed (figure 5.2), with a single 
band observed following development.  This band correlated with the expected 
results from the unmodified protein, with no other bands being visible under 
multiple exposure times.  This suggests that the only compound available for 
presentation to the keratinocytes was an unmodified piperacillin molecule, as 
no other bands were detected. 
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Figure 5.2.  Western blot analysis of supernatants collected from a keratinocyte assay 
performed on purified patient samples.  Piperacillin-HSA controls (top left) corresponded 
with the same band location as the patient supernatants of low and high concentrations 
of drug (top right).  No modification of serum was observed (bottom left).  Only a single 
band was observed at 66.5kDa.  Shown above are results from a western blot using anti 
benzyl-penicillin antibody, with a 10 second development time.  The lack of multiple 
bands suggests no processing is occurring via keratinocyte action. 
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5.4.3 Generation of drug-specific T-lymphocyte clones from skin-derived 
lymphocytes 
 
Clones were generated using the established protocols discussed in previous 
chapters.  Successful generation of T-lymphocyte clones was observed, with a 
total of 86 piperacillin-responsive specific clones generated across the 2 
patient samples.  690 clones were tested in total, giving a specificity rate of 
12.5%.  In addition, these clones expressed a strong CD4+ phenotype, with 83% 
of clones shown to express this marker.  CD8+ clones were also observed 
(17%), though at much lower quantities.  A clone was considered to respond 
when a reading greater than 2 on the stimulation index was observed (cpm 
drug treated / cpm control) as shown by the horizontal line in figure 5.3. 
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Figure 5.3.  Proliferation of piperacillin specific T-cell clone generation from skin of two 
hypersensitive patients.  The clones were generated though a serial dilution technique 
(0.3cells/well – 10cells/well) and cultured for 2 weeks, with clones showing expansion 
picked and used for specificity analysis. Proliferative responses were analysed by 
culturing T-cells either in the presence or absence of piperacillin (2mM) for 48h in 
triplicate.  Radioactive 3[H]-thymidine was incorporated into the assay for the final 16h, 
with the plates then harvested and proliferation measured via a beta counter as CPM.  
Clones with a stimulation index of SI>2, where the SI is calculated as (CPM drug treated / 
CPM control) were selected for further analysis. 
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5.4.4 Drug-specific T-lymphocyte skin clones express a pro-inflammatory Th22 
cytokine profile, in the absence of interleukin-17A 
 
A total of 12 clones from each patient were chosen for analysis of cytokine 
secretion via ELISpot.  In total, 7 cytokines and cytolytic molecules were 
investigated; interferon-gamma, interleukin-13, interleukin-17A, interleukin-
22, perforin, granzyme B and fas ligand (figure 5.4). Interferon-gamma and 
interleukin-13 secretion was detected from all of the piperacillin-treated 
clones.  The predominant phenotype that was observed was that of a pro-
inflammatory nature, with high levels of interferon-γ.  Interleukin-22 was 
detected from over 50% of clones.  These clones secreted differing levels of the 
cytotoxic molecules fas ligand, granzyme B and perforin following exposure to 
piperacillin.   Interleukin-17A was not found to be secreted from any tested 
clones. 
Additionally, the cytokines secreted from these clones were compared to 
piperacillin non-responsive clones isolated from the same biopsy.  The non 
drug-specific clones did not secrete cytokines in the presence of piperacillin 
(figure 5.5).  However, interferon-γ, interleukin-13, interleukin-22 (from 
certain clones), perforin, granzyme B and fas ligand were detected when the 
clones were activated with PHA.     
 
 
 
 
 208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 209 
 
 
Figure 5.4.  Cytokine secretion from a selection of piperacillin-responsive clones 
generated from the skin of hypersensitive patients.  ELISpot analysis was performed 
following drug-treated (2mM piperacillin) and control (medium alone) treatment.  
Testing was conducted to interferon-gamma, interleukin-13, interleukin-17A, 
interleukin-22, Perforin, Granzyme B and fas ligand.   
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Figure 5.5.  Cytokine secretion from a selection of clones that were non-responsive to 
piperacillin, generated from the skin of hypersensitive patients.  ELISpot analysis was 
performed following drug-treated (2mM piperacillin) and control (medium alone) 
treatment.  Testing was conducted to interferon-gamma, interleukin-13, interleukin-17A, 
interleukin-22, Perforin, Granzyme B and fas ligand.  
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5.4.5 Expression of chemokine receptors on T-cells from blood and skin of 
hypersensitive patients 
 
Following on from previous thesis chapters’ investigations with blood derived 
clones, the expression of different chemokine receptors was examined to 
determine if any functional differences could be observed between blood and 
skin derived cells (figure 5.6).  Expression of 12 chemokine receptors, CLA and 
E-CAD were compared on piperacillin-specific blood and skin-derived clones 
(n=24-36 per group). Skin-derived clones that were not activated with 
piperacillin were used as an additional comparator. Blood and skin-derived 
piperacillin-specific clones expressed significantly higher levels of CCR1, when 
compared with non-specific clones. Blood-derived piperacillin-specific clones 
expressed higher levels of CCR9 and CCR10 when compared with the skin-
derived piperacillin-specific and non-specific clones. In contrast, CXCR1, CLA 
and E-CAD were expressed at higher levels on the piperacillin-specific skin-
derived clones. Finally, CCR2, 3 and 4 were expressed at slightly higher levels 
on skin-derived clones, when the two populations of piperacillin-specific clone 
were compared. 
The movement of piperacillin-specific blood- and skin-derived clones towards 
6 chemokines (CCL2, 4, 17, 25, 27 and CXCL16) was measured using trans-well 
plates to elucidate whether receptor expression was associated with different 
migratory characteristics as shown in figure 5.7. All clones were found to 
migrate across the trans-well membrane, in a time-dependent manner, in the 
presence of the CCR4 and CCR10 ligands CCL17 and CCL27, respectively. 
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Furthermore, the blood-derived clones, which expressed significantly higher 
levels of CCR9, migrated in the presence of CCL25, a ligand for CCR9.   
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Figure 5.6.  Chemokine receptor expression on the cell surface of piperacillin-specific 
blood and skin derived clones.  Non responsive clones isolated from skin of the 
hypersensitive patients were used as an additional comparison.  Clone specificity in all 
cases was determined through stimulation index values (SI <2 = non-specific, SI >2 = 
specific).  Relative chemokine receptor expression was determined through a fold-change 
in expression of stained cells compared to isotype controls via flow cytometry.  CCR1, 
CCR2, CCR4, CCR10, CXCR1, CXCR6, CLA and E-Cad were investigated, covering multiple 
Th subsets and homing abilities.  * - P=0.05, ** - P=0.005, *** - P=<0.001. 
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Figure 5.7.  Migration of skin derived piperacillin specific clones in response to specific 
chemokines.  1x105 cells were placed in the top of a trans-well plate, with chemokines in 
the lower half.  Migration was measured as percentage total migration across the 
membrane at specific time points, with percentages worked out through visual analysis 
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through counting using a haemocytometer.  Above each graph the respective ligand-
receptor combination is detailed. 
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5.4.6 Modulation of the aryl hydrocarbon receptor can prevent priming of 
piperacillin-specific interleukin-22 secreting T-cells from healthy 
volunteers 
 
Data generated so far in this thesis suggests that piperacillin specific T-cells 
display a Th22 phenotype.  In order to investigate the origins of the drug 
specific T-cells, the aryl hydrocarbon receptor was identified as a target for 
modulation.  Previous studies have identified a link between the development 
of a Th22 phenotype and aryl hydrocarbon receptor signalling, so modulation 
of this pathway could lead to further proof that Th22 secreting T-cells are 
important in the development of piperacillin hypersensitivity. 
To test this hypothesis, naïve T-lymphocytes were cultured with piperacillin in 
a dendritic cell priming assay as described in chapter 3, with the addition of 
either an aryl hydrocarbon receptor agonist or antagonist in the priming co-
cultures.  These modifications gave the potential for a polarised Th22 response 
to be either driven (in the case of the agonist) or abrogated (for the 
antagonist).  The proliferative responses of these modulated priming assays 
are shown in figure 5.8.  Both modulated conditions showed successful 
priming with piperacillin comparable to earlier results, as indicated through 
the PHA proliferative readings.  However no significant proliferative response 
was observed in antagonist-treated cells, in opposition to the significant 
responses seen in agonist conditions.  Priming of the naïve T-lymphocytes was 
also conducted to nitroso-sulfamethoxazole as in previous experiments as a 
model hapten. 
To investigate whether the generation of piperacillin-specific IL-22 secreting 
T-cells is regulated through aryl hydrocarbon receptor (AhR), naïve T-cell 
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priming was studied in the presence of an AhR agonist (VAF347) or antagonist 
(CH-223191). Re-stimulation of T-cells primed in the presence of the AhR 
agonist resulted in the secretion of interferon-, interleukin-13, interleukin-22, 
perforin, granzyme B and FasL.  T-cells primed in the presence of the AhR 
antagonist secreted IFN-, IL-13, perforin, granzyme B and FasL following re-
stimulation with piperacillin; however, IL-22 secretion was no longer detected 
(figure 5.9, figure 5.10). 
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Figure 5.8.  Proliferative responses following naïve T-cell priming with aryl 
hydrocarbon receptor modulators.  The agonist used was VAF347 (50nM), with the 
antagonist used being CH-223191 (100nM).  Proliferation was measured via 
incorporation of radioactive 3[H]-thymidine, then reading via a beta-counter.  PHA 
(5μg/ml) was included as a positive control, with wells containing only mature dendritic 
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cells but no primed lymphocytes included as a negative control.  Statistical significance 
was determined through one-way ANOVA analysis compared to the 0 control well.  * - 
P=0.05, ** - P=0.005, *** - P=<0.001. 
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Figure 5.9.  Cytokine secretions from naïve T-cells primed to piperacillin in the presence 
of an AhR modulator.  The agonist used was VAF347 (50nM), with the antagonist used 
being CH-223191 (100nM).  ELISpots to titrated piperacillin (mM), as well as PHA 
(5μg/ml) as a positive control were performed.  0 corresponds to medium alone (no pip).  
The ‘No T Cells’ condition is a negative control with dendritic cells only (+2mM pip).  
Interferon-gamma, interleukin-13, interleukin-17A, interleukin-22, perforin, granzyme B 
and fas ligand were all investigated.   
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Figure 5.10.  Cytokine secretions from naïve T-cells primed to piperacillin in the 
presence of an AhR modulator.  The agonist used was VAF347 (50nM), with the 
antagonist used being CH-223191 (100nM).  ELISpots to titrated piperacillin (mM), as 
well as PHA (5μg/ml) as a positive control were performed.  Interferon-gamma, 
interleukin-13, interleukin-17A, interleukin-22, perforin, granzyme B and fas ligand 
were all investigated.  Results were recorded using an AID ELISpot reader, with SFU 
taken as a measure of cytokine secretion. 
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5.5 DISCUSSION 
 
Recent advances in the understanding of beta-lactam hypersensitivity have 
focused on the mechanistic causes of the condition.  The current most valuable 
way of investigating these conditions is to look at the site of the reaction itself, 
rather than from peripheral blood PBMC samples as have been conducted in 
the past.  Piperacillin hypersensitivity, the focus of the study, is a delayed 
reaction with the mean time of symptom onset estimated to be 9.1 days after 
initial drug administration (Whitaker, Naisbitt et al. 2012).  The skin is the 
major site of tissue injury; however, a small number of patients present with 
drug-induced fever and arthralgia with no apparent skin injury. 
In order to investigate cutaneous reactions associated with piperacillin 
exposure, lymphocytes were isolated from the reaction site.  Following skin 
testing, drug specific T-cells were clones and phenotyped to explore their 
function. 
Previous studies have formulated a method to isolate resident lymphocytes 
from skin biopsies (Clark, Chong et al. 2006; Lorenz and Stebut 2014).  Three 
distinct sub-types of memory T-lymphocytes exist throughout the body that 
could be responsible for the reactions that are observed:  Tcm central memory 
T-lymphocytes, Tem effector memory T-lymphocytes and Trm resident memory 
T-lymphocytes (Shin and Iwasaki 2013).  Of these, the resident memory T-
lymphocytes might be the cells involved in the development of hypersensitivity 
reactions, due to the tissue selective nature of the observed response. 
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The ability of hypersensitive patient PBMC to respond to drug in vitro when 
placed into a simple proliferation assays has been reported by several 
independent research groups (Disis, Schiffman et al. 2000; Naisbitt, Farrell et 
al. 2003; Merk 2005).  Less is known about the ability for cells isolated from 
specific reaction sites to respond to drug challenge.  Little work has been done 
to investigate the role of skin derived T-cells in drug allergy.  Only Nassif and 
Britschgi have looked into skin-derived T-cells in disease states, so much more 
work is needed to elucidate pathomechanisms of tissue injury (Britschgi, 
Steiner et al. 2001; Nassif, Bensussan et al. 2002).  In figure 5.1, the 
responsiveness of skin derived T-cells to piperacillin is tested through using a 
proliferation assay and piperacillin.  The positive responses observed in both 
patients show that the isolated lymphocytes respond vigorously in response to 
drug challenge.  These data indicate that; first, the protocol was successful at 
isolating lymphocytes from skin, and second, that the isolated lymphocytes are 
able to respond to the drug challenge.  Thus, the cells obtained through this 
protocol are viable, responsive to the drug in question and suitable for further 
mechanistic investigations. 
Piperacillin is a powerful broad spectrum beta-lactam antibiotic used in the 
treatment of multiple recurrent infections, typically seen in patients suffering 
with cystic fibrosis.  It has a molecular weight of 517 and can form a reactive 
penicilloyl intermediate through breaking of the beta-lactam ring.  The derived 
intermediate will bind irreversibly to protein lysine residues, most notably 
human serum albumin (Paterson and Bonomo 2005; Ghibellini, Bridges et al. 
2007).  Tissue injury in the skin is mediated primarily through the actions of 
lymphocytes against keratinocytes (Barbaud, Béné et al. 1997; Nestle, Kaplan 
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et al. 2009).  To investigate whether piperacillin modifies skin proteins, 
keratinocytes cultured with piperacillin in serum containing medium was 
conducted (figure 5.2).  Piperacillin was found to bind covalently to serum 
albumin; however, modification of keratinocyte protein from both 
hypersensitive patients was not detected.  These data are in agreement with 
our previous work using immune cells in serum containing medium (Whitaker, 
Meng et al. 2011; El-Ghaiesh, Monshi et al. 2012).  Piperacillin was found to 
bind to selective lysine residues on albumin in a dose and time-dependent 
manner.  Moreover, at non-toxic concentrations (similar to those used 
throughout this work), albumin binding effectively prevented the generation of 
piperacillin adducts with cells.  How these in vitro data relate to piperacillin 
protein binding is not known.  Experiments are underway using biopsy 
specimens to determine whether selective piperacillin protein adducts are 
formed in patient skin, as well as whether quantitative differences in the levels 
of binding are seen in tolerant and hypersensitive patients. 
Antigen-specific lymphocytes typically make up a small percentage of the total 
circulating lymphocyte population.  Due to the small numbers of piperacillin-
specific lymphocytes that would be obtained from a relatively small punch 
biopsy, the easiest (and most suitable) way to assess the potential reactivity of 
these lymphocytes is through clonal expansion and analysis of individual cells.  
The method utilised for this cloning procedure is the same as described in 
earlier chapters, with the purified cutaneous T-lymphocytes used for the 
cloning procedure.  Piperacillin responsive clones were isolated from the skin 
of both hypersensitive patients (figure 5.3).  In total, 690 clones were tested 
across both patients, with 96 shown to be drug responsive under these 
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conditions – giving a relative specificity rate of 13.9% for all the tested clones.  
This value is comparable with the number of piperacillin specific clones 
identified in patient blood.  As shown below in figure 5.11, all the clones were 
tested for expression of phenotypic CD4 or CD8 markers.  The clones showed a 
predominately CD4+ phenotype, though clones expressing CD8+ were also 
detected in lower frequencies in both patients. 
 
ID Type # Tested # Specific % CD4+ % CD8+ 
Donor 1 Skin 354 48 89 11 
Donor 2 Skin 336 48 82 18 
 
Figure 5.11.  Generation of piperacillin specific T-cell clones from two patients 
hypersensitive to piperacillin.  Clones were isolated from a 2mm punch biopsy.  Isolated 
cells were then magnetically separated, with the purified T-lymphocytes cultured in the 
presence of PHA for 2 weeks to expand any specific cells.  Serial dilutions were then 
performed on both patient samples, with clones that were growing picked and used for 
specificity testing.  Specificity to piperacillin was determined through a proliferation 
assay where a stimulation index greater than 2 was positive (cpm drug treated wells / 
cpm control wells).  Phenotypic CD4/CD8 analysis was performed through flow 
cytometry, with expression of either CD4 or CD8 as acquired by the cytometer. 
 
Once the phenotype was recorded, clones were then selected for further in 
depth analysis, primarily the investigation of cytokine secretion and migratory 
characteristics.   
Alongside the investigations of interferon-gamma, interleukin-13, interleukin-
17A and interleukin-22, the cytotoxic markers perforin, granzyme B and fas 
ligand were also tested.  These markers, if present, could explain why the drug-
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specific T-cells cause tissue injury.  Other studies have shown that cytolytic 
markers are secreted by drug specific T-cells from patients with 
hypersensitivity reactions (Eyerich, Eyerich et al. 2009).  Thus, their 
involvement in piperacillin hypersensitivity was investigated (Yawalkar, 
Hunger et al. 2001; Posadas, Padial et al. 2002; Pichler 2003).  Ten clones from 
each patient shown to be proliferative in the presence of piperacillin were 
tested (figure 5.4).   
Given that human skin is protected by skin-resident and re-circulating T-cells 
with distinct functional activity, it was important to investigate T-cells isolated 
from inflamed skin (Watanabe, Gehad et al. 2015).  These studies gained 
further credence when Gaide et al. demonstrated, using a mouse model of 
contact dermatitis, that skin resident and central memory T-cells derive from a 
common origin (Gaide, Emerson et al. 2015).  The authors reported that skin 
resident cells responded rapidly following antigen challenge, whereas central 
memory cells were recruited to the tissue more slowly to mediate a delayed 
response.  Skin biopsies were taken from 2 of the 4 hypersensitive patients 
following positive skin testing.  Piperacillin-specific clones were generated by 
serial dilution and mitogen stimulation then subjected to detailed phenotypic 
and functional analysis.  Similar to the blood-derived clones, approximately 
85% of piperacillin-responsive clones were CD4+ and drug treatment resulted 
in the secretion of IFN-, IL-13 and IL-22, but not IL-17.  However, eleven out of 
twelve skin-derived CD4+ and CD8+ IL-22 secreting clones were found to 
secrete IFN-.  IL-22 binds to receptors expressed on cells such as 
keratinocytes to mediate innate responses in skin.  Although IL-22 has been 
described as a protective cytokine, it also promotes pathogenic responses 
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when secreted, as we have found, in the presence of other cytokines 
(Mirshafiey, Simhag et al. 2015).  For example, CD4+ and CD8+ T-cells that 
secrete IFN- and IL-22 are implicated in the pathogenesis of chronic skin 
conditions such as psoriasis (Kagami, Rizzo et al. 2010).  
Fas L, perforin and granzyme B are T-cell secretory molecules that act in 
unison to induce apoptosis in tissue cells.  Early studies by Posadas et al. 
reported up-regulated levels of perforin and granzyme B in PBMC isolated 
from patients with acute mild and severe forms of drug-induced skin injury 
(Posadas, Padial et al. 2002).  Moreover, a strong correlation was observed 
between the level of cytolytic molecules and severity of the disease.  In 
contrast, fas ligand was only observed in patients with Stevens-Johnson 
syndrome and toxic epidermal necrolysis.  More recently, Zawodiniak et al. 
utilised a granzyme B ELISpot to detect cytotoxic T-cells in blood of patients 
with various forms of drug-induced skin injury (Zawodniak, Lochmatter et al. 
2010).  Herein, we utilized drug-specific clones isolated from blood and skin of 
the same hypersensitive patients to measure and compare fas ligand, perforin 
and granzyme B secretion.  Piperacillin specific skin-derived clones secreted 
high levels of granzyme B when activated with drug, which to some extent 
explains the findings of Zawodiniak et al.  In contrast, perforin and fas ligand 
secretion was largely restricted to the skin-derived clones.  These data show 
that (1) drug-specific skin resident T-cells are the most likely mediators of 
tissue injury and (2) analysis of blood-derived T-cells alone underestimates the 
importance of cytolytic molecules in the disease pathogenesis. 
The same analysis was performed on clones generated from skin, which were 
not stimulated to proliferate with piperacillin (figure 5.5).  PHA was also used 
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as a positive control to assess the maximal secretory ability of the clones.  As 
expected, these clones did not secrete cytokines or cytolytic molecules in 
response to piperacillin.  Interestingly, the clones secreted multiple cytokines 
including interleukin-17A and interleukin-22 following PHA stimulation.  
Furthermore, interleukin-17A was secreted from several clones following PHA 
treatment, showing that the cells present in the skin have the potential to 
secrete interleukin-17A, but do not do so following drug challenge.  The 
collective data found from ELISpot analysis of specific and non-specific clones 
isolated from the skin of patients indicates that drug specific T-cells display a 
Th22 phenotype.  If IL-17A is involved in the disease pathogenesis, it must be 
secreted from non drug-specific T-cells via bystander activation as has been 
noted recently in patients with contact dermatitis (Büdinger, Neuser et al. 
2001). 
The next step was to investigate the different markers that are expressed on 
both specific and non-specific clones isolated from patient skin.  In the 
previous chapter, chemokine receptors expressed on the surface of blood 
specific piperacillin clones were measured, with differing levels of all tested 
receptors noted (see Chapter 4).  The same chemokine receptors were tested 
on skin-derived clones, with the aim being to compare and contrast any 
differences between the three different classes that were studied; piperacillin 
blood-specific clones, piperacillin skin-specific clones and piperacillin skin 
non-specific clones.  Chemokine receptors have different roles, with each of 
them involved in chemotaxis to specific ligands.  Chemokine receptors CCR1, 
CCR4 and CCR10 are highly expressed on T-cells that migrate to skin.  The data 
shown in the previous chapter demonstrated that piperacillin-specific blood 
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derived clones migrate in the presence of ligands for CCR4 and CCR10.  CCR1 
has been determined to be involved in the recruitment of both activated T-
lymphocytes and monocytes in response to ligand activation, such as through 
the RANTES molecule.  CCR4 has previously been shown to play a role as a 
chemoattractant on circulating memory lymphocytes, while CCR10 is heavily 
implicated in skin homing of T-lymphocytes (Hudak, Hagen et al. 2002; 
Campbell, O'Connell et al. 2007; Xia, Hu et al. 2014). 
Significant differences were noted between blood and skin derived clones, 
alongside non drug specific clones.  CCR2, CCR4, CXCR1, CLA and E-cadherin 
were all shown to be up-regulated in skin-specific clones when compared to 
blood specific clones.  Both CLA and E-cadherin are strongly implicated in skin 
homing (Mendes-Aguiar, Gomes-Silva et al. 2009).  CCR4 and CXCR1 are 
involved in lymphocyte recruitment and activation, as well as neutrophil 
activation (Cummings, Martin et al. 1999).  These differences noted between 
the blood and skin derived clones show that there are subsets of lymphocytes 
in hypersensitive patients that can migrate to the skin and activate an immune 
response.  Comparisons between specific skin derived and drug non-specific 
clones showed significant differences in CCR1, CXCR6 and CLA expression.  All 
were up-regulated on drug-specific clones.  CXCR6 interacts with the 
macrophage recruitment molecule CXCL16, while CCR1 interacts with RANTES 
– involved in recruitment to sites of inflammation – as well as MIP-1a, another 
molecule involved in the recruitment and activation of macrophages (Cook 
1996; Galkina, Harry et al. 2007).  These differences show that there is a 
recruitment pathway for specific lymphocytes to activate and migrate to the 
skin in response to drug exposure in patients with hypersensitivity.  
 235 
 
Additionally, skin derived drug specific clones exhibit multiple macrophage 
recruitment pathways (Soler, Humphreys et al. 2003). 
After confirming that the piperacillin-specific circulating and resident T-
lymphocytes express skin homing characteristics, the next step was to confirm 
if they had the ability to migrate.  To do this, a chemotaxis assay was 
performed similar to the previous chapter, this time utilising the skin-specific 
clones.  The same ligands were incorporated into the assay, with CCL2, CCL4, 
CCL17, CCL25, CCL27, RANTES, CXCL9 and CXCL16 taken as ligands for the 
chemokine receptors CCR2, CCR5, CCR4, CCR9, CCR10, CCR1, CXCR3 and 
CXCR6 respectively.  
Migration of the clones occurred in a time-dependent manner.  In addition, the 
total percentage migration that was seen from the respective clones was 
associated with the relative expression of the receptors on the clones, as 
shown in figure 5.7. 
A subset of T-cells expressing skin homing chemokine receptors CCR4 and 
CCR10 have been shown to secrete IL-22 and hence are thought to be 
important mediators of skin pathophysiology (Duhen, Geiger et al. 2009).  
Furthermore, ligands for CCR4 (CCL17) and CCR10 (CCL27), which contribute 
towards the recruitment of IL-22 secreting cells, have been found at high levels 
in lesional skin of patients with atopic dermatitis (Homey, Alenius et al. 2002; 
Kakinuma, Wakugawa et al. 2003).  Skin-derived CD4+ and CD8+ clones 
expressed CCR4 and CLA in higher levels than the blood-derived clones.  
Alternatively the blood-derived clones expressed higher levels of CCR10.  Most 
importantly, both skin and blood-derived clones migrated towards CCL17 and 
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CCL27 (i.e., ligand for the 2 chemokine receptors).  Interestingly, the blood 
derived clones expressed high levels of CCR9; a receptor more traditionally 
associated with homing towards the gastrointestinal tract (Zabel, Agace et al. 
1999) and migrated in the presence of the CCR9 ligand CCL25, which suggests 
that drug-specific T-cells in blood have the capacity to migrate to different 
locations around the body.  This data, when taken together with earlier results, 
gives strong evidence that skin resident and skin migrating T-cells with a Th22 
phenotype are involved in piperacillin hypersensitivity.  Additional studies are 
required to explore the role of IL-22 secreting T-cells in other forms of drug 
hypersensitivity. 
In order to explore the origins of piperacillin specific Th22 cells, the aryl 
hydrocarbon receptor, a transcription factor, was identified as a potential 
regulatory factor.  The AhR is involved in the Th22 signalling pathway, as well 
as the induction of several metabolising enzymes including members of the 
P450 superfamily (Ramirez, Brembilla et al. 2010; Basu, O’Quinn et al. 2012).  
To test whether AhR signalling regulates the production of Th22 secreting cells, 
AhR modulators were incorporated into the dendritic cells naïve lymphocyte 
priming assay described in Chapter 3.  Both an agonist (VAF347) and an 
antagonist (CH-223191) were incorporated into the priming stage of the assay, 
in order to assess the resulting phenotype of the cells present post priming.  
The initial aim was to assess if successful priming would occur under these 
conditions containing the AhR modulators.  As seen in figure 5.8, the priming 
assay was able to be completed in both cases of agonist and antagonist 
presence.  The data shown is from three separate assays using different 
volunteer samples, with successful priming to piperacillin shown in the agonist 
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treated cells.  The values obtained using agonist-contained priming conditions 
were comparable to the untreated priming values as shown in Chapter 3, 
suggesting that the presence of a Th22 polarising AhR agonist had no effect on 
the ability for piperacillin priming to occur.  However, in the case of the AhR 
antagonist-treated primed cells, no significant priming was noted at all 
concentrations of the drug.  PHA treated cells were still responsive, showing 
the cells were still viable.  This antagonist-treatment halted the ability of the 
priming assay to respond to piperacillin, suggesting that the addition of an AhR 
antagonist halted the ability for the cells to respond to piperacillin as was 
normally seen through other priming assays which contained no modulators of 
the receptor.  This would confirm the theory that a Th22 response is involved 
in the piperacillin response. 
The T-cells primed in the presence of AhR agonist and antagonist were 
investigated via ELISpot using a panel of cytokines:  interferon-gamma, 
interleukin-13, interleukin-17A, interleukin-22, perforin, granzyme B and fas 
ligand.  Shown in figure 5.9 are the complete cytokine secretion profiles 
secreted by piperacillin specific T-cells from two of the three healthy 
volunteers.   
The key difference between the agonist-primed and antagonist-primed T-cells 
was the level of interleukin-22 secreted from piperacillin specific T-cells.  In 
the agonist-treated cells, interleukin-22 secretion was observed, which is 
consistent with results obtained earlier chapters.  However, in antagonist-
treated cells, interleukin-22 secretion was completely abrogated, with no 
detectable interleukin-22 observed upon optimal drug challenge. 
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The transcription factor AhR regulates the differentiation of naïve T-cells into 
IL-22 secreting cells. Selective AhR antagonists have been shown to perturb 
production of IL-22 secreting cells from naïve pre-cursors, whereas memory T-
cells are refractory to AhR regulation (Veldhoen, Hirota et al. 2008; Baba, 
Rubio et al. 2012).  T-cells primed to piperacillin in the presence of VAF347 
secreted IFN-, IL-13 and IL-22 alongside cytolytic molecules perforin, 
granzyme B and Fas L following re-stimulation with the drug. In parallel 
experiments with CH-223191, the differentiation of naïve T-cells into 
piperacillin-specific IL-22 secreting cells was blocked, while all other secretory 
molecules were detected at essentially the same level. Thus, AhR signalling is 
critical for the generation of drug-specific IL-22 secreting T-cells.   
Some slight reduction in perforin secretions were noted across all donor 
samples in the antagonist-treated cells, potentially suggesting that the 
antagonist to the AhR might reduce the level of cytotoxicity induced by antigen 
specific T-cells; however, this requires further investigation. 
Taken as a whole, the data collected from investigations into patient skin 
samples strongly suggest that a Th22 phenotype predominates amongst 
lymphocytes that are responsive to piperacillin.  Also, the presence of an aryl 
hydrocarbon receptor antagonist in the priming of naïve lymphocytes gave 
evidence to suggest a role for both interleukin-22 and the Th22 lymphocyte 
subset in the development and progression of piperacillin hypersensitivity. 
  
 239 
 
CHAPTER 6 – INVESTIGATION INTO THE 
IMMUNOGENICITY OF THE COX-2 SELECTIVE NON-
STEROIDAL ANTI-INFLAMMATORY LUMIRACOXIB 
 
6.1       INTRODUCTION ...................................................................................................................................... 240 
6.2 AIMS AND HYPOTHESIS ..................................................................................................................... 244 
6.3 METHODS ................................................................................................................................................... 245 
6.4 RESULTS...................................................................................................................................................... 246 
6.4.1 Lumiracoxib and its metabolites show clear dose-dependent toxicity when 
cultured with PBMC from healthy volunteers .......................................................................................... 246 
6.4.2 Priming of naïve T-lymphocytes from HLA-DRB1*15:01+ individuals to 
lumiracoxib was unsuccessful ........................................................................................................................ 249 
6.4.3 Lumiracoxib (metabolite) -specific lymphocytes from HLA-DRB1*15:01+ 
individuals are not detected following bulk culture of PBMC ............................................................ 255 
6.4.4 Drug-specific T-lymphocyte clones are not detected from HLA-DRB1*15:01+ 
naïve lymphocyte cultures after priming to lumiracoxib..................................................................... 258 
6.4.5    Long term bulk priming of naïve lymphocytes to lumiracoxib and its 
metabolites shows intermittently specific responses ............................................................................. 260 
6.5 DISCUSSION ............................................................................................................................................... 263 
 240 
 
6.1 INTRODUCTION 
 
Non-steroidal anti-inflammatory drugs are one of the most widely prescribed 
drugs across the globe (Conaghan 2012).  They do not contain an active opioid 
group, and as such are widely used in the treatment of pain, especially in cases 
where addiction could become, or is already a problem (Holdgate and Pollock 
2004).  They exert their mechanism of action through the inhibition of the 
cyclooxygenase enzyme, with the majority of NSAIDs inhibiting both the COX-1 
and COX-2 isoforms non-selectively (Cryer and Feldman 1998; Knights, 
Mangoni et al. 2010).  Selective inhibition of the COX enzymes comes about 
through the structural difference that is conferred through an amino acid 
substitution at position 523 between the two isoforms; COX-1 contains an 
isoleucine while COX-2 contains a valine (Gierse, McDonald et al. 1996; 
Kurumbail, Stevens et al. 1996; Walker, Kurumbail et al. 2001).   
Cyclooxygenase is involved in the production of prostaglandins from the 
precursor arachidonic acid.  These prostaglandins are the signalling molecules 
in many inflammatory pathways, and as such are involved in the production of 
pain (Vane 1971; Marnett, Rowlinson et al. 1999). 
The NSAID class has numerous properties; however, they are chiefly involved 
in the regulation of fever through their antipyretic activity.  Fever is caused 
through the action of prostaglandin E2.  Inhibition of the COX enzyme leads to 
reduction of levels of this prostaglandin, therefore reducing the body 
temperature (Aronoff and Neilson ; Rainsford 2007). 
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NSAIDs are generally well tolerated, with side effects of a mild nature being the 
most prevalent.  Of these side effects, dyspepsia and mild bleeding via gastric 
ulcers are the most commonly reported (Green 2001; Rostom, Dube et al. 
2002).  However, there have been incidences where potentially life threatening 
adverse drug reactions have been observed, such as myocardial infarction and 
kidney failure (De Broe and Elseviers 1998; Trelle, Reichenbach et al. 2011). 
Of the two isoforms, both COX-1 and COX-2 have different expressions and 
mechanisms of action.  COX-1 is constitutively expressed throughout the body 
and is involved as a ‘housekeeping’ enzyme in a multitude of physiological 
processes.  COX-2 however is involved exclusively in inflammatory processes, 
and as such is considered a highly promising target for potential future drugs 
(Dubois, Abramson et al. 1998; Fitzpatrick 2004).  Development of these COX-2 
selective inhibitors was implemented for this reason, alongside the reduced 
risk of the generation of ulcers (Traversa, Walker et al. 1995). 
These COX-2 selective inhibitors became collectively known as ‘coxibs’.  
Targeting the COX-2 enzyme selectively is possible through the isoleucine > 
valine substitution mentioned earlier.  This substitution allows a small 
hydrophobic side pocket on the COX-2 enzyme to be interacted with by 
selective compounds, resulting in binding to the open site that is not present 
on the COX-1 enzyme due to the steric hindrance of the larger isoleucine amino 
acid structure (Dubois, Abramson et al. 1998).  Unlike the non-specific NSAID-
enzyme reactions, the coxibs exhibit irreversible binding to their receptors.  
These coxibs initially appeared to be successful in targeting the desired 
receptor and in the treatment of pain.  However, beginning in 2004 with 
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rofecoxib, multiple serious adverse effects were reported resulting in the 
withdrawal of several drugs in this class.  A number of the coxibs were 
withdrawn due to reported serious cardiovascular events, though other 
toxicities and adverse conditions were reported (Bresalier, Sandler et al. 2005; 
Nussmeier, Whelton et al. 2005; Solomon, McMurray et al. 2005). 
One of these drugs, lumiracoxib, is an analogue of the widely prescribed 
painkiller diclofenac as shown in figure 6.1.  It was originally approved in 
2006 for the treatment of rheumatoid arthritis and acute pain, yet was 
withdrawn a year later due to serious liver damage resulting in the need for 
liver transplantation (Zhang, Ding et al. 2006; Geusens and Lems 2008).  The 
TARGET study, involving 18,000 subjects, investigated the safety and efficacy 
of this drug alongside naproxen and ibuprofen yet no serious adverse effects 
were reported (Schnitzer, Burmester et al. 2004).   
 
 
Figure 6.1.  Chemical structures of diclofenac (A, left) and lumiracoxib (B, right).  
Lumiracoxib is an analogue of the NSAID diclofenac, with a similar structure.  
Highlighted on the structure of lumiracoxib (B) are the differences in structures between 
the drugs, with a fluorine replacing a chlorine on a benzene ring and an additional 
methyl group on the other benzene ring.  Diclofenac is often found in salt form, with 
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either sodium or potassium being commonly used – turning the carboxylic acid –COOH 
group into a –COO- Na+/K+. 
 
Numerous major and minor metabolites are formed following hepatic 
metabolism of lumiracoxib.  The mechanism of liver injury is yet to be fully 
defined - though a recent genetic study has implicated a potential involvement 
of the adaptive immune system, with a HLA-DRB1*15:01+ haplotype 
representing an important risk factor (Singer, Lewitzky et al. 2010).  It should 
be noted that drug-specific T-cells have not been characterised in patients with 
liver injury as it is no longer possible to access such patients due to drug 
withdrawal. 
Strong genetic associations have been reported for a wide range of drugs over 
recent years.  The most widely studied of these is the association of abacavir 
hypersensitivity with expression of the HLA-B*57:01 gene, as reported by 
Mallal in 2002 (Mallal, Nolan et al. 2002; Mallal, Phillips et al. 2008). 
T-lymphocyte mediated responses can be classified into two broad categories:  
Class I and Class II.  Lumiracoxib is associated with a HLA class II allele; thus, 
one would expect that the majority of T-cells activated with the drug would be 
CD4+.    It is important to emphasise that the drug HLA class II interactions are 
much less well defined that the class I associations.  In fact to date, nobody in 
the field has shown that drug binding to an HLA class II molecule leads to the 
activation of CD4+ T-cells. 
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6.2 AIMS AND HYPOTHESIS 
 
The withdrawal of multiple ‘coxib’ class drugs has removed a valuable tool in 
the treatment of both pain and fever.  The serious adverse effects that are 
observed, such as the liver toxicity in the case of lumiracoxib, are so rare that 
even large scale FDA approved studies failed to identify the potential of the 
drug to cause liver injury.  The withdrawal of drugs at this late stage is a major 
clinical and financial problem for drug companies, as the development of 
compounds up to the point of approval can regularly exceed $1 billion.  If 
anything could be done to provide a clearer understanding of these rare, 
idiosyncratic reactions in a way that either clarifies the benefit / risk ratio 
early in development, or provides a risk mitigation plan, then it is clearly of 
great financial and treatment benefit. 
As such, work in this chapter sought to investigate whether T-lymphocytes 
could be successfully primed to either lumiracoxib or its metabolites.  The 
investigation of lumiracoxib-specific clones would allow for the greater 
understanding of the mechanism involved in the pathogenesis of the liver 
toxicity.   
Therefore, the hypothesis for this chapter of work was that: 
‘The response observed in lumiracoxib-induced liver injury is due to 
activation of CD4+ T-lymphocytes only in individuals expressing the risk 
allele HLA-DRB1*15:01.’ 
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6.3 METHODS 
 
All experiments that were performed in this chapter were explained in greater 
detail in Materials and Methods Chapter 2.  These include: 
 Peripheral blood mononuclear cell isolation (2.5.1) 
 Magnetic separation of cell subsets (2.5.2) 
 Proliferation Assay (2.5.3) 
 ELISpot (2.5.7) 
 Flow cytometry (2.5.8) 
 T-lymphocyte cloning (2.5.9) 
 EBV generation (2.5.10) 
 T-lymphocyte priming assay (2.5.14) 
  
 246 
 
6.4 RESULTS 
 
6.4.1 Lumiracoxib and its metabolites show clear dose-dependent toxicity when 
cultured with PBMC from healthy volunteers 
 
In order to investigate potential lymphocytic involvement in the progression of 
lumiracoxib-induced liver injury, the ability to incorporate the drug into our in 
vitro assays had to be established.  Through collaboration with Novartis, 
samples of the parent compound lumiracoxib and its major / minor 
metabolites NVP-LBH019, NVP-LBK286, CGS036501 and NVP-LBG677 were 
obtained (shown in figure 6.3).  All of these compounds were not soluble in 
normal culture media, meaning that dimethyl sulfoxide was used as a solvent 
to dissolve any drug prior to dilution of stock in medium.   
Compound Name Observed Toxicity 
(µM) (>LD50) 
Optimal Value Chosen 
(µM) 
 
Lumiracoxib 
 
 
300 
 
100 
 
NVP-LBH019 
 
 
100 
 
50 
 
NVP-LBK286 
 
 
100 
 
50 
 
GCS036501 
 
 
100 
 
30 
 
NVP-LBG677 
 
 
30 
 
10 
 
Figure 6.2.  Inhibition of lymphocyte proliferation with lumiracoxib and its metabolites.  1x105 
donor PBMC were cultured per well in triplicate on a 96well U-bottomed plate.  Concentrations of 
the compounds were co-cultured with the PBMC for 5 days in a semi-log manner (0.1µM-1mM), 
with PHA added to each well (2µg/ml) on day 3.  Proliferative responses were recorded through 
the incorporation of 3[H]-thymidine (0.5µl/well) for 16h and analysis through a beta-counter.  
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Based on observable LD50 values from the assays, the optimal values stated (right) were chosen 
for future experiments. 
These compounds were tested in a standard proliferation assay to explore the 
maximum concentrations that do not inhibit the T-cell response.  As shown in 
figure 6.4, a range of concentrations were tested in order to determine optimal 
values for use.  Inhibition of lymphocyte proliferation occurred at different 
concentrations for each of the compounds.  In each case, maximal toxicity was 
observed at the highest two doses (1000µM and 300µM), with differing toxicity 
observed at lower concentrations.  Based on the results obtained, the optimal 
concentrations of each compound for incorporation into the in vitro T-cell 
priming studies was determined and shown in figure 6.2. 
 
 
Figure 6.3.  Chemical structures of the four investigated lumiracoxib metabolites.  All 
metabolites share a similar structure with the parent compound lumiracoxib; with the 
same double benzene rings, -COOH carboxylic acid and –NH amine groups present on all 
of the compounds.  Changes in chemical structure occur on the lower benzene, with the 
presence or absence of an –OH hydroxyl group, as well as on the top benzene structure 
with the carboxylic acid group changing into either an –OH hydroxyl or –CH3 methyl 
group. 
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Figure 6.4.  Inhibition of lymphocyte proliferation following culture of PBMC with 
lumiracoxib and its metabolites.  Lumiracoxib and the metabolites were tested in a 
standard lymphocyte proliferation assay in order to determine optimal concentrations 
for future assay incorporation.  1x105 donor PBMC per well were cultured in triplicate in 
96well U-bottomed plates.  Concentrations of the drug compounds were co-cultured with 
the PBMC for 5 days in a semi-log manner (0.1µM-1mM), with PHA added to each well 
(2µg/ml) on day 3.  Proliferative responses were recorded through the incorporation of 
3[H]-thymidine (0.5µl/well) for 16h and analysis through a beta-counter.  Differing LD50 
were observed for each compound.   
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6.4.2 Priming of naïve T-lymphocytes from HLA-DRB1*15:01+ individuals to 
lumiracoxib was unsuccessful 
 
Utilising the method described in previous chapters, the next stage of the 
investigation was to explore whether the naïve T-lymphocytes that were 
isolated through magnetic separation from PBMC of HLA-DRB1*15:01+ 
individuals were primed to lumiracoxib.  Priming experiments were conducted 
using the optimal values as described in figure 6.2.  In total, three donors 
containing the HLA-DRB1*15:01+ allele were primed to the parent drug 
lumiracoxib.  No significant proliferative responses were observed when the 
primed naïve T-cells were re-challenged with lumiracoxib or SMX-NO, an 
irrelevant drug control (figure 6.5).  Significant responses were observed from 
PHA-stimulated cells, confirming that the cells were viable, but not responsive 
to the drug (SI of PHA-stimulated conditions 6.7-12.3, omitted on graphs for 
clarity).  Additionally, priming was conducted to the metabolites of lumiracoxib 
as discussed in 6.4.1.  Similarly, no significant responses were observed when 
the primed cells were re-stimulated with the test compounds (figure 6.6).  
Proliferative responses were measured using CFSE staining and analysis, 
looking at the percentage of dividing cells in a population.  This assay was used 
to explore whether it was more sensitive than [3H]-thymidine incorporation 
for the detection of drug-specific T-cell responses.  No increase in a dividing 
cell population was observed with the lumiracoxib metabolites indicating that 
lymphocytes were not activated.  Priming of naïve T-cells and CFSE staining 
was conducted with sulfamethoxazole-nitroso as a positive control, which has 
been previously shown to prime naïve T-lymphocytes.  As expected, T-cell 
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proliferation was observed when the primed cells were co-stimulated with 
SMX-NO. 
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Figure 6.5.  Proliferative responses of naïve T-lymphocytes following priming to 
lumiracoxib.  Naïve T-lymphocytes were isolated from a HLA-DRB1*15:01+ donor and 
placed into a dendritic cell priming assay as described in detail in Chapter 2.  Priming 
was conducted to lumiracoxib (well concentration 100µM) based on results obtained in 
previous assays shown in figure 6.2.  Following 2 week priming culture, proliferative 
responses were recorded using differing concentrations of lumiracoxib, with 25µM 
sulfamethoxazole-nitroso included as a non-specific activation control and no T-
lymphocytes included as a negative control – the dendritic cells present being stimulated 
with lumiracoxib (100µM).  Proliferation was recorded via 3[H]-thymidine incorporation 
(0.5µl/well) for 16h and analysis through a beta-counter.  No statistically significant 
responses were recorded for any of the conditions (NS = P>0.05, one-way ANOVA, 
comparison to non-specific stimulation via 25µM sulfamethoxazole-nitroso). 
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Figure 6.6.  Percentage of dividing cells following priming to different lumiracoxib 
metabolites and sulfamethoxazole-nitroso using CFSE staining.  For each HLA-
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DRB1*1501+ donor, CFSE staining was performed to investigate the population of 
dividing cells as a measure of proliferation and response to drug re-challenge following 
priming.  For each donor, priming was conducted to either sulfamethoxazole-nitroso (as 
a positive control) or the lumiracoxib metabolites as stated in figure 6.2.  For CFSE 
analysis via flow cytometry, 0.5µl of 5mM CFSE antibody was cultured with the primed 
lymphocytes prior to analysis, with 1x104 cells used for each culture condition.  Values 
were calculated as percentage expression of CFSE stain compared to unstained control.  
In sulfamethoxazole-nitroso primed conditions, non-specific stimulation was tested with 
lumiracoxib (100µM).  In lumiracoxib-metabolite primed conditions, non-specific 
stimulation was tested using sulfamethoxazole-nitroso (25µM). 
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6.4.3 Lumiracoxib (metabolite) -specific lymphocytes from HLA-DRB1*15:01+ 
individuals are not detected following bulk culture of PBMC 
 
An alternative approach to detect drug responsive T-cells in PBMC of healthy 
drug naïve donors is to simply culture PBMC with drug in what is commonly 
referred to as a bulk culture.  The PBMC can be re-stimulated with drug and 
autologous APC every 2-4 weeks.  To investigate whether newly primed 
lymphocytes harvested from the dendritic cell priming assay secrete cytokines 
following drug (metabolite) treatment, T-cells were incorporated into an 
ELISpot assay.  Due to the low numbers of cells available for the assay, only 
interferon-gamma was investigated.  Figure 6.7 shows that interferon-gamma 
was not secreted from the drug (metabolite) treated conditions, with both of 
the conditions showing clear wells.  PHA stimulated wells showed high levels 
of interferon-gamma secretion, confirming cell viability. 
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Figure 6.7.  Interferon-gamma ELISpot analysing the secretion of cytokines from 
lumiracoxib primed T-lymphocytes.  The primed T-cells were re-stimulated with APC and 
lumiracoxib (metabolite) alongside positive and negative controls.  Negative control 
conditions were achieved through medium + cells alone.  PHA (2µg/ml) was used as a 
positive control.  Representative metabolite results shown (CGS036501).  All results were 
comparable.  5x104 cells/well for each donor and condition were tested.  No significant 
differences were seen through visual or statistical analysis of the control and drug-
treated wells for either the lumiracoxib or metabolite-treated conditions (NS P=>0.05, t-
test). 
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6.4.4 Drug-specific T-lymphocyte clones are not detected from HLA-
DRB1*15:01+ naïve lymphocyte cultures after priming to lumiracoxib 
 
In order to investigate whether drug-specific lymphocytes were present 
following the priming of naïve T-cells with lumiracoxib, cloning was performed 
using cells harvested from the priming assay.  Due to time limitations, only 4 of 
the samples were used for cloning – two each from the lumiracoxib and 
metabolite (-501 and -677) conditions.  Figure 6.8 shows the results of the 
clone generation.  Over 900 clones were generated.  However, no clones 
displayed specificity to either lumiracoxib or its metabolites.  Upon initial 
testing, several clones’ stimulation index values were shown to be above 2 – 
indicative of a positive response – but these were shown to be false positives 
upon retesting at a later date. 
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Figure 6.8.  Table showing the clone generation of T-cell clones from lumiracoxib 
primed cells.  Clones were generated through the serial dilution using 0.3, 1, 3, 10 
cells/well.  Clones were re-stimulated on day 14 and expanding clones were picked for 
analysis.  In total, 945 clones were tested, with 0 shown to be specific to the tested 
compound (specificity rate 0.0%).  Specificity was determined through proliferation 
analysis where a stimulation index of greater than 2 was considered to be specific for the 
drug in question (SI = cpm drug-treated / cpm control). 
  
Donor Drug # Clones Tested # Clones Specific 
Donor 2 
 
Lumiracoxib 
 
213 0 
Donor 3 
 
Lumiracoxib 
 
194 0 
Donor B 
 
NVP-LBH019 
 
153 0 
 
NVP-LBK286 
 
35 0 
 
CGS036501 
 
66 0 
 
NVP-LBG677 
 
88 0 
Donor C 
 
CGS036501 
 
124 0 
 
NVP-LBG677 
 
72 0 
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6.4.5 Long term bulk priming of naïve lymphocytes to lumiracoxib and its 
metabolites shows intermittently specific responses 
 
All of the previous T-cell priming experiments yielded negative results.  Thus, 
one final investigation was conducted prior to concluding that it was not 
possible to isolate lumiracoxib-responsive T-cells from healthy donors 
expressing the risk allele.  In this case, an extended priming assay was 
conducted, with PBMC cultured with the compounds for 10 weeks prior to use 
in proliferation assays and T-cell cloning.  These cells were fed with fresh 
medium containing the drugs over the course of the incubation period, with 
allogeneic irradiated PBMC used as antigen presenting cells added every 2 
weeks. 
In total, PBMC from 6 donors expressing HLA-DRB1*15:01 were investigated, 
with cultures performed to the parent compound lumiracoxib along with the 
metabolites CGS036501 and NVP-LBG677, giving a total of 18 different culture 
conditions.  As shown in figure 6.9, the vast majority of the tested drug-treated 
PBMC  primed bulks did not show a significant response upon re-challenge 
with the compounds after 10 weeks (SI value <2).  However, one lumiracoxib 
primed sample, as well as 2 GCS036501 samples did display an SI value of 
greater than 2, meaning potentially that drug-responsive T-cells were present.  
These ‘successfully’ primed samples were used for the generation of T-cell 
clones.  Of the clones generated (n=75), none were activated with the test 
compounds (SI<2). 
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Figure 6.9.  Proliferative responses observed following long term bulk priming to 
lumiracoxib and its metabolites.  Six donors expressing the HLA-DRB1*15:01+ allele were 
investigated for long term (10-week) bulk priming, followed by clone generation as 
described in Chapter 2.  Analysis was performed after 10 weeks via a proliferation assay, 
where a stimulation index of greater than 2 was considered to be specific to the tested 
compound (SI = cpm drug-treated / cpm control).  The SI value of 2.0 is shown by a 
horizontal red line on the graphs.  The same six donor samples were used for all three 
bulk priming conditions. 
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6.5 DISCUSSION 
 
Drug hypersensitivity reactions are major clinical concerns that are still poorly 
understood.  Though strides have been taken in recent years to uncover the 
mechanisms involved in drug hypersensitivity, there is still a lot more to be 
learned about this condition, both from a mechanistic and genetic standpoint.  
Of the research that has already been reported, there are two distinct classes of 
drug hypersensitivity reaction; those restricted to HLA class I and class II 
alleles.  Of the available data, Class I reactions predominate, with these 
reactions being observed in multiple drugs.  Flucloxacillin (Monshi, Faulkner et 
al. 2013; Nattrass, Faulkner et al. 2015), abacavir (Chessman, Kostenko et al. 
2008), carbamazepine (Mauri-Hellweg, Bettens et al. 1995; Wu, Farrell et al. 
2007) and allopurinol (Pichler 2004; Roujeau 2006) have all been shown to 
elicit a class I restricted reaction.  Moreover, the expression of a risk allele is 
associated with the drug-specific activation of CD8+ T-cells.  Of the previously 
mentioned compounds, abacavir is the best studied.  Expression of the HLA 
allele HLA-B*57:01 correlates with the development of abacavir 
hypersensitivity (Martin, Nolan et al. 2004; Chessman, Kostenko et al. 2008; 
Mallal, Phillips et al. 2008).  The correlations between flucloxacillin and HLA-
B*57:01, carbamazepine and both HLA-A*31:01 as well as HLA-B*15:02 and 
allopurinol and HLA-B*58:01 have also been described (Hung, Chung et al. 
2005; Man, Kwan et al. 2007; Daly, Donaldson et al. 2009; McCormack, Alfirevic 
et al. 2011).  Each of these associations lead to a drug specific CD8+ T-
lymphocyte mediated reaction.   
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Lumiracoxib was withdrawn after reports emerged of acute liver toxicity after 
widespread usage of the compound (Singer, Lewitzky et al. 2010).  Though the 
compound itself is no longer used, the availability of metabolites make 
lumiracoxib an ideal candidate to explore whether drug binding to the HLA 
risk allele is associated with the specific activation of CD4+ T-cells.  
First, toxicity assays were conducted in order to optimise the final drug 
concentrations for use in the immunological investigations.  In total, 5 
compounds were tested in order to determine optimal assay drug 
concentrations.  Different values were obtained for each of the compounds (i.e. 
different LD50 were observed).  Based on these data, concentrations were 
selected for the analysis of T-cell responses (figure 6.2, figure 6.3). 
Lumiracoxib was initially used to investigate the priming of naïve T-
lymphocytes using a dendritic cell priming assay.  In total, 3 HLA-DRB1*15:01+ 
volunteer samples were studied, with results shown in figure 6.5.  No 
significant priming to lumiracoxib was observed.  This was assessed by 
studying proliferative responses and cytokine release following re-stimulation 
of the primed T-cells.  Sulfamethoxazole-nitroso was used as a positive control 
to confirm the functionality of the assay. 
 Following from these negative results with lumiracoxib, further assays were 
conducted, this time using lumiracoxib metabolites (structures shown in 
figure 6.3).  Again, three volunteer samples were used for priming, with all 
four metabolites used in separate experiments with cells from each volunteer.  
In addition, priming was again conducted to sulfamethoxazole-nitroso, as this 
compound has previously been shown to successfully prime naïve T-
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lymphocytes (Faulkner, Martinsson et al. 2012).  As seen in figure 6.6, similar 
results were obtained with the lumiracoxib metabolites.  No significant 
priming of naïve T-cells was observed with the metabolites.  In contrast, the 
nitroso primed cells showed significant dose-response proliferation following 
re-stimulation.  Thus, it is highly likely that priming to either lumiracoxib or its 
metabolites had not occurred.   
The data obtained in figure 6.6 shows CFSE analysis of cell populations post 
priming.  CFSE staining has been reported as an accurate and sensitive way to 
measure proliferation of a population as total percentage of dividing cells 
(Lyons, Blake et al. 2013).  This was performed via flow cytometry analysis, 
with CFSE incorporation used to measure dividing cells to assess whether it is 
a more sensitive readout to detect drug antigen-specific T-cell responses.  
Though no observable proliferation was observed following priming to either 
lumiracoxib or its metabolites, there is a chance that the readouts were not 
sufficiently sensitive to detect low numbers of antigen specific T-cells.  
ELISpots have been shown to provide highly sensitive results that otherwise 
would not be able to be detected through traditional proliferative analysis 
(McCutcheon, Wehner et al. 1997).  
To investigate whether this is the case, ELISpot assays were performed using 
the primed cells looking for interferon-gamma secretions when the 
lymphocytes were cultured with medium alone, drug (either lumiracoxib or its 
metabolites) or PHA.  Neither the lumiracoxib nor the metabolite primed 
conditions showed interferon-gamma secretions following drug re-challenge.  
The drug treated wells were comparable with the control wells, once again 
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suggesting that the lymphocytes cultured in the priming assay do not have the 
ability to respond to lumiracoxib challenge.  Interestingly, the cells do show a 
strong secretory response when challenged with PHA, confirming cell viability 
and cytokine secretion capacity. 
Though negative results were obtained from both proliferation assays and 
ELISpot analysis, the rarity of the reported liver injury suggests that 
lymphocytes would only be detected in a small number of patients (Schnitzer, 
Burmester et al. 2004).  To investigate whether T-cells were present in low 
numbers, serial dilution was utilised to generate clones that may be specific to 
either lumiracoxib or its metabolites.  These were performed using the primed 
lymphocytes from the earlier assays.  In total, 945 potential clones were 
generated across 4 donor samples, both to lumiracoxib and the four tested 
metabolites, with no specific clones generated.  Initially, several potential 
clones exhibited specific responses with stimulation index values of greater 
than 2.  However, these were shown to be false positives, as none of the clones 
were specific upon multiple retests.  Only certain primed bulks were chosen to 
be used in the clone generation stage due to poor cell numbers from other 
donors as well as time limitations.   
A final attempt was made to generate a T-cell response in vitro to these 
compounds, through the use of a modification to the original priming assay 
(Faulkner, Martinsson et al. 2012).  This was done through the culture of HLA-
DRB1*15:01+ donor PBMC in vitro as a bulk for 10 weeks, with regular 
additions of fresh medium, the compounds and APC at their established 
optimal concentrations.  This extended time span would potentially give cells 
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more time to expand; therefore drug-specific T-cell responses might be 
detectable.  As shown in figure 6.9, long term bulk priming was conducted to 
lumiracoxib, as well as the metabolites CGS036501 and NVP-LBG677.  These 
bulks were set up to six donors in each case, with the results of drug challenge 
shown in the figure.  Interestingly, there were a total of 3 bulks that showed a 
significant response to the compounds upon challenge (two from the same 
donor across different compounds).  These results were obtained using 
proliferation as a readout.  These responses suggest that there is the potential 
for lymphocytes from HLA-DRB1*15:01+ individuals to respond to lumiracoxib 
and its metabolites in vitro, though the success rate is still low.  It is worth 
noting however, that clone generation from these long term bulks was 
conducted in cases where initial specificity was seen, with no drug-specific 
clones being detected.  The bulks themselves were of poor viability at the end 
of the long term bulk priming.   
All of this data taken as a whole would suggest that the in vitro study of 
lumiracoxib-induced T-cell responses is unable to be conducted using 
established methods.  It is still possible that reactions are mediated by T-cells; 
however, new methods must be developed to study this and other forms of 
HLA class II restricted drug hypersensitivity.  Furthermore, HLA-DRB1*15:01 
was utilised as a risk allele for this work.  There are several other haplotypes 
that have been shown to be involved in lumiracoxib-induced liver injury which 
were not looked at (Singer, Lewitzky et al. 2010; Alfirevic and Pirmohamed 
2011; Pavlos, Mallal et al. 2012).  It is therefore reasonable to hypothesise that 
one of these other alleles could be involved in the observed hepatotoxicity.  
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CHAPTER 7 – FINAL DISCUSSION 
 
Before commenting on the results that this thesis has generated as a whole, 
first certain limitations of the study need to be addressed.  While every effort 
was made to generate robust data, some problems emerged that were unable 
to be avoided.  Firstly, the availability of patient samples was somewhat 
limited.  The samples from patients with cystic fibrosis were kindly donated to 
us from the St James’ Regional Cystic Fibrosis Center in Leeds.  These samples 
were provided based on availability of patients, in addition to given consent 
and reactions that were occurring during the study.  Critically, skin samples 
were only obtained from two patients due to these factors, predominantly 
consent.  While understandable, the lack of a readily available patient cohort to 
obtain multiple clinical samples limited the scope of the investigations that 
were able to be undertaken throughout this thesis.  Though efforts were made 
to keep a supply of working samples (via freezing of excess cells, supernatants 
etc.), the small number of patient samples available for research was a major 
limitation.  Replication of this data would be made easier through the 
availability of a replicate cohort of patients with cystic fibrosis, though the 
feasibility of this is questionable. 
In addition; time, cost and cell number constraints were present throughout 
the work in multiple experiments.  While attempts were made to replicate data 
using sets of samples, limitations in available cell numbers meant that 
replicates were low.  However, statistical analysis was still able to be 
performed on many of the experiments.  Importantly, the skin sample work is 
worthy of further study.  The ethics obtained for these experiments allowed for 
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a single small punch biopsy to be obtained following an intradermal test.  This 
resulted in <4 million T-cells being isolated from the sample, greatly limiting 
the work that could be performed.  In addition, no repeat samples were able to 
be obtained, along with the lack of relevant ethics to obtain healthy volunteer 
skin samples for comparison.  Further work would be enhanced through the 
investigation of these responses in both patients and volunteers. 
Adverse reactions to drugs are a major concern for healthcare across the globe.  
They are one of the most common causes of hospital admissions, with studies 
putting the relative frequency of hospital admissions due to ADRs as high as 
7% (Pirmohamed, James et al. 2004).  The problems caused by these reactions 
to drugs can be classified in two broad terms:  on target (type A) and off target 
(type B).  The type A reactions are the most widely reported type of adverse 
reaction, and can usually be rectified through alteration of the drug dosage, as 
the resultant side effects are due to the known pharmacology of the compound.  
Type B reactions are much less prevalent, but can cause life-threatening 
complications that cannot easily be predicted through known pharmacological 
mechanisms (Guengerich 2006; Bender, Scheiber et al. 2007; Zaccara, 
Franciotta et al. 2007).  These are a major concern both for healthcare 
professionals, due to their serious nature, and drug manufacturers, as the 
complications from type B reactions can often lead to the withdrawal of a drug.  
This is important for two reasons: first, bringing a compound to market can 
regularly exceed $1billion;  second, these withdrawals can often affect 
distribution of life-saving drugs, orphan drugs or drugs which are the only 
currently available treatment for a specific condition (Kaplowitz 2005; Ulrich 
2007).   
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Understanding of the mechanistic basis of hypersensitivity reactions was 
compiled in 1963, with the classification proposed by Phillip Gell and Robert 
Coombs (Gell and Coombs 1963; Descotes and Choquet-Kastylevsky 2001).  
This was the first time that the different clinical manifestations of 
hypersensitivity had been considered with the goal of elucidating the 
mechanisms that were involved.  It wasn’t until the 5th edition of the book, 
published in 1993, that a separate focus was placed on mechanisms of allergy 
and IgE-mediated diseases.  The Type I-IV classification that was outlined by 
Gell and Coombs was based on the time to onset of reaction and the functional 
mediators that bring about the allergic disease.  In subsequent decades most 
mechanistic studies focused on Type I immediate reactions involving IgE 
antibodies and the activation of mast cells.  In contrast, the other forms of 
hypersensitivity, especially the delayed T-lymphocyte mediated Type IV 
reactions, remained relatively poorly understood. 
The Gell and Coombs classifications are still useful today.  For example, β-
lactam antibiotics cause reactions in patients that fall under each of Gell and 
Coombs classification (Torres and Blanca 2010).  However, the classification 
does have important limitations.  First, antigen-specific antibodies and T-cells 
are detectable in individual patients presenting with a hypersensitivity 
reaction and this cannot be rationalized according to Gell and Coombs 
classification.  Secondly, it does not account for the different populations of T-
cell with different effector functions that have been described in the 
immunological literature.  For this reason, expansion of the classification was 
required.  The delayed type hypersensitivity (Type IV) was expanded upon by 
 271 
 
Pichler, subdividing them into Type IVa-d (Pichler 2003).  This expansion was 
designed to take into consideration the T-cells involved in different reactions. 
This classification was well received, allowing the greater understanding of 
role of T-lymphocytes in hypersensitivity reactions with a delayed onset, but 
different clinical presentations.  However, once again it is obvious that the 
classification currently in use is not completely fit for purpose.  Recent 
research has elucidated newer reactivity conditions, such as DIHS / DRESS, as 
well as newer helper T-lymphocyte subclasses such as the Th9 / Th17 / Th22 
phenotypes (Bettelli, Carrier et al. 2006; Ben M'Rad, Leclerc-Mercier et al. 
2009; Kagami, Rizzo et al. 2010; Schlapbach, Gehad et al. 2014).  Furthermore, 
in the last decade our knowledge of the mechanistic basis of drug 
hypersensitivity has increased exponentially.  For example, we now know that 
(1) herpes virus reactivation is implicated in certain reactions (Picard, Janela 
et al. 2010), (2) HLA allele expression is an important determinant for 
susceptibility (Pirmohamed, Ostrov et al. 2015) and (3) specific forms of drug-
induced kidney and liver injury should fall under the definition of drug 
hypersensitivity (Wuillemin, Terracciano et al. 2014; Kim, Saide et al. 2015).  
Despite this, our knowledge of the T-cells that instigate and/or regulate drug 
hypersensitivity reactions has not progressed significantly beyond the 
classification proposed by Pichler. 
Work conducted over the recent years has shown that both CD4+ and CD8+ 
memory T-cells are able to secrete unique cytokine profiles upon stimulation, 
with the characteristic secretions being; Th1 - IFNhigh IL-4low, Th2 - IFNlow IL-
4high IL-5high IL-13high, Th17 - IL-17Ahigh IL-22high and Th22 - IL-17Alow IL-22high.  
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This picture is not as clear as it could be however, due to the ability of both IL-
17A and IL-22 to be secreted by Th1/Th2 cells.  The potential role in skin-
mediated conditions of both IL-17A and IL-22 is highlighted through the 
presence of the receptors for these cytokines being expressed on 
keratinocytes, along with other epithelial cells.  In addition, Th17 and Th22 cells 
are known to express skin-homing chemokine receptors, further enhancing 
their potential involvement (Boniface, Bernard et al. 2005; Nograles, Zaba et al. 
2008; Cho, Suh et al. 2012).   
Due to the fact that human skin is known to be patrolled by populations of both 
circulating and resident memory T-lymphocytes, the work conducted 
throughout this thesis focused on the investigation of drug-specific T-
lymphocytes from both blood and skin of patients that were hypersensitive to 
piperacillin (Watanabe, Gehad et al. 2015).  The role of interleukin-22 
especially was of interest, and such investigations into the aryl hydrocarbon 
receptor were undertaken to assess its involvement in the generation of drug-
specific IL-22 secreting T-cells.  Piperacillin was chosen for two reasons.  First, 
it is known to form drug antigens both in vitro and directly in patients post 
administration through lysine modification of proteins (Whitaker, Meng et al. 
2011). Second, it is commonly prescribed and its use is associated with a high 
incidence of hypersensitivity. 
Investigations fell into three distinct sections; (1) assessment of the phenotype 
and function of both blood-derived T-lymphocytes from hypersensitive 
patients, (2) comparison of the drug-specific lymphocytes from blood and 
inflamed skin and (3) analysis of healthy volunteer samples and priming of 
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naïve T-cells.  Because of the functional protection given to human skin by 
resident and recirculating T-lymphocytes, it was of critical importance to 
compare the T-cell populations in blood and skin.  These comparisons were 
given further importance after a mouse model of contact dermatitis showed 
that skin resident memory T-lymphocytes and central memory T-lymphocytes 
both come from a common origin (Gaide, Emerson et al. 2015). 
The generation of piperacillin specific T-lymphocyte clones from both the 
blood and skin of hypersensitive patients showed dominant CD4+ phenotype, 
with approximately 85% of drug-specific T-cells isolated from blood and the 
tissue shown to be CD4+.  The skin-derived specific clones were shown to 
secrete interferon-gamma, along with interleukin-22 and cytolytic molecules.  
Though interleukin-22 has been reported as a protective cytokine, there is also 
evidence that it can be involved in the pathogenesis of certain diseases such as 
psoriasis (Kagami, Rizzo et al. 2010).  Collectively, the data generated shows 
that interleukin-22 signalling is involved in piperacillin-mediated 
maculopapular eruptions.  The most interesting outcome of the project was 
detected when the profile of cytokines secreted by blood and skin-derived 
clones were compared, as shown in figure 7.1.  Piperacillin-specific blood 
derived clones showed a mixed Th1, Th2 and Th1/Th2 profile when analysed, 
with the CD8+ clones shown to display predominantly a Th2 section profile.  In 
contrast, the skin-derived piperacillin-specific clones showed a much more 
highly polarised profile, with strong Th1 / Th2 responses being observed.  In 
this case, the CD8+ clones secreted a Th1 profile following drug stimulation.  
Analysis of the interleukin-22 secreting clones from the skin showed a strong 
Th1 profile, suggesting that the hypersensitivity observed in patients following 
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piperacillin exposure is likely mediated through the action of a subset of Th1+ 
interleukin-22 secreting T-lymphocytes.     
 
Figure 7.1.  Profile of cytokines secreted from piperacillin-specific T-cell clones derived 
from blood and inflamed skin of hypersensitive patients. T-cell clones (n=43, blood; n=24, 
skin) were cultured with irradiated antigen presenting cells and piperacillin (2mM) and 
cytokine secretion was quantified by ELISpot. (Left) Comparison of IFN-γ and IL-13 
secreted by individual blood- and skin-derived T-cell clones. Dashed lines at 100 spot 
forming units (SFU) were used to classify clones according to classical Th1, Th2, Th1/Th2 
fingerprint. Shaded circles depict CD8+ clones.  SFU in drug-treated wells with SFU in 
control wells subtracted are shown in all images. (Center) Mean ± SD IL-22 secretion 
from Th1, Th2 and Th1/Th2 clones. (Right) Comparison of the level of IFN-γ and IL-13 
secreted by individual IL-22high (IL-22 SFU of 100 or above in piperacillin-treated wells 
with control values subtracted) blood- and skin-derived T-cell clones. Each circle 
represents an individual clone; shaded circles depict CD8+ clones. 
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Analysis of the migration of the clones confirmed that they were able to 
migrate towards skin through the expression of skin-homing chemokine 
receptors (e.g., CDR4 and CDR10).  A subset of T-lymphocytes that are known 
to express high levels of CCR4 and CCR10 have been shown to secrete IL-22.  
For this reason, they can be considered to have a role in skin-targeting 
reactions such as those seen in piperacillin hypersensitivity (Duhen, Geiger et 
al. 2009).  In addition, ligands for CCR4 and CCR10, which contribute towards 
the recruitment of IL-22 secreting cells, have been found in the skin of patients 
with atopic dermatitis (Homey, Alenius et al. 2002; Kakinuma, Wakugawa et al. 
2003).  Importantly, piperacillin-specific skin-derived CD4+ and CD8+ clones 
expressed CCR4 and CLA in higher levels than the blood-derived clones.  In 
contrast, the blood-derived clones expressed higher levels of the skin-homing 
CCR10.  Critically, both skin and blood-derived clones migrated towards CCL17 
and CCL27, ligands for the skin-homing chemokine receptors.  Blood derived 
clones also expressed high levels of CCR9, a receptor closely associated with 
homing towards the gastrointestinal tract (Zabel, Agace et al. 1999), and 
migrated in the presence of the CCR9 ligand CCL25, which suggests that drug-
specific T-lymphocytes that are circulating in the blood have the capacity to 
migrate to different locations around the body. 
Investigations were then performed using naïve T-lymphocytes from healthy 
donors to explore whether it was possible to prime T-cells to piperacillin in 
vitro.  Following re-stimulation of the primed cells with piperacillin, significant 
proliferation was observed. Importantly, the piperacillin-specific T-cells 
secreted the same cytokines as the patient cells (i.e., IFN-, IL-22 and IL-13). 
Moreover, piperacillin-specific IL-17 secretion was not detected.  Importantly, 
 276 
 
IL-22 was seen in the absence of Th22 polarizing cytokines such as IL-6 and 
TNF-α (Duhen, Geiger et al. 2009).  In fact, priming of naïve T-cells to 
piperacillin under Th17 or Th22 polarizing conditions did not increase the 
levels of IL-22 secreted from primed cells.  T-cells cloned from the piperacillin-
primed naïve T-cells were skewed towards a CD8+ phenotype, in contrast to 
the highly CD4+ patient clones, and drug stimulation resulted in the secretion of 
high levels of IFN- and moderate levels of both IL-13 and IL-22.  Analysis of 
individual clones revealed that the three clones secreting high levels of IL-22 
were CD8+ and they did not secrete Th1 or Th2 cytokines. 
The aryl hydrocarbon receptor regulates the differentiation of naïve T-
lymphocytes into IL-22 secreting cells.  Selective AhR antagonists have been 
shown to inhibit production of IL-22 secreting cells from naïve pre-cursors, 
whereas memory T-cells are refractory to AhR regulation (Veldhoen, Hirota et 
al. 2008; Baba, Rubio et al. 2012).  In the final component of the work, naïve T-
lymphocytes were primed against piperacillin in the presence of an AhR 
agonist (VAF347) and antagonist (CH-223191).  T-lymphocytes primed to 
piperacillin in the presence of VAF347 secreted IFN-, IL-13 and IL-22 
alongside cytolytic molecules perforin, granzyme B and fas ligand following re-
stimulation with the drug.  Concurrent experiments with CH-223191 showed 
that the differentiation of naïve T-cells into piperacillin-specific IL-22 secreting 
cells was blocked, while all other secretory molecules were observed at similar 
levels.  Therefore, it has been shown that AhR signalling is critical for the 
generation of drug-specific IL-22 secreting T-lymphocytes.   
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The majority of studies exploring the relationship between expression of an 
HLA risk allele and development of a hypersensitivity reaction have focused on 
HLA class I linked reactions.  For example, carbamazepine’s linkage with HLA-
B*31:01, flucloxacillin and HLA-B*57:01, allopurinol with HLA-B*58:01 and 
abacavir’s strong association with HLA-B*57:01 have all been shown to relate 
to the activation of drug-specific T-lymphocytes.  The HLA class I associations 
lead to the selective activation of CD8+ T-cells (Mallal, Phillips et al. 2008; 
Tassaneeyakul, Jantararoungtong et al. 2009; Monshi, Faulkner et al. 2013).  
This work is very useful for studying the underlying genetic components of 
certain drug hypersensitivity reactions, though does not take into account the 
MHC class II response that can also be present.  For this reason, we chose to 
investigate lumiracoxib – a drug associated with HLA-class II-restricted liver 
injury.  The programme of work utilized established cell culture methods to 
determine whether it was possible to generate drug-specific T-cells in donors 
expressing the risk allele and, if so, characterise the phenotype of the 
responding cells and HLA restriction. Sulfamethoxazole nitroso was used as a 
positive control, which has previously been shown to stimulate CD4+ and CD8+ 
T-cells from healthy volunteers to proliferate and secrete cytokines.  In 
contrast to sulfamethoxazole nitroso, T-cells responsive to lumiracoxib were 
not detected.  In subsequent experiments lumiracoxib metabolites kindly 
donated by Novartis were tested using the same experimental design.  
However, similar negative results were obtained with the metabolites.  It is 
possible that drug (metabolite)-responsive T-cells are being generated in low 
numbers in the in vitro culture conditions.  For this reason, T-cells were cloned 
from the lumiracoxib and lumiracoxib metabolite cultures.  Almost 1000 clones 
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were tested, but none displayed reactivity against lumiracoxib or its 
metabolites.  These results could be due to a number of reasons, of which two 
merit the most consideration.  Firstly, the knowledge of genetic associations 
have greatly enhanced our ability to target medications for different people, 
however there is a chance that our knowledge of the HLA associations with 
each compound is incomplete.  Lumiracoxib hepatotoxicity is known to be 
linked with a –DQA1*01:02+-DQB1*06:02+-DRB1*15:01+-DRB5*01:01+ 
haplotype, yet the undertaken work only focused on the HLA-DRB1*15:01+ 
allele (Singer, Lewitzky et al. 2010).  It is therefore possible that susceptibility 
relates to an alternative (or multiple) HLA allele.  Also, though in vitro work 
aims to replicate the conditions found in an organ, specific conditions are not 
easily mimicked.  The hepatotoxicity observed in lumiracoxib reactions could 
be due to reactive metabolites and protein adducts formed directly in 
hepatocytes themselves, meaning that the correct antigen would not be 
generated in the in vitro conditions (Li, Slatter et al. 2008).  Work with 
sulfamethoxazole and its metabolite sulfamethoxazole-nitroso has shown that 
cross-reactivity does not always exist between related compounds; thus, the 
metabolites potentially responsible for lumiracoxib’s liver injury might not 
cross react with the parent compound (Wulf and Matuszewski 2013).   
In conclusion, this work shows that both circulating and skin-resident CD4+ 
and CD8+ T-lymphocytes that secrete IL-22, but not IL-17, alongside cytolytic 
molecules are important mediators of maculopapular drug eruptions in 
humans – with the differentiation of naïve T-cells into drug-specific Th/Tc22 
cells being dependent on AhR receptor signalling. 
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